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ABSTRACT
Immunotherapies harness the inherent potential of the body to destroy foreign or infected cells,
by stimulating new or enhancing existing immune responses. One way to boost insufficient
native immunity might be to engineer lymphoid tissue at disease sites (e.g., tumors). Such
neotissues could be formed by attracting or transferring immune cells into a defined
microenvironment supportive of their activation. In addition to having therapeutic potential, such
artificial lymphoid scaffolds could be used as in vitro models to investigate how immune cells
respond to changing properties of their environment (e.g., architecture or biochemistry). We
developed and tested macroporous poly(ethylene glycol) (PEG) hydrogel scaffolds as a platform
for lymphoid tissue models and immunotherapy. By applying the method of colloidal crystal
templating to materials and length scales appropriate for soft tissues, PEG hydrogels with arrays
of ordered, interconnected pores were prepared. These combined the attractive properties of
hydrogels, including biochemical versatility and tissue-mimetic mechanical properties, with the
benefits of a macroporous structure, including improved nutrient transport and a defined space
for cell interactions. Moreover, the ordered pore arrangement provided high interconnectivity at
unprecedented (low) porosities. We primarily tested the migratory responses of T cells to these
novel hydrogel scaffolds, due to the importance of rapid T cell motility in promoting efficient
immune responses. Varying the choice of adhesion ligand coating the scaffolds prompted
significant T cell trafficking only for the case of intercellular-adhesion-molecule I (ICAM-1),
and ultimately, a composite scaffold structure was required to attain in vivo-like cell migration.
In this modified structure, the porous PEG hydrogel provided mechanical stability and the ability
to deliver proteins of interest, while an infused collagen matrix supported intra-scaffold
migration of loaded T cells and dendritic cells. We tested the effect of scaffold architecture in the
composites, and found that increasing the PEG pore size enhanced T cell motility. We also
demonstrated the delivery of the chemokine CCL21 - a cytokine likely to be useful for
immunotherapy - to cells within composite scaffolds. This hybrid scaffold approach combines
the strengths of the synthetic and biopolymer hydrogels used in a complementary fashion, and
may be generally useful for tissue engineering.
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1 Background and Significance
The present work is motivated both by fundamental cell biology questions and by therapeutic
applications in the field of immunology. These motivating problems may be addressed by in
vitro lymphoid tissue models and by in vivo therapeutic tissue engineering, respectively. For this
work, we developed a novel macroporous polymer scaffold, modified it with adhesion and
signaling proteins, and studied the in vitro behavior of immune cells within the resulting
construct. We were particularly concerned with creating a lymphoid microenvironment
supportive of T cell migration, due to the importance of rapid T cell motility in promoting
efficient immune responses. This chapter will introduce key facets of the immune response,
followed by a discussion of prior relevant work in immunotherapy and tissue engineering.
Finally, our specific objectives and contribution to the field will be outlined.
1. 1 Cells and signals in the immune response
1.1.1 Organization of lymph node microenvironment
The primary function of lymph nodes is to provide a supportive environment in which adaptive
immune responses to pathogens (bacteria, viruses, etc.) are initiated, and to this effect lymph
nodes are present at regular intervals throughout the human body (1). Each lymph node is a
complex organ with several distinctive features, including a compartmentalized structure. T and
B lymphocytes - white blood cells that play a key role in the immune response - are segregated
into distinct zones: B cells are primarily present in follicles that have relatively little extracellular
matrix (ECM), while T cells typically reside in the lymph node paracortex or T zone, a cell-rich
area with a loosely woven but substantial ECM (see Figure 1-1). Other secondary lymphoid
organs (such as the spleen) have similar structures and purpose, while primary lymphoid organs
are where immune cells develop.
The T zone extracellular matrix is known as the reticular network, due to its distinctive
microfibrous structure. Thick collagen fibers (0.5-5 ltm in diameter) lie -5-35 jim apart in all
directions, creating pores in which lymphocytes are packed to high density (2-4). The collagen-
core fibers are covered by a basement membrane-like layer including fibronectin, laminins, and
perlecan (5), and are largely ensheathed by a layer of fibroblastic reticular cells (FRCs) - a
stromal component of secondary lymphoid organs - and by dendritic cells (3, 6, 7). We became
interested in mimicking this architecture and biochemical composition in synthetic scaffolds, as
described more completely in sections 1.2-1.4. Within the T zone, T cells may become activated
upon encountering their cognate antigen presented by a dendritic cell; this process is described in
the following section.
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Figure 1-1 Lymph node architecture and cellular composition. Immunostaining of lymph
node sections was performed by Katakai et al. (3). (A) T cells expressing CD3 (shown in red)
and B cells expressing B220 (shown in green) segregate to distinct areas of the lymph node. (B)
ER-TR7 antigen (expressed and secreted by lymphoid fibroblasts) forms a denser network in the
T cell-rich paracortex than in the B cell-rich follicles. The chemokine CCL21 (to be discussed in
section 1.1.3) is present in the T cell areas almost exclusively.
1.1.2 T cell priming and migration in secondary lymphoid organs
The immune system is composed of innate and adaptive components, both of which act to
eliminate foreign pathogens. Innate immunity is a fast response of limited specificity, while
adaptive immunity is slower but highly specific, and has the additional characteristic of memory.
In a typical adaptive immune response, dendritic cells (DCs) ingest or otherwise acquire
pathogenic elements in the peripheral tissues of the body, and then undergo a maturation process
while they travel to the secondary lymphoid organs (such as spleen, lymph nodes, and Peyer's
patches). There they display pathogen-derived antigens at their surfaces for inspection by T
lymphocytes and other cells (see Figure 1-2). Each T cell has receptors specific for a single
antigenic epitope, receptors whose population diversity is kept high by somatic recombination of
multiple germ-line elements during cell development (1, 8). Because of this random generation
and great diversity, few (typically on the order of I in 10' (9, 10) or fewer) T cells have receptors
cognate to any given antigen, and these cells must rapidly find a DC presenting said antigen in
order to initiate a primary immune response in a timely and effective manner. Naive T cells -
cells that have not previously encountered antigen - constitutively circulate between the blood
and lymph nodes in turn, entering the lymphoid tissue via high endothelial venules (HEV) (11).
If they are not stimulated, most na've T cells will eventually die, because they compete for a
limited pool of survival-maintaining cytokines (1, 12). DCs are the only antigen-presenting cells
capable of activating naYve T cells, due perhaps to such factors as their very high level of co-
stimulatory molecules (13).
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Figure 1-2 Schematic of events in the primary immune response. Dendritic cells encounter
pathogens in peripheral tissues such as skin, ingest and break them up into small surface-
presented antigens, and then travel to the lymph nodes. NaYve T cells emerge from venules (blue
line) into the T zone of the lymph node, where they encounter DCs that may activate them.
Upon activation by antigen-bearing DCs, many naive T cells become effector cells, i.e., cells
that effect the elimination of the invading pathogen. CD8' cytolitic/cytotoxic T cells do this by
lysing pathogen-infected cells (14). CD4' helper T cells perform helper (stimulation) functions
for cells such as antibody-secreting B cells and CD8' T cells, by secreting cytokines as well by
direct cell-cell contact (15). Eventually the effector cells die, but a small fraction of activated
naive cells also become long-lived memory cells. Immune responses to previously encountered
pathogens are more rapid and more effective, due to the continued presence of these memory
cells (16). In our work, we focused on studying naive as well as activated CD4÷ T cells, due to
their central role in interacting with multiple immune cell types.
In the past few years, imaging of lymph nodes in live anesthetized mice (intravital
microscopy) has given a new window into the behavior of immune cells during both resting and
immune-activated conditions. Both CD4' and CD8÷ T cells rapidly migrate throughout the lymph
nodes at ~ 10 [tm/min on average, and contact DCs for ~ 3 min. per encounter in the absence of
antigenic stimulation (10, 17). DCs themselves move at only 2-3 [tm/min on average and are
largely present as a stationary network, though their extensive dendrites increase their effective
cell size (6, 17). Together, these factors mean that each DC can encounter 500-5000 naive T cells
per hour (10, 17).
The above studies have shown that T cell migration specifically is one key element in the
success of primary immune responses. Several aspects of the lymph node microenvironment,
including architecture (see section 1.1.1), cellular organization, and soluble signaling molecules
(see section 1.1.3), are also likely to promote efficient and effective immune responses, some of
them via influencing cell migration. We were thus interested in recreating some of these
important factors in an artificial lymphoid microenvironment, and measuring the resulting T cell
migration responses. Variation of environmental parameters coupled with migration assessments
served both as a study of how microenvironmental cues influence T cell migration, and helped to
determine the utility of a given synthetic scaffold for immune-based therapies.
1. 1.3 Role of chemokines in lymphoid organ development and function
Cytokines are soluble (or surface-presented) polypeptides involved in cell communication: one
cell type secretes (or presents) a cytokine in order to influence the behavior of target cells (of the
same or another lineage) that express a receptor for that cytokine. Binding of a cytokine ligand to
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its target receptor may result in cell proliferation, differentiation, or act as a survival cue, to give
a few common functions of cytokines (18). Cytokines are particularly abundant in the lymphoid
system - there exists a large sub-class called interleukins - and chemokines are an important
class of cytokines that affect cell migration (19, 20).
Several chemokines are constitutively produced in the secondary lymphoid organs, and are
thus known as homeostatic lymphoid chemokines. These include CXCL13 in the B cell areas of
lymph nodes, and CXCL12, CCL19 and CCL21 in the T cell areas (see Figure 1-3). T cells (and
to some extent B cells) express the CCR7 receptor, which binds both CCL19 and CCL21, while
only B cells express the CXCL13-binding receptor CXCR5. CCL21 and CCL 19 are strong
inducers of T cell chemotaxis, that is, T cells will follow a gradient of increasing chemokine
concentration (21), and CXCL13 has similar effects on B cells (22). Upon activation, B cells
upregulate CCR7 and subsequently travel to the border between the T cell and B cell zones in the
lymph node to receive T cell help (23). Similarly, DCs that have been stimulated to mature (e.g.,
by an encounter with pathogen) upregulate CCR7 and become responsive to CCL19/21. This
causes the DCs to travel from peripheral tissues to lymph nodes where they can activate T cells.
(U)
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Figure 1-3 Homeostatic chemokine expression in lymph nodes. Luther et al. performed in situ
hybridization experiments on lymph node sections to test for localization of different chemokines
(24). (A) The T cell zone - marked 't' - includes many cells staining for CCL21 (also called
SLC) and/or CCL19 (ELC). (B) In the B cell-rich follicles - marked 'f' - there is little to no
staining for CCL21 and CCL19.
These three chemokines - CCL21, CCL19, and CXCL13 - thus appear to be involved in
homing of lymphocytes and dendritic cells to their respective compartments in the lymphoid
organs, and this is true under not only activated but also under homeostatic and developmental
conditions (23, 25). The latter is evidenced by studies with knockout mice lacking the genes for
CCR7, CCL19, or CCL21: such mice have disrupted lymphoid architecture and cellular
composition (24, 26). Murine CXCR5 and CXCL13 knockouts have more severe defects,
including the lack of some types of lymph nodes (27).
In addition to their role in cell homing in the adult, lymphoid chemokines also play a role in
lymphoid organogenesis, downstream of lymphotoxin (LT). Mice lacking the genes for the LTct
or LTI3 chains, or the LTI receptor, develop few or even none of their secondary lymphoid
organs (28-31), which may be compared to the less severe effects of T zone chemokine deletion.
In the developing Peyer's patches (lymphoid tissue nodules that line the small intestine),
interactions between LT-P receptors on stromal cells and LT-presenting 'inducer' cells cause the
secretion of chemokines such as CCL21 by stromal cells, which in turn influences lymphocyte
development (32); similar processes are believed to occur in lymph nodes (33). Transgenic
expression of members of both the lymphotoxin and lymphoid chemokine families has been
attempted in several cell types, and causes varying degrees of neotissue development (34-36).
For example, induced expression of CCL21 in pancreatic islet cells is enough to stimulate
formation of 'tertiary' lymphoid tissues with organized cell compartments in the pancreas within
six weeks after birth (36-38).
Although cytokines and cells involved in homing and development have been relatively
well-defined, much less is known about what signals affect homeostatic migration of cells,
particularly naive T lymphocytes, once they reach the lymph nodes during normal circulation
(39). An in vitro model of lymphoid tissue could be used to test the effect of different soluble
factors in a 3D tissue-like environment, in which the type and concentration of chemokine may
be defined and varied at will, as can physical factors such as cell density and pore size.
While an in vitro model of lymph nodes could be used to dissect microenvironmental cues
governing lymph node function, it might also be useful as an in vivo platform for
immunotherapy, particularly in concert with soluble signals such as chemokines. Chemokines
have at least two qualities - promotion of lymphoid cell chemoattraction and of lymphoid
neotissue development - which may be useful in immunotherapies, as described below.
1.2 New strategies in cancer immunotherapies
Understanding and manipulating the immune response to tumors could assist in development of
new cancer therapies. Many tumors display weakly immunogenic antigens that stimulate an
incomplete adaptive immune response, causing an influx of tumor-infiltrating lymphocytes
(TILs). The presence of TILs correlates with increased survival in many cancers, including
ovarian (40), as well as breast, bladder, and prostate (41). In the second most lethal cancer -
colorectal (42) - the number (and type) of invading immune cells has been shown to correlate
positively with duration of patient survival, and to predict survival better than the current
histopathological standard (43). Thus, the adaptive immune response to transformed cells does
appear to have some ability to eradicate tumors.
However, cancers also can employ a variety of strategies that cause immune suppression or
immune ignorance. These methods include recruitment of immunosuppressive T regulatory cells,
tumor secretion of immunosuppressive factors such as TGFI3, tumor cell downregulation of
'recognizable' elements such as MHC, and the tumor stroma as a physical barrier (44). To take a
specific instance, tumor cells can modulate the surrounding cytokine environment to halt the
maturation of antigen-presenting cells such as DCs, which upon encountering T cells will then
render them tolerant to tumor antigens rather than active against them (45). Somewhat
paradoxically, several aspects of the innate immune response can worsen cancer (46): chronic
inflammation due to innate immune cell infiltrates and inflammatory cytokines can promote
immunosuppression, and cancer can both cause and be exacerbated by such persistant
inflammation (47). Combating or evading immunosuppression while boosting the specific,
adaptive immune response against tumor antigens is thus a desired goal in immunotherapy (44,
48).
One method of enhancing immune function may be to stimulate the de novo formation of
organized lymphoid tissue, since the architecture and cell compartmentalization in secondary
lymphoid organs is believed to make immune responses highly efficient (2, 3, 49). As described
in section 1.1.3, a number of cytokines play a role in progressive stages of immune
organogenesis or neogenesis, including those in the lymphotoxin and chemokine families.
Although lymphoid neogenesis in previously healthy adults is associated with certain
pathologies, particularly of the autoimmune and chronic inflammation variety (50, 51), studies of
cytokine targeting or cell transfection in tumors have indicated a therapeutic role for the
formation of lymphoid-like tissue proximate to a cancerous mass.
In one study, targeting of LTa to murine pulmonary and subcutaneous tumors effectively
eliminated them, and resulted in large T cell and other immune cell infiltrates at the tumor site
(52). Alternatively, tumor cells can themselves be harnessed to create a lymphoid-like
environment by genetic modification. For example, tumor stromal cells that were transfected
with LIGHT (homologous to Lymphotoxins, exhibits Inducible expression, and competes with
HSV Glycoprotein D for HVEM, a receptor expressed by I lymphocytes), a cytokine ligand for
LTi3 receptor, stimulated invading stromal cells to express CCL21 as well as lymphoid tissue-
associated adhesion molecules, resulting in T cell infiltrates that fought the tumor (53). Finally,
chemokines themselves have been directly injected at tumor sites. CCL21 injection in a lung
mouse model caused notable tumor regression/eradication, an increase in immune cell infiltrates
in the tumor, and a decrease in immunosuppressive cytokines typically associated with tumors
(54). CCL21 transfection of tumor cells has also been attempted, and the authors showed that in
that case one operating anti-tumor mechanism was inhibition of angiogenesis (55).
We believe that CCL21 in particular may be an ideal candidate for immunotherapy, for the
above-mentioned reasons - ability to combat immunosuppression, angiostatic activity in mice -
as well as others. This chemokine attracts both naive T cells and mature dendritic cells (DCs),
and causes a greater ratio of naive:memory T cells than does LTa when ectopically expressed in
pancreas (35, 36). This is beneficial because only naive cells can respond to a new antigen, while
the attracted memory cells may have already been primed against an irrelevant (i.e., not a tumor)
antigen. CCL21 also attracts CD4' and CD8÷ cells nearly equally (21, 56), which is desirable
since CD8' cells need helper functions provided by CD4÷ T cells for the strongest response
possible (57).
Due to the short half-life of injected proteins such as CCL21 in vivo, they have to be injected
frequently (e.g., every other day) to have a lasting effect. This is both expensive and undesirable
for patient compliance. Further, systemic injections of cytokines may cause unintended side
effects, while frequent injection directly at a tumor site can only be performed in cases where the
tumor is near enough to the skin surface. Injection at deeper tumor sites (e.g., during resection)
can realistically only be performed rarely, due to the invasiveness of the procedure. As an
alternative, delivery to a tumor site of cells that transgenically express a needed protein would
seem to alleviate some of these problems, by providing an inexhaustible supply of chemokine.
However, this strategy comes with all the risks of gene therapy (such as stimulating new tumors
to form) (58), as well as the labor and expense of creating a transfected cell line.
Due to the drawbacks and complications described above, we became interested in the
development of strategies to synthetically induce the de novo formation of tertiary lymphoid
tissue at ectopic sites via implantable scaffolds that release chemokine in a controlled fashion
(see Figure 1-4). These could be used both as a potential therapeutic strategy for the treatment of
solid tumors, and as a tool to understand cues controlling ectopic lymphoid tissue formation or
other basic questions in immune biology. Such a strategy has certain advantages, in that a
scaffold could simultaneously provide release of biological factors (such as CCL21) and provide
a defined space and suitable architecture for cell interactions, which may be more effective than
merely injecting both cells and soluble factors. This approach could be combined with adoptive
transfer therapies by pre-loading the scaffold with tumor-specific cells expanded ex vivo, or be
used simply to attract cells already within the body. One disadvantage of this system, however, is
that the chemokine may still be cleared too rapidly, as there is a limit to how much can be loaded
on the scaffold surfaces. Further, the invasiveness of the implantation procedure would limit it to
cases where operation at the tumor site is already required. Nevertheless, lymphoid scaffolds
may be useful in precisely such cases. In the following section, we describe our selection/design
rationale for producing lymphoid scaffolds.
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Figure 1-4 Schematic of immunotherapy approach. A porous scaffold (beige, with pores
outlined in black) that releases CCL21 (small red circles) could be implanted at a tumor site,
forming a chemokine gradient that attracts T cells and dendritic cells (large green circles). For
simplicity, the radially symmetric gradient is shown at only one side of the scaffold.
1.3 Materials selection for tissue engineering and tissue models
1.3.1 General considerations for biomaterials
The use of natural and artificial materials in biology and medicine has a long-standing history.
The three major classes of materials - polymers, ceramics, and metals - have all been used
successfully as biomaterials, and materials selection depends on the exact purpose at hand (59).
In the quintessential tissue engineering paradigm, a scaffold, usually porous, is loaded with cells
and/or soluble factors, implanted at a wound or disease site, and slowly degrades as it is replaced
with new cells and tissue (60-63). Hard tissues such as bone require scaffolds with mechanical
properties typical of metals and ceramics (and some hard polymers), while soft tissues such as
skin or cartilage may be more suitably replaced or guided by polymeric scaffolds.
In additional to mechanical properties, the exact chemical and especially biochemical
properties that are desired for a scaffold vary from application to application. One often wants to
support the viability and activity of one cell type - using appropriate adhesion ligands, soluble
growth factors, etc. - while excluding bacteria, the formation of blood clots that are dangerous to
the patient, and toxic and immunogenic elements. Collectively, the interaction of a material with
the body without causing harm is known as biocompatibility, while selective targeting of cells
and promotion of behaviors such as differentiation or adhesion is known as bioactivity.
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1.3.2 Polymeric hydrogels for tissue engineering
Both mechanical and chemical properties are readily altered in many polymer systems, by the
introduction of cross-linking reagents (or mechanically strong co-polymers) and labile moieties,
respectively. Polymeric hydrogels, which swell in water but remain insoluble, are particularly
attractive for tissue engineering: their high water content facilitates diffusion of aqueous
nutrients and oxygen throughout these structures, and mimics the permeability and mechanical
properties of natural soft tissues (64, 65). Hydrogels are typically formed under mild conditions
that do not require the use of organic solvents, meaning that there is no danger of residual toxins
from solvent sources causing damage to cells later. Both synthetic and natural hydrogels often
form quickly from liquids at room or physiological temperatures. For some applications,
hydrogels are favored for their ability to be mixed directly with cells and injected into arbitrarily
shaped wounds for in situ gelation (66-68).
Natural gel biopolymers used as biomaterials include alginate (an ion-complexed
polysacharride), other polysacharrides such as chitosan and hyaluronic acid, the peptide fibrin
that is involved in blood clotting, and the ECM gels collagen and gelatin (denatured collagen).
Each of these materials has certain advantages: the mechanical strength, gelation time, and
degradability of alginate can all be regulated by mixing of multiple alginate elements (69), fibrin
can be extracted from autologous sources (i.e., human serum) (65), and gelatin can be treated to
expose positive or negative surface charges for attachment of negatively or positively charged
proteins, respectively (70). However, most natural biopolymers suffer from poor mechanical
strength, possible immunogenicity due to derivation from xenologous sources, and a high degree
of variation between lots and even within a single gel (65). This variation makes the ultimate
behavior - such as degradation rate - difficult to predict (71).
Synthetic hydrogels have the advantage of both reproducibility and tuneability. Many such
hydrogels are made by photopolymerization chemistry, which offers the additional advantages of
spatial and temporal control of gelation, high conversion rates, and energy efficient production
(72). The main drawback of synthetics is that the biocompatibility of these materials and their
degradation products may be difficult to predict and must be carefully tested. The most common
photopolymerizable polymers studied for use in tissue engineering applications so far have been
poly(vinyl alcohol), poly(2-hydroxyethyl methacrylate), and poly(ethylene glycol), known as
PVA, poly(HEMA), and PEG, respectively (72-74).
PEG is a commonly used biomaterial, and has proven its biocompatability in some
applications well enough to meet FDA approval standards (65). One reason it is so attractive is
that PEG in a broad range of molecular weights and architectures exhibits a natural resistance to
protein adsorption and cell adhesion, likely due to steric interactions and its many non-covalent
(e.g., hydrogen) bonds with water (75). Otherwise inert PEG can be made bioactive by chemical
modification and conjugation of proteins or protein analogues. Dr. Jeffrey Hubbell's lab
pioneered the introduction of bioactivity into PEG gels made by radical chain polymerization of
PEG diacrylates. The bioactivity is introduced by co-polymerizing adhesive or enzyme-sensitive
peptides on PEG-monoacrylate (PEGA) tethers or as PEGA-peptide-PEGA blocks (76). The
introduction of specific bioactivity is desirable for targeting certain cell types. For example, the
PEG-tethered peptide RGD has been used to promote spreading and organization of osteoblasts
(67), and even to stimulate vascularization and connective tissue formation in vivo (77), while
PEG gels presenting the peptide VAPG are selective for smooth muscle cells while preventing
fibroblast and endothelial cell adhesion (78).
For these reasons, we focused on cross-linked PEG hydrogels in our studies. We initially
studied cell responses to peptide-modified gels similar to those described above, and later
developed a method for attaching whole adhesion proteins to PEG. In this method (further
explained in Ch. 4), biotinylated proteins were attached to biotin-containing scaffolds by using
streptavidin as a bridging molecule.
1.3.3 Fabrication strategies for porous scaffolds
Porosity at various length scales has been introduced in natural as well as artificial polymers, in
both hydrophilic hydrogels and more hydrophobic polymers. Pores are used to enhance diffusion
of nutrients, gases, and other biologically relevant compounds, as well as to allow cell loading or
ingrowth within a structure. Interconnectivity between pores is key for taking full advantage of
increased diffusion and space for cell development and interactions.
The polyesters poly(lactic acid) and poly(glycolic) acid, PLA and PGA, are perhaps the most
ubiquitous biomaterials used clinically to date (59). These hydrophobic polymers are typically
obtained in powdered form, dissolved in organic solvents, and made porous by methods such as
salt leaching, phase separation, gas foaming, and solid freeform fabrication. Co-polymers of PLA
and PGA are readily degradable on different time scales (based on the PLA:PGA ratio) with
metabolizable acidic byproducts. However, these polymers have the disadvantage of lacking
readily modifiable groups for attaching biological moieties.
For a soft tissue application, hydrogels are more suitable and attractive than PLA-co-PGA,
for the reasons described in the previous section. However, since much of the work on pore
formation has been done with hydrophobic polymers, pore-forming methods will first be
discussed in this context. Solid freeform fabrication was originally designed with such polymers
in mind. In a typical process, arbitrary 3D structures are created from loose powdered polymer
using a layer-by-layer approach. Each 2D layer is 'drawn' by the use of a binding solvent to
solidify the polymer particles (79). In recent years, some methods for analogous (layer-by-layer
or arbitrary freeform shape) fabrication of hydrogels have been developed, using light rather than
solvent. However, feature size and architecture is limited (resolution ~ 100 [tm, (80)). In a gas
foaming approach, carbon dioxide is dissolved in P(L)GA at high pressure, and pores
spontaneously form after inducing a pressure drop (81). Alone, this procedure causes a closed
pore structure, which for many applications is inadequate. However, gas foaming can be used in
combination with particulate leaching, which tends to improve interconnectivity (82). In
particulate leaching techniques, porogens such as salt or sugar crystals are used as a template on
which to cast polymer-solvent solutions (or are mixed directly with polymer particles) prior to
polymerization or fusion of the polymer, then removed by addition of water or another
appropriate solvent (83, 84). Depending on the weight fraction of salt and other factors, pores
may or may not be interconnected. Ways to increase connectivity in such techniques were
recently developed: Murphy et al. fused salt crystals together using a humidified atmosphere
prior to casting polymer on the template (85), and Ma et al. exposed paraffin sphere templates to
high temperatures to melt the spheres together prior to casting of PLA-co-PGA (and then sphere
removal by dissolution in organic solvents) (86).
We took our inspiration from salt leaching techniques because of their simplicity and cost-
effectiveness, but wanted to develop a method more suitable for hydrogels. The literature for
creating porous hydrogels is less vast than that for hydrophobic polymers, perhaps due to the
already good diffusion properties of water-swollen polymers, the fact that some cells may be
encapsulated and grown directly in hydrogels without causing them harm, and also because of
the relatively weak mechanical properties of even bulk hydrogels. However, in some cases the
lack of macroporosity in typical hydrogel networks may be an impediment to cellular invasion
and neovascularization in vivo, even when the gel is designed with cross-links that may be
cleaved by migrating cells. Porous hydrogels have been made by three primary methods:
temperature-induced phase separation (87), templating by solid materials (e.g., fibers) (88, 89),
and the use of foaming agents such as carbonates and organic solvents (90). For drug release and
other applications, macroporous hydrogel foams have been made using porogens/foaming agents
to create highly absorbent structures (91, 92). These foams typically have pores in the 100's of
p~m, and a high porosity and swelling ratio. However, we were interested in mimicking the 10's
of [tm scale of the reticular network (see section 1.1.1) with a less swellable and more
mechanically strong construct. Further, we were interested in specifying the interconnected
architecture exactly, so that all pores would be connected to their neighbors.
In order to achieve such a pore structure, we applied the process of colloidal crystal
templating to length scales and materials suitable for tissue engineering. This templating method
has previously been used to create ordered arrays of pores at the submicron scale in dieletric
materials for photonics applications such as waveguides (93). Two materials are required for this
method: particles of an appropriate size that can be arranged into a crystalline array, and the
scaffold material that is to comprise the final porous structure. The particles must be removable
from the scaffold by solvent etching, calcination, or other techniques. The scaffold material,
meanwhile, must be able to coat the template, but then to become stable and hold its shape (e.g.,
to undergo a liquid to solid transition after addition to the template). The details of colloidal
crystal templating are further described in Chapter 2.
1.3.4 Cytokine delivery within scaffolds
A key part of a given biological microenvironment is the presence of soluble factors, such as
growth factors and chemokines. In fact, about 12% of genes with known function in the human
genome are used for cell signaling and intercellular communication (94). As described earlier
(see section 1.2), we hypothesized that delivery of the chemokine CCL21 from a scaffold could
promote ectopic lymphoid tissue formation if implanted at a tumor site. Having chosen a
material and pore-forming method for such a scaffold, we considered strategies to incorporate
cytokines. As with pore formation, the introduction of cytokines into a scaffold system has been
accomplished using a wide variety of methods (reviewed in (95-98)).
Three main categories of growth factor incorporation in porous polymer scaffolds may be
described: direct mixing of growth factor with polymer, surface attachment of growth factor to
polymer, and release of growth factor from a separate delivery device (e.g., microspheres) loaded
in the porous matrix. Dr. David Mooney's group alone has explored several strategies for the
incorporation of the angiogenesis-promoting factor VEGF in hydrophobic polymers, such as
direct mixing with PLGA polymer (99), addition to a mixture of PLGA and alginate to improve
protein incorporation efficiency and stability (100), and release from PLGA microspheres within
PLGA scaffolds to improve temporal control over release (101). In any delivery system, the
method of incorporation may affect how well the bioactivity of the protein is maintained, as well
how predictably its release rates can be controlled.
In our case, direct mixing of the cytokine with the polymer was unlikely to work. Although
most proteins can survive the short UV exposure required for photopolymerization, in our
fabrication strategy the gel solidification is followed by template leaching in pure acetic acid
(described in Ch. 2). This high concentration of acid may denature proteins, or some protein may
escape the scaffold and dissolve in the large amount of solvent. Both surface attachment and
microsphere release of growth factor, however, should be feasible in our scaffolds. To reduce the
components in the system, we began by pursuing surface attachment of chemokine to the cross-
linked PEG gels.
PEG gels in non-porous form have been previously studied as growth factor release vehicles
by a few groups. For instance, Mann and West reported that PEG-tethered TGF-P (transforming
growth factor P) increased matrix production by encapsulated cells better than unmodified TGF-
p that was merely physically trapped in PEG hydrogels (102). Gobin and West found similarly
good functionality of PEG-tethered EGF (epidermal growth factor) released from degradable
hydrogel matrices (103). However, this method might not be expected to work for all cytokines,
since chemical modification may destabilize the protein structure or mask the relevant epitope
for interaction. One promising strategy for retaining long-term release and functionality using
untouched proteins is the inclusion of heparin, which has specific interactions with many
molecules of interest. Researchers have implemented a number of strategies to incorporate
heparin in gels and in scaffolds, demonstrating that both covalent and non-covalent interactions
can prove useful (104-107). Using a PEG-based system, Pratt et al. directly encapsulated BMP-2
(bone morphogenetic protein 2) in hydrogels (77), or instead bound heparin and BMP-2 to the
PEG matrix via inclusion of a co-polymerized heparin-binding peptide (108), and found that the
presence of heparin improved cytokine activity.
The molecules we are interested in delivering to a specified site, namely chemokines, are
known to anchor reversibly to ECM and cell surfaces by binding to heparan sulfate, and have
been shown in vitro to bind to its analogue heparin (109, 110). CCL21 has especially strong
binding to the anionic polymer heparin, due to the chemokine's strong net positive charge at
neutral pH (111-114). However, we would expect this ionic complex to dissociate and thus for
the scaffold to slowly release CCL21 over time, as the dissociation constant KD for CCL21-
heparin is estimated to be ~ 5 nM (112). It is also possible that surface-bound chemokine may
have an effect on cell migration even if it is not released, as has been shown for some
chemokines presented by endothelial cells (or cell-mimetic synthetic surfaces) to T cells (25,
115). We thus attached heparin to the surfaces of PEG macroporous hydrogels and used this
biopolymer to sequester CCL21 for delivery to cells.
1.3.5 Summary of lymphoid scaffold design
As discussed above, scaffolds for tissue modeling or tissue engineering platforms must fulfill
several criteria: biocompatibility, mechanical integrity, as well as high interconnectivity of pores
for cell migration and nutrient diffusion. Besides these generalized criteria, scaffolds must also
meet the demands of the application at hand. We hypothesized that several key features of the
lymph node microenvironment would need to be recapitulated in order for successful use as a
therapeutic or modeling construct, as defined by cell viability, migratory capacity, and efficient
interactions. Namely, we proposed to model the unique macroporous architecture, cellular
composition, and ECM or integrin ligands presented in the lymph node, and to study the effects
of systematic variation of these parameters.
For this effort, we decided to develop and implement a novel templating method for
fabricating macroporous hydrogels. We chose PEG as the primary material component due to its
protein-resistant properties, ability to be quickly undergo gelation via photopolymerization, and
ease of chemical modification. This final property makes for ready incorporation of specific
bioactivity by co-polymerization as well as post-polymerization modifications. In order to create
highly interconnected pores in a hydrogel, we planned to modify the typical particulate leaching
paradigm by creating ordered arrays of pores rather than relying on random arrangements of the
templating material. We planned to achieve this by creating colloidal crystal templates from
polymer microspheres with diameters on the 10's of [tm scale. Over the course of this project,
several iterations of scaffolds were made: peptide-modified, protein-modified, composite
scaffolds filled with collagen gel, and finally scaffolds for chemokine delivery. By creating
macroporous gels that could be modified with adhesion and signaling proteins, we sought to
mimic the architecture and biochemical composition of the lymph node.
1.4 Lymphoid scaffolds: motivation and significance
Two types of applications for lymphoid scaffolds may be envisioned: those that use an in vitro
tissue model to study fundamental questions in immune biology, and those that intend to
ultimately make scaffolds effective in clinical therapies.
We initially focused on the first goal. In particular, we were interested in the role of the
lymphoid microenvironment in shaping T cell migration and the kinetics of priming by DCs.
Several years ago, these signals were not well-defined, and a systematic study in an in vitro
model seemed a promising approach. Specifically, factors affecting migration within lymph
nodes were far less well understood than those that drive homing to lymph nodes. Very recently,
intravital microscopy of murine lymph nodes, in concert with the ever-growing development of
transgenic mouse models, has shed light on several of the questions we intended to study. For
example, we originally proposed to investigate what migration strategies T cells use to sample
dendritic cells for antigen, by creating environments where we defined the relative numbers of
polyclonal T cells, antigen-specific T cells, antigen-bearing DCs, and DCs lacking antigen. Such
ratios could long be defined in vivo by adoptive transfer strategies, but only recently could they
also be imaged in live animals. In 2003, Miller et al. showed that basal T cell migration appears
random, and that the search for antigen occurs by a stochastic process (116). Some have
hypothesized that cell organization, particularly placement of incoming antigen-bearing DCs
near HEVs (which is also where T cells enter lymph nodes) helps to make random sampling
efficient enough to promote immune responses (117). In contrast to the random migration
hypothesis, more recently Dr. Ronald Germain's group has shown that small localized
chemokine gradients can influence cell migration to an extent, because CD8÷ T cells are attracted
to antigen-presenting DCs more than would be expected by chance if CD4÷ T cells are also
present (118). At this stage, the remaining questions in T cell migration are subtle and involve
the simultaneous tracking of many cell populations, which can only reasonably be done by 2-
photon microscopy, whether in vivo or in vitro.
Although we perceived a diminished need for an in vitro model, one could imagine such a
construct nevertheless being useful for studies of human immune cells, which clearly cannot be
studied by intravital methods. However, the second issue faced during the course of this project
was design complexity, and subsequent lack of reproducibility. Despite the complexity of the
multi-step fabrication process, the model was still quite simplified compared to a real lymph
node, and further modifications were likely to result in further compromised reproducibility.
Despite these setbacks, it became clear that our scaffold system could be well-suited to use in
tissue engineering for immunotherapy (see section 1.2). Immune-based therapeutics are a
promising area of research, and constructs that boost immunity during cancer are particularly of
interest. As an alternative to cytokine injection and targeting methods, we pursued a scaffold-
based method for creating an environment supportive of robust T cell migration. Suematsu et al.
were the first to describe and carry-out a scaffold-based lymphoid tissue-engineering strategy in
2004; however, at present their system appears to require delivery of genetically engineered
stromal cells in order to have lymphoid induction properties (119, 120). Our scaffold system
represents an attempt at developing a lymphoid tissue engineering system free of all but
autologous cells.
In the immunotherapy framework, some requirements on the scaffold would be relaxed while
other new ones would arise. Specifically, the need for exact mimicry of the lymph node T zone
would be reduced. Rather, we would create an intermediate-stage scaffold meant to induce
further modifications in its surrounding environment, resulting finally in a lymph node-like
structure. We maintained our goal of studying T cell migration in varying microenvironments,
but now allowed the means toward the end result of robust migration to be less mimetic. Thus,
rather than attempting to find the protein-cell combinations and densities that could allow
migration in an open porous architecture similar to the reticular network, we ultimately used the
well-known migration substrate collagen to make a composite scaffold. In this structure, collagen
was infused in the porous PEG-based hydrogel and then heated to form a fibrillar gel. Such
tightly woven collagen nanofibers are uncharacteristic of the T zone area of the lymph node, thus
reducing the mimetic properties we originally envisioned, but can support T cell migration and
priming. Meanwhile, the porous scaffold provided superior mechanical properties compared to
collagen alone, as well as the potential for cytokine delivery.
Besides the composite structure, the main novel aspect we introduced for tissue engineering
(as opposed to in vitro model) scaffolds was the incorporation of motility factors onto the
scaffold surface. As described in section 1.2, scaffolds for immunotherapy could be used with
adoptively transferred cells, whose motility and function should be maintained by an appropriate
microenvironment, and attracting host cells to the scaffold could be desired as well. Delivery of
CCL21 would be ideal in this type of application, because CCL21 can stimulate both chemotaxis
(for attracting new cells) and also, as we discovered, potent chemokinesis (for sustained
migration of cells initially placed within the construct), along with playing a role in formation of
neotissues (see sections 1.1.3, 1.2, and Chapter 3). One new requirement that we did not yet
address in more than a preliminary way is that of degradability; that is, most of the work was
done with non-degradable scaffolds intended for an in vitro model, and for comparison purposes
,this was continued throughout the entire thesis. However, minor modifications to the scaffold
.chemistry could be made in the future by co-polymerization of enzyme-sensitive linkage; these
peptide fragments would allow the polymer network to be degraded by natural proteases (76).
At this time, we showed that our scaffolds are a supportive environment for T cell migration,
.and performed some initial studies demonstrating dendritic cell and stromal cell spreading and
viability in these constructs. In the future, cell invasion studies and more complete determination
• of chemokine delivery parameters should be performed, followed by in vivo studies of
functionality.
1.5 Overall Objectives and Specific Aims
The purpose of this thesis was to design and fabricate a novel scaffold appropriate for lymph
node tissue engineering, and to perform some initial studies of lymphoid cell behavior in this
model lymph node T zone construct. The revised specific aims were as follows:
1) Develop porous polymeric scaffold for model T zone.
a. Select appropriate materials and design and implement a fabrication process.
b. Characterize the morphology and mechanical properties of the resulting scaffold.
2) Study factors that are known to influence T cell motility.
a. Determine effect of homeostatic chemokines on lymphocytes interacting with 2D
substrates, with or without adhesion proteins.
b. Study whether chemokines have an ultimate effect on T cell activation.
3) Integrate lymphoid cells into scaffold.
a. Develop cell loading procedures for T cells, DCs, and fibroblasts.
b. Examine response of cells to scaffold and improve design accordingly.
4) Carry out a systematic study of scaffold parameters on T cell motility.
a. Determine effect of coating scaffold with two important protein ligands.
b. Study effect of pore size in final chosen (composite) scaffold construct.
5) Develop initial system for releasing chemokine from the scaffold.
The above experiments would be a first step in investigating what types of scaffolds are
appropriate for lymphoid tissue engineering, and in determining what factors may best be
exploited in a 3D environment to influence T cell motility.
2 Development of inverse opal scaffolds for model lymph
node 'T zone'
2. 1 Introduction
For the reasons outlined in section 1.3.2, hydrogels are a class of materials well-suited for
engineering soft tissues with a high water content, including lymphoid tissues. Briefly, hydrogels
mimic the elasticity and permeability of such tissues, and also are easily conjugated with
functional moieties. In particular, protein-resistant PEGs that are modified with peptides or other
bioactive signals provide a flexible platform for developing tissue engineering strategies. Such
gels have been used to encapsulate cells and growth factors for cartilage and other tissue
engineering applications (66, 67, 77, 78, 121, 122), as well as for models of cell migration (103,
122).
An encapsulation strategy may not be appropriate for all cells and tissues, however. These
bioactive PEG gels have primarily been made using radical photopolymerization, and toxicity to
cells varies both with photoinitiator used (and its concentration) and the cell type (123, 124). In
our experience with lymphocytes, they are sensitive to even mildly cytotoxic compounds (e.g.,
some fluorescent dyes) and viability of gel-encapsulated lymphocytes might be difficult to
maintain. Further, unlike many soft tissues that have a dense ECM, the reticular networks of
secondary lymphoid organs comprise a loosely woven fibrous network; we were initially
interested in mimicking this macroporous architecture (see section 1.1.1). Finally, despite the
relatively good diffusivity within water-swollen hydrogels, diffusion of nutrients and oxygen
could be further improved by the introduction of porosity.
Altogether, bioactive hydrogels having a cellular structure of interconnecting macropores
would be attractive scaffolds for drug delivery and tissue engineering, by combining tissue-like
elasticity with enhanced pathways for mass transport and cell migration (64, 125-127). However,
to obtain high degrees of pore interconnectivity using available stochastic porogen methods
(developed primarily for hydrophobic thermoplastic polymers), void fractions exceeding 95%
must be introduced (85, 99, 128, 129). This high porosity causes severe deterioration of the
polymer's mechanical properties, such that only a limited selection of stiff materials can be
utilized and still maintain tissue-like moduli after processing (126, 130). In this chapter we
describe the development of a method to prepare soft hydrogels with interconnected porosity at
moderate (- 65%) void fractions, thus maintaining compressive stiffnesses comparable to native
tissues. This was achieved by fabricating gels with ordered, interconnected macrovoids (20-60
p.m diameter) via colloidal crystal templating.
Colloidal crystal templating has been extensively applied in the field of photonics to fabricate
materials with periodic variations in refractive index, as well as in membranes, chromatography
media, and solid-phase catalysis substrates (131-134). The colloidal template is comprised of a
crystalline arrangement of monodisperse microspheres (typically silica or polystyrene), which
can be used as an extractable template for the fabrication of inorganics, metals, or polymers
having close-packed voids of ~0.05-5 ptm diameter (commonly referred to as inverse opal
structures). Such structures have features which, if adapted to appropriate length scales, would be
of great interest as scaffolds for tissue engineering: a monodisperse open cellular structure;
potentially perfect, ordered connectivity between voids; and improved mechanical properties
compared to more porous (and typically less interconnected) structures generated by stochastic
porogen methods.
Two ubiquitous biomaterials, cross-linked poly(ethylene glycol) and gelatin, were templated.
As described above and in section 1.3.2, bioactive PEG gels have been extensively used in tissue
engineering and drug delivery applications, but to our knowledge always in solid gel form thus
far. Gelatin has the same attractive properties of hydrogels that synthetic PEGs have, and unlike
PEG, it has inherent bioactivity and biodegradability. It also has inferior mechanical properties
and other drawbacks (as described in section 1.3.2), but nevertheless is useful as a biomaterial,
particularly for drug delivery (70). The generality of the colloidal templating approach should
make it applicable to materials of interest for a broad range of bioengineering applications.
Preliminary experiments that we conducted to examine cell behavior in these novel scaffolds
utilized PEG gels modified with RGD peptide. However, since this most commonly investigated
adhesion sequence was of no use for most subsets of lymphoid cells, we later developed methods
to attach whole proteins to the scaffolds. The studies of cell responses to these scaffolds are
described in Chapter 4.
2.2 Materials and Methods
2.2.1 Preparation of colloidal crystal templates
A suspension of monodisperse poly(methyl methacrylate) (PMMA) microspheres (Fluka) was
concentrated to ~65% solids in 70% aqueous ethanol. The microsphere suspension (30-50 [IL
total in 2-3 additions) was deposited in 4.8 mm diameter poly(dimethyl siloxane) wells adhered
to glass slides, and agitated until dry (2-4 h) at 400-450 rpm on a 3/8 inch orbit shaker (IKA) at
20 'C. Partially ordered templates were then resuspended a second time directly in the wells, and
shaken/dried to form well-ordered crystals. A range of microsphere concentrations and shaker
speeds was acceptable for forming crystals; the above text describes the method we used most
recently that gave the most consistent results.
2.2.2 Preparation of sintered templates
PMMA templates were prepared per section 2.2.1, then placed in a pre-heated oven (200 oC) for
0, 8, 16, or 24 h. To avoid melting under force of gravity in any one direction for too long,
scaffolds were turned five times at near-equal time intervals, such that they melted first with the
coverslip face down, and once resting on each of the four edges of the coverslip.
2.2.3 Preparation of PEG scaffolds
Chemicals were from Sigma-Aldrich and used as received unless otherwise noted. A hydrogel
precursor solution was prepared containing 20 % (w/v) PEG dimethacrylate (PEGDMA, 1000
Da, Polysciences), 0.15 M triethylamine, and 0.8 % hexyl phenyl ketone photoinitiator in 3:1
(v/v) pH 7.4 HEPES buffer (4-(2-hydroxyethyl)piperazine-l-ethansulfonic acid-buffered saline)
and ethanol. The precursor (10-12 ýtL) was gently pipetted onto a colloidal template, perfused by
centrifugation (2 min, 1500 rpm), and exposed to UV light (365 nm, 12 mW/cm 2) for 90 seconds
to polymerize the liquid into a gel. The polymerized construct was transferred to acetic acid to
dissolve the microspheres over 48 hrs, to phosphate-buffered saline pH 7.4 (PBS) for 24 h, then
briefly sterilized in 70% aqueous ethanol and finally equilibrated in sterile PBS. The final
synthesis conditions we chose were described above; however, some experiments were
performed with 875 Da PEG, varying concentrations of ethanol, and/or 2,2-dimethyl-2-phenyl-
acetophenone as the radical initiator.
2.2.4 Preparation of functional PEG scaffolds
Fluorescent scaffolds were prepared by including 0.003 wt % methacryloxethyl thiocarbonyl
rhodamine (Polysciences) in the gel precursor solution. To prepare peptide-containing bioactive
scaffolds, hydrogel precursor solution containing 1:160 mol:mol RGD-PEGA:PEGDMA was
polymerized around colloidal crystal templates as before. Peptide-modified PEG acrylates
(RGD-PEGA) were prepared by reacting 0.5 molar excess acryloyl-PEG-N-hydroxy-succinimide
(PEGA-NHS, 3400 Da, Nektar Therapeutics) with the adhesion peptide (135) GWGRGDSP or a
control peptide GWGRDGSP (MIT Biopolymers Laboratory) in 0.1 M sodium bicarbonate
buffer (pH 8.3) for 2 h at 20 oC, then dialyzing overnight to remove excess PEGA-NHS (3500
Da cutoff dialysis cassettes, Pierce) (122). Finally, the RGD-PEGA was filtered, lyophilized,
resuspended at -40 mg/mL, and stored at -20 oC.
2.2.5 Preparation of scaffolds for SEM
PEG scaffolds were serially dehydrated (10, 25, 50, 75, and 90% ethanol at 10 min each; 100%
overnight), razor-cut, and observed using a LEO VP-438 at 5kV. Gelatin scaffolds were frozen
in liquid nitrogen, fractured, and lyophilized for 24 h prior to observation with a LEO VP-438,
which was used in variable pressure mode (20 Pa) at 20 kV.
2.2.6 Confocal microscopy
Fluorescent scaffolds were observed using a Zeiss LSM 510 with either a 40X Apochromat
water-corrected objective, or a 40X Acroplan water-immersion objective.
2.2.7 Mechanical properties testing:
Compressive moduli of hydrated PEG and gelatin scaffolds were measured at a constant strain
rate (5 [tm/s) using a precision motor stage (Micromechanics, UK) and a 25 g load cell
(Transducer Techniques, CA). Data is reported as mean ± standard error for three scaffolds per
condition.
2.2.8 Preparation of gelatin scaffolds
PMMA templates were heated to 70 oC and pre-wet with 70% ethanol, after which gelatin
solution at 70 'C (Sigma Type A, ~ 300 Bloom, 200 mg/mL, prepared in 25% aqueous ethanol)
was immediately added and perfused by centrifugation (5 min, 2000 rpm, 30 oC). After cooling
to room temperature for 30 minutes, gels were flash frozen in liquid nitrogen and lyophilized
overnight. Dehydrated gels were then treated with EDC and NHS (0.20 mM N-Ethyl-N'-(3-
dimethylaminopropyl)carbodiimide and 0.07 mM N-hydroxysuccinimide for 3 hrs at 20 oC) to
form covalent cross-links that remain stable during template dissolution (136). After the PMMA
template was dissolved in acetic acid, the construct was rinsed and equilibrated in PBS pH 7.4.
2.2.9 Observation of scaffolds made using sintered templates
Fluorescent scaffolds were prepared as usual from the sintered templates, then observed on a
Zeiss LSM 510 confocal microscope using a water-immersion objective (0.8 numerical
aperture). Five 210x210x-70 [tm 3D fields were observed per scaffold, with successive z-plane
images collected at ~1 tm increments. Each field was observed in Volocity software
(Improvision, Inc.), and throat pore diameters were quantified by observation of the y-z plane at
the x location that gave the smallest pore diameter for any given pore. Two independent
experiments were performed with similar results, examining 70-100 pores per scaffold.
2.3 Results
2.3.1 Scaffold development: materials and fabrication
As a basis to develop a porous artificial lymphoid tissue construct, we used a synthesis pioneered
by West and Hubbell for solid gels (76), in which PEG diacrylates are co-polymerized with
peptide-PEG monoacrylates in order to present tethered adhesion sequences (see Figure 2-1).
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Figure 2-1 Schematic of hydrogel polymerization chemistry. PEG-monoacrylates conjugated
to adhesion peptides such as RGD were copolymerized with PEG-dimethacrylate (PEGDMA) to
form a cross-linked PEG gel network with surface adhesion peptide presentation.
Several changes were made to the original protocol developed by West. First, a lower
molecular weight PEG than 4000-6000 Da was used, in order to strengthen mechanical
properties, which would be relatively weakened by the proposed porous structure. We tested
both 1000 Da and 875 Da PEGDMA. Second, the PEG precursor solution was prepared in a
mixture of saline buffer solution and ethanol rather than in pure buffer. The use of ethanol
improved wetting of the colloidal template by the pre-polymer solution, due to the alcohol's
reduced surface energy compared to water. Better wetting would in turn be expected to reduce
defects caused by incomplete penetration of the polymer into the template.
We found that ethanol also dramatically enhanced the transparency of the final product, when
we performed initial testing of different formulations with thick bulk gels (rather than thin
porous scaffolds). Transparency was a desirable quality due to the reliance of the ultimate project
on many imaging studies (e.g., of cell migration within scaffolds). The reason for the observed
improvement in transparency might be due to the breaking up or alternative organization of PEG
I
micelles; such micelles are known to occur in aqueous solutions of acrylate PEGs and promote
their polymerization (137).
Finally, the photoinitiator 1-hydroxy-cyclohexyl-phenyl-ketone (HPK) was used rather than
2,2-dimethyl-2-phenyl-acetophenone (DMPA). Although HPK does not work as rapidly as
DMPA, its solubility in aqueous ethanol rather than the organic N-vinyl pyrrolidone is attractive
for creating a homogeneous solution and ultimately transparent product. Table 2-1 shows the
transparency of different PEG formulations.
Table 2-1 Transparency of different gel formulations.
PEG MW Initiator Ethanol (%) Resulting Gel
875 DMPA 25-50 opaque
875 HPK 25-50 opaque
1000 DMPA 25-50 opaque
1000 HPK 25-50 transparent
Although the presence of ethanol enhanced gel transparency, it also increased the
polymerization time needed to form a gel, and decreased the mechanical properties (as
ascertained by qualitative observation of gels). Stiff gels were formed when using 0-25%
ethanol, soft gels were formed using 50% ethanol, and gelation did not occur when using 75-
100% ethanol. Thus, we used 25% ethanol in our final precursor solution formulation.
Having settled on the conditions for polymerization of our system, we next focused our
attention to developing a fabrication method for creating interconnected pores in the gel. To
adapt colloidal crystal templating to the fabrication of tissue engineering scaffolds appropriate
for the migration and growth of living cells within the structure, we prepared 1-2 mm-thick
templates from monodisperse polymer microspheres with 20-60 pm diameters (see Figure 2-2).
Colloidal crystal templates can be prepared from submicron-diameter particle suspensions
simply by controlled evaporation, with random thermal motion enabling the spheres to evolve to
close-packed structures as they are concentrated (132, 133). For the large microspheres used in
our templates, however, Brownian forces were insufficient to promote ordering: controlled
evaporation alone did not lead to close packing of large microspheres, resulting in imperfect
templated gel structures (138). To overcome this problem and achieve highly-ordered colloidal
templates, we incubated microspheres suspended in aqueous ethanol solutions atop an orbital
shaker, and allowed them to dry. We had also attempted thermal methods to allow spheres to
reach their equilibrium state, but found that continuous mechanical agitation worked best.
Smaller microsphere sizes tended to form crystals somewhat less easily than larger ones,
requiring higher speeds and higher particle densities to do so reliably.
Dry polymer microspheres
under continuous agitation
to make colloidal template.
Infuse template with liquid
precursor such as PEGDMA.
Solidify precursor, for
example, with UV light.
Dissolve template to form
inverse opal porous structure.
Figure 2-2 Schematic of colloidal crystal templating process for hydrogels.
Finally, we needed to select a solvent that would dissolve the PMMA microspheres without
having an adverse effect on the surrounding PEG gel. We wanted to avoid the use of harsh
organic solvents that might be difficult to fully remove from the gel, and thus might cause
cytotoxicity problems for cells added to the scaffolds later on. Acetic acid was chosen because of
its high solubility in water, and the fact that in very low amounts it is not harmful to cells. A
sample scaffold made using the chemistry and procedures described above is shown in Figure
2-3 below.
A
Figure 2-3 Macroscopic appearance of lymphoid scaffolds. Digital micrographs showing the
top (A) and side (B) views of a typical scaffold. Scaffolds are indicated by arrows.
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2.3.2 Scaffold characterization: morphology
The morphology of templated PEG hydrogels was examined by optical, fluorescence, and
scanning electron microscopy. The few layers nearest to the surface of the scaffold could be
examined in the hydrated state by optical microscopy. Brightfield micrographs demonstrate the
long-range, hexagonally close-packed order of the main pores, whose diameter was exactly
determined by the size of the templating spheres (Figure 2-4A). Ordered cellular structures could
be made with pores at least as small as eight and at least as large as eighty microns.
In order to look slightly deeper into the scaffolds, and more importantly to probe the structure
in three dimensions, confocal fluorescence microscopy was utilized on scaffolds doped with a
rhodamine methacrylate. Regions of sphere-sphere contact in the original template created
ordered arrays of inter-cell pores. These interconnecting throat pores were visible even in the x-y
plane, as a break in fluorescence in between struts (Figure 2-4B). Scaffolds typically had -78%
of the pores expected for a perfect structure, as determined by counting visible breaks in multiple
image fields; this is well above the threshold for a fully percolating structure (139, 140). Serial x-
y confocal images were taken in fine-grained (c. 1 tm) steps to allow for 3D computational
reconstruction, which gave a clearer view of throat pores on edge (Figure 2-4C, D). A
quantitative measure of overall porosity was obtained by determining scaffold volumes from
multiple confocal 3D intensity-thresholded fields covering a total volume of 0.005 mm3 .
Scaffolds formed from 20 [tm diameter sphere templates had 65 ± 3% porosity, somewhat lower
than the theoretical value of 74% due to defects, though many -25x20 [m areas had 70-73%
porosity. The major defect observed in structures was imperfections in packing that caused
lateral inter-cell pores to be missing.
A
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Figure 2-4 Morphology of scaffolds in the hydrated state. (A) Brightfield optical micrographs
taken within hydrated PEG gels templated with 20, 40, or 60 Ltm diameter microspheres (scale
bars 50 iim). (B) Confocal image of a fluorescently labeled, hydrated PEG scaffold taken
through the mid-plane of a single layer within the structure (scale bar 40 km). Breaks in
fluorescence intensity around each void of the structure occur at open throat pores (denoted for
one void with arrows). (C) 3D reconstruction of serial z-section confocal images taken in 0.5 ptm
steps shows the lateral throat pores formed at points of sphere-sphere contact in the colloidal
crystal template: a small section of one scaffold layer is shown at a 1350 angle. (D) A 3D
reconstruction of a fuller section of scaffold (210x210x55 pm) is shown.
To probe morphology within the center of mm-thick structures, cross-sections of dehydrated
scaffolds were also examined by scanning electron microscopy (SEM). Upon dehydration,
scaffolds shrank by ~ 40% (determined by comparison of confocal images of hydrated scaffolds
to dehydrated EM images), but did so uniformly. Scaffold pores were close-packed and
interconnected for distances spanning tens of layers (Figure 2-5A). Further, the surface of the
scaffold was primarily open, with small pores resulting from the incomplete penetration of the
precursor solution to the contact areas between templating spheres and the surface of the glass
they were fabricated on (Figure 2-5, B-C). This open surface is in contrast to some stochastic
porogen methods used for fabrication of tissue engineering scaffolds that create dense or
nonporous skin layers which may block entry of cells into implanted structures (81, 141).
However, the openness of the surface was highly dependent on the amount of polymer added to
the template, and a partial skin of bulk gel sometimes formed if excess polymer was used.
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Figure 2-5 Morphology of scaffold cross-sections and surfaces. (A-B) Scanning electron
micrographs of dehydrated scaffolds. (A) A cross-section spanning over ten layers of a scaffold
made with a 20 [tm void size is shown (scale bar 18 Rm, corrected for shrinkage due to
dehydration; 10 [tm uncorrected). (B) Free surfaces of scaffolds also exhibited arrays of pores, as
illustrated by this scaffold with a 20 Rtm void size (scale bar 20 [tm, corrected). (C) Scanning
electron micrograph of a lyophilized scaffold-template construct prior to sphere dissolution. The
exposed microsphere surfaces are visible as bright spots. A small hole in the scaffold shows the
microsphere bodies below (arrow). Scale bar 100 [lm, uncorrected.
The size of the interconnecting throat pores was determined by software-aided analysis of
SEM micrographs. The inter-layer throat pore size was consistently found to be -25% of the
main void size, as shown in Table 2-2. Thus, templated scaffolds with 40 ýtm or greater void size
had throat pore diameters _ 10 ýtm, consistent with those reported to support tissue invasion in
vivo (142-144).
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Table 2-2 Templated PEG scaffold pore sizes.
Nominal cell Dehydrated throat Throat pore diameter, No. pores
size (pm) pore diameter (ýpm) correctedLal (pm) examined
20 2.94 ± 0.57 5.15 ± 1.00 53
40 5.53 ± 0.87 9.67 ± 1.53 111
60 8.86 ± 1.81 15.5 ± 3.17 116
[alThroat pore size determined from SEM micrographs of scaffolds was corrected by dividing by the fractional
shrinkage observed in the dehydrated structure relative to the dimensions of the hydrated scaffold measured in situ
by confocal microscopy.
2.3.3 Scaffold characterization: mechanical properties
The high degree of void interconnectivity observed in templated gels was achieved at
significantly lower total porosities than are required in stochastic porogen methods (due to the
ordered arrangement of void space), and this resulted in quantifiably improved mechanical
properties. The compressive modulus of the original composition of gel precursor solution
(PEGDMA and 0.6 mole % RGD-PEGA, see 2.2.3-2.2.4) was measured for the bulk gel and for
scaffolds with three different pore sizes, and compared to theoretical predictions. Using a model
of bending response in porous structures, Gibson and Ashby derived a relationship between the
elastic modulus of cellular materials (Ec,,,eia) and their solid counterparts (Esoid):
Eceu""lr = C(I- P) 2 (1)
Esolid
where C is a constant (typically - 1) and P is the porosity. Equation (1) predicts the
modulus of structures with 95-99% porosity to be 0.25%-0.01% of the bulk solid, in agreement
with reported data on tissue engineering scaffolds (85, 128, 129). Such porosity levels lead to
extremely low moduli for soft hydrogel structures, and thus prior studies of macroporous soft
gels have thus typically been confined to small void sizes (127, 145) (5 15 ptm) and/or low total
porosities (146, 147) (5 35%). Compressive moduli of our templated PEG hydrogels in the
hydrated state were found to be comparable to soft tissues, which range from ~1 to a few tens of
kPa (148, 149). According to equation (1), E,,e,npteEsolid = 0.120 ± 0.05 for the PEG hydrogels,
which indicates ~ 65% porosity, in agreement with the results from confocal analysis described
in the previous section. (A value of 0.067 would be predicted for close-packed void structures
with the maximal theoretical porosity of 74%). Thus, the templated structure combines excellent
cell interconnectivity with relative stiffnesses 10-1000-fold greater than those predicted for
disordered structures, where high porosity is requisite for high interconnectivity (E74 ,,,,,ous/E,,,
porous = 676).
Table 2-3 Templated PEG scaffold compressive moduli.
Nominal cell size ([tm) Compressive moduluslal (kPa)
20 16.0 + 4.3
40 18.0 ± 4.2
60 22.6 + 5.0
talModulus of non-templated PEG hydrogel was 160 ± 53 kPa.
2.3.4 Generality of CCT approach for tissue engineering: gelatin scaffolds
An attractive feature of the colloidal crystal templating (CCT) approach is its potentially broad
applicability for scaffold fabrication: any aqueous solution undergoing a permanent liquid-to-
solid transition can in principle be templated with an ordered microstructure. To demonstrate
this, we also templated the biological hydrogel formed by gelatin, by introducing heated gelatin
solution into a colloidal template as done for the synthetic PEG hydrogels, and solidifying the
solution by cooling followed by carbodiimide crosslinking (Figure 2-6).
EDC/NHS collagenase
1) Gelation upon 2) Carbodiimide 3) Biodegradable
cooling: physically treatment: covalently natural ECM network.
cross-linked gelatin. cross-linked gelatin.
Figure 2-6 Schematic of gelatin scaffold life-cycle.
Gelatin hydrogels prepared in this manner were examined by optical and electron microscopy.
Upon extraction of the templating microspheres, an ordered gelatin scaffold with interconnecting
pores remained, as shown in the brightfield and electron micrographs of Figure 2-7. Throat pore
diameters were consistently ~ 40% of the nominal pore diameter (cf. ~ 25% for PEG gels), thus
creating large pathways for cell migration even at the minimum 20 Rlm void diameter, as shown
in Table 2-4. Acetic acid treatment of the gelatin scaffolds did not negatively impact cell
attachment to the templated scaffolds: NR6 fibroblasts and primary T cells attached and migrated
within the ECM scaffolds as in the RGD-PEG scaffolds (see Chapter 4, and data not shown).
Compressive moduli of gelatin scaffolds were determined as for the PEG gels, and mechanical
properties, though reduced, remained suitable for mimicking soft tissues (see Table 2-4).
Further, the drop in modulus from bulk to porous gelatin was again consistent with the Gibson-
Ashby theory, with Eempia,,esoid = 0. 100 + 0.026. Similar fabrication approaches should make
the colloidal crystal templating technique applicable to a variety of biomaterials.
Figure 2-7 Morphology of templated gelatin scaffolds. (A) Brightfield optical micrograph of
hydrated gelatin scaffold templated with 60 ptm diameter microspheres (scale bar 40 [Im). (B)
SEM micrograph of freeze-fractured gelatin scaffold with 20 tm void size (scale bar 40 km).
Table 2-4 Templated gelatin scaffold pore sizes and compressive moduli.
Nominal cell Throat pore No. pores Compressive
size ([tm) diameter (pm)Lal examined modulus[b[ (kPa)
20 8.82 ± 2.66 54 3.1 ± 0.7
40 16.7 + 4.28 49 3.3 ± 1.7
60 21.8 + 5.50 50 5.0 ± 2.5
[•] Corrected for shrinkage due to dehydration.
[bj Modulus of non-porous gelatin was 37.5 ± 13.7 kPa
2.3.5 Control over porosity at multiple length scales by sintering
The exact architecture of the scaffold pores was influenced both by the preparation of a
microsphere template and by the subsequent infusion of a liquid precursor solution. Two length
scales are of interest: the diameter of the main pore chamber, which was determined almost
perfectly by the size of the templating microsphere, and the diameter of the interconnecting pores
between chambers, which depended on a variety of factors, as outlined below.
In comparing hydrogel scaffolds prepared from PEG with those prepared from gelatin, it
became apparent the relative size of the interconnecting pores depended on the material
comprising the scaffold. In the case of PEG, interconnecting pores were typically 25 % of the
nominal pore diameter (Table 2-3), while for gelatin this proportional size was 40%. A number
of factors might contribute to this, such as relative surface energies and thus energy of adhesion
between PMMA and PEG versus PMMA and gelatin, as well as differences in viscosity, vapor
pressure, and related parameters.
Although these solid-liquid interactions (related to wetting) were very important, we
reasoned that we could have some control over the throat pores by altering the structure of the
templating spheres themselves. Specifically, we sought to increase the surface area of the contact
points between spheres, where liquids do not tend to fully penetrate. This area could be increased
by annealing the template at elevated temperature, a process known as sintering. Others have
described increased neck size in sintered PMMA microspheres that are about ten-fold larger in
diameter than the ones used in our studies (150).
Confocal microscopy was used to examine fluorescent (rhodamine-doped) scaffolds prepared
from sintered templates. Templates were prepared as usual, then kept in a heated oven for up to
24 hours prior to addition of the prepolymer solution. Sintered templates did not imbibe the
precursor solution as quickly as did non-sintered templates; however, ultimate scaffold
thicknesses were comparable, indicating that liquid did eventually reach the bottom of the
template during centrifugation.
In initial experiments, sintering appeared to have a detrimental effect on the mechanical
properties of the final scaffold product, due presumably to the increase in porosity. Scaffolds
were soft and appeared collapsed in confocal images. This was corrected by adding 2 wt %
bis/acrylamide (19:1) to the prepolymer solution as an additional cross-linker, and scaffolds
made from this formulation were observed in an un-collapsed state. Confocal microscopy was
used to obtain serial sections of these scaffolds, and the size of the intra-layer interconnecting
throat pores was measured within reconstructed y-z planes using Volocity software. Figure 2-8
shows x-y and y-z views of non-sintered and sintered scaffolds. In the x-y views, the struts are
clearly thicker in the non-sintered scaffolds, while in the y-z views the throat pores clearly have
smaller average diameter.
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Figure 2-8 Morphology of sintered scaffolds. (A) Surface (x-y) and edge (y-z) views of non-
sintered scaffolds. Struts between pores are relatively thick, and interconnecting pores are
relatively small. (B) Surface and edge views for a scaffold made from a 24 h sintered template.
Struts between pores are relatively thinner than for non-sintered scaffolds, though the bottom
half of the x-y view exhibits some missing-pore defects. The side view demonstrates large throat
pores, but also a large area of polymer without any pores. (C) A template sintered for 16 h was
used to acquire this side view. Throat pores are comparably large, but defects in this area are less
than in the 24 h case. White arrowheads indicate intra-layer throat pores.
We quantified the correlation between sintering time and resultant throat pore size when
annealing at temperatures just below the glass transition temperature of PMMA (c. 200 'C), and
the results are shown in Table 2-5 below. The average increase in pore size for the longest
sintered template compared to an unmodified one is ~34%.
Table 2-5 Sintering colloidal templates increases resulting scaffold throat pore size.
Time sintered (h) Throat pore size'[a (Rm)
0 10.2 ± 1.9
8 10.8 ± 2.3
16 12.9 ± 2.5
24 13.7 + 2.8
I"l Average ± standard deviation of pooled data from two independent experiments.
What this data does not indicate, however, is that sintering colloidal templates for extended
periods of time caused melting defects over large surface areas of the resulting scaffolds. Figure
2-9 showcases the wide variation of scaffold quality when using a template sintered for 24 h: the
left-hand image is nearly perfect, while the right-hand one has large gaps and some large areas of
fused polymer.
A
Figure 2-9 Morphology of defect-free and damaged areas of scaffolds made from sintered
templates. (A-B) Both scaffolds were made from templates sintered for 24 h. (A) An almost
defect-free area shows thin struts and large pores. (B) A highly damaged area shows large gaps
as well as large areas of non-porous polymer.
In conclusion, although throat pore size in the un-damaged portions of scaffolds increased
with sintering time, sintering is not a viable option for significantly altering scaffold architecture
at this length scale only, without having undesirable effects on the regularity of the structure.
2.4 Discussion
We developed a novel method of fabricating porous hydrogel scaffolds that has several distinct
advantages over most other methods of creating porosity to date. Previous methods of using
porogens to create voids in a polymer matrix prior to dissolution of the porogen have been
stochastic in nature, prepared by simple mixing of the particle (e.g., sodium chloride salt) and the
polymer, or casting of the polymer onto a randomly arranged particle template (82-84). Even in
recently developed 'salt fusion' methods, the particle template becomes connected but is not
ordered in a crystalline fashion, which creates an inconsistent porosity that may be difficult to
predict (85). Such random mixing processes requires a high porogen fraction, and ultimately a
high porosity in the structure (>95%) to achieve the high pore interconnectivity that is so crucial
for nutrient diffusion and cell spreading. By creating an ordered crystal of particles - in our case,
PMMA microspheres - and then infusing it with liquid, we were able to achieve high pore
interconnectivity at ~ 65% porosity (74% theoretical).
The method of colloidal crystal templating, newly applied here to scaffolds appropriate for
tissue engineering, may be used with any material that undergoes a permanent transition from
liquid to solid (or semi-solid gel). Thus, we developed protocols for two very different common
biomaterials: synthetic PEG, and the natural biopolymer gelatin. The PEG gels were solidified
using photopolymerization chemistry, while gelatin was cooled from a hot solution and
subsequently lyophilized and cross-linked by carbodiimide chemistry.
Microscopic examination of both types of gels showed similar structures: hexagonally close-
packed, interconnected pores in three dimensions. However, PEG and gelatin scaffolds differed
in several ways. The interconnecting throat pores in PEG scaffolds were ~ 25% of the main void
diameter, while for gelatin this value was increased to 40%. This implies that the gelatin was not
able to coat the microspheres as well as PEG was, which is supported by the fact that we needed
to pre-wet templates with ethanol in order to improve penetration by gelatin. Further, gelatin
scaffolds sometimes had a thick layer of bulk gel on the top face due to incomplete infusion, as
ascertained by SEM (data not shown). The walls of the gelatin scaffolds also appeared to be
thinner than those of the PEG scaffolds. This was likely due to the fact that, although gelatin was
used at the same weight concentration as PEG, cross-linking efficiency for gelatin tends to be
low and the final material is not expected to be as mechanically robust. In fact, for the 50-100
kDa gelatin used here, the average molecular weight between cross-links would be expected to
be at least 2-4 times greater than that for PEGDMA (151).
Despite the slight expected difference in porosity for PEG versus gelatin scaffolds due to the
throat pore and wall thickness disparities, mechanical properties testing of PEG and gelatin
scaffolds indicated a similar overall porosity as compared to the bulk gels of each substance. The
compressive modulus of solid PEG gel, at 160 _t 53 kPa, was four-fold higher than that of solid
gelatin, at 37.5 ± 13.7 kPa. However, in both instances the compressive modulus of the porous
scaffold was ten-fold lower than that of the bulk gel, at ~ 19 and - 4 kPa, respectively, in good
agreement with Gibson-Ashby theory and our empirical determination of porosity. For
comparison, scaffolds with 95% porosity would be expected to have moduli of 0.4 and 0.01 kPa.
Finally, we determined for the case of PEG gels whether it was feasible to independently
vary porosity on multiple length scales. Some groups that use particulate leaching methods have
improved the interconnectivity of their structures by fusing the particle template together (85,
128). Although our structures are already well interconnected, we used a similar strategy to
attempt to change the throat pore size while leaving the main void size constant, by sintering
PMMA microsphere templates at temperatures near the glass transition temperature of PMMA.
We found that sintering did increase the size of the throat pores, by up to 34%. However, the
increased pore size was associated with an increase in large melting defects that left large holes
in the scaffold structure. This may be due to the change in polymer flow mechanisms that occurs
at the transition when air becomes the dispersed phase rather than the continuous phase in the
melting sphere template. Narkis has reported that this transition (and its attendant increase in
template defects) occurs when the average radius of the necks between two spheres exceeds 30%
of the particle radii (150). For our system, this occurs at a neck diameter of 12 [im for a 40 [Im
particle template. Since the throat pores are likely to be approximately the size of the polymer
necks, we cannot increase the throat pores to be much greater than 12 ytm without incurring large
defects, in agreement with our data described in section 2.3.5.
Two other groups concurrently developed tissue engineering scaffolds based on colloidal
crystal templating similar to the ones we describe here (152, 153). Kotov used very slow (multi-
day) evaporation at elevated temperatures to achieve colloidal crystals that could be infused with
a biocompatible silica (152), and demonstrated by modeling that the diffusion of nutrients into
these scaffolds is ~ 1/2 as fast as in free solution (154). Another group has since made porous
scaffolds specifically from peptide-PEG gels, using a combination of gas-foaming and
photopolymerization (155). Foaming processes result in structures with a disordered porosity and
a wide distribution of pore sizes. Such structures are thus likely to be mechanically weak relative
to ones made by colloidal crystal templating. Further, the more direct (rather than empirical)
control over pore size in a templating approach may sometimes be desired.
We believe that the scaffolds we developed can be useful for soft tissue engineering
applications where moderate mechanical strength and a high nutrient amount are required. In
particular, we are interested in studying T cells in an artificial lymphoid-like environment, as the
macroporous nature of the gel scaffold we have described here is well suited to mimic the lymph
node T zone ECM.

3 Factors influencing T cell motility: adhesion proteins and
chemokines
3. 1 Introduction
Concurrently with initial studies of immune cells in our scaffold structures, we pursued
simplified systematic methods to determine some basic parameters that could be used to
influence T cell migration within the scaffolds. It is known that T cells isolated from murine
secondary lymphoid organs or human peripheral blood are largely rounded and non-motile, even
if cultured in contact with some adhesive substrates (39, 156-158). However, time-lapse
fluorescence imaging of intact murine lymph nodes has revealed that T cells exhibit dramatic,
sustained motility during homeostasis and during some phases of antigen (Ag) priming, which
may be critical for efficient Ag surveillance ((10, 116, 159), reviewed in (39, 160)). Thus, the
polarized, migrating phenotype of naive lymphocytes in vivo is likely supported by signals
present in the tissues. Along with the architecture and cellular composition, one notable feature
of the lymph node microenvironment is the constitutive presence of high levels of the so-called
homeostatic or lymphoid chemokines.
Homeostatic chemokines include CCL21, CCL19, and CXCL12 in the T cell areas of
secondary lymphoid organs. These soluble small molecules act as biological signaling agents
that may induce cell chemotaxis (migration induced by a gradient of the chemotactic factor)
and/or chemokinesis (increase in cell velocity induced in uniform concentrations of the
chemokine). During T cell transit across high endothelial cells (from blood to lymph nodes),
pronounced chemokine concentration gradients might be encountered, and chemotaxis is likely
the predominant mechanism at play. In contrast, the rapid, apparently randomly-directed
migration of T cells observed in vivo (39, 159-161) could be the result of short-range direction
and redirection in response to very localized chemokine gradients within the T cell zone (162), or
alternatively, could represent a chemokinetic response to near-uniform levels of chemokine in
the tissue. Using in vitro culture systems, Kaiser et al. recently reported that CCL19 secreted by
mature dendritic cells (DCs) stimulated pronounced motility in co-cultured human naive T cells;
addition of soluble CCL19 at uniform concentrations to naive T cells cultured on immature DCs
(which do not produce CCL19) elicited a similar induction of random motility (158). In light of
the evidence, we hypothesized that chemokinesis triggered by homeostatic chemokines could be
a general mechanism supporting steady-state lymphocyte motility within secondary lymphoid
organs. If true, chemokines could be directly used within artificial lymphoid tissue constructs
without need to somehow present the chemokine in gradient form.
We began by determining if naive T cells could be made to undergo chemokinesis by
minimal signals in a 2D environment. Notably, in the first studies examining the effects of
homeostatic chemokines on lymphocyte migration, chemokinesis was not observed (e.g., refs
(21, 163, 164)). However, these in vitro studies utilized modified Boyden chamber assays, in
which cells migrate across a thin porous membrane in response to chemoattractant; the type of
migration elicited is assessed by introducing chemokine either to the culture chamber opposite
the cells (to assay chemotaxis) or at equal concentrations on both sides of the membrane (for
chemokinesis). The use of such 'checkerboard' filterplate assays to detect and distinguish
between types of migration can be problematic (165), and in some cases factors that appeared to
be only chemotactic in such assays have shown clear chemokinetic effects when more direct
assays of cell migration were employed (166).
We thus used direct videomicroscopic observation to test whether the most abundant
chemokine in the T cell areas of lymph nodes and spleen, CCL21, could trigger chemokinesis in
resting murine T lymphocytes. We found that this was the case, and that the strength of
chemokinesis was influenced by the adhesive substrate presented to the cells. Further, using in
vitro assays designed to model the relative infrequency of Ag-specific T cell-Ag-bearing DC
encounters that occur during primary immune responses, we found that treatment of T-DC co-
cultures with CCL21 led to an early increase in CD69 upregulation kinetics and a two-fold
enhancement in the number of Ag-specific T cells recovered after 4 days. These results provide a
possible explanation for the lack of naive murine lymphocyte motility in purified cultures
relative to their behavior in lymphoid organs, and suggest that the high levels of chemokines
present in secondary lymphoid organs do not require concentration gradients to have a
significant impact on lymphocyte migration. This foundational work paved the way for our
studies of T cell behavior in 3D scaffolds, described in Chapter 4.
3.2 Materials and Methods
3.2.1 Cell isolation
All animal work was approved by the MIT Committee on Animal Care, in accordance with
federal, state, and local regulations. C57B1/6 and OT-II mice were obtained from Jackson
Laboratory, as were Bl/6 transgenic mice expressing enhanced green fluorescent protein in all
cells (GFP Bl1/6 mice). DC were derived from the bone marrow of C57B1/6 mice after Inaba's
procedure, cultured with 5 ng/mL GM-CSF (R&D Systems), and used on day 7 (167). CD4÷ T
cells were isolated from spleens or lymph nodes of 6-12 wk-old mice by MACS negative
selection (Miltenyi Biotec CD4' T cell isolation kit), yielding > 90% CD4' cells, > 60%
CD62L"'CD44Iow naive T cells. For some experiments, cells were further purified: CD4÷ T cells
were separated into CD62L' and CD62L- fractions by MACS positive selection (Miltenyi
CD4÷CD62L' T cell isolation kit), or were sorted into CD62L+CD4410 and CD62L+CD44hi
populations on a FACSAria (BD Biosciences). Cells were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum (FCS), 10 mM HEPES, 100 U/mL penicillin, 100
[tg/mL streptomycin, 2 mM L-glutamine, and 50 RM 2-mercaptoethanol.
3.2.2 Cell treatments
Cells were incubated with 1-10,000 ng/mL recombinant mouse CCL19 or CCL21 (R&D
Systems) for 20 min prior to initiation of imaging to allow the chemokine to take full effect.
Phorbol-1 2-myristate- 13-acetate (PMA) ester treatment (Sigma Aldrich) was performed at 50
ng/mL, with imaging likewise initiated at 20 min. For LFA-1 blocking studies, anti-LFA-l clone
M17/4 or isotype control antibody was used. All antibodies were from BD Pharmingen and used
at 10 [g/mL. In videomicroscopy studies utilizing pertussis toxin (PTX), cells were treated with
100 ng/mL PTX or PTX B oligomer (Sigma) for 10 min at 37 'C, washed twice with warm
medium, and rested for 90-120 min before use. In co-culture studies, both a high dose (100
ng/mL), and a low dose (2 ng/mL) of PTX were tested; results followed the same trends for both
doses. For chemokine removal experiments, cells were washed in 10 mL warm medium,
incubated for 1 h in 2 mL fresh medium under light shaking (< 200 rpm), and washed twice more
before imaging.
3.2.3 Videomicroscopy tracking of T cell polarization and chemokinesis.
Eight-well chambered coverslips (Lab-Tek, Nalge Nunc) were incubated with 5 [pg/cm2 of
fibronectin (FN) for 2 hours at 21 oC, or 10 lpg/mL recombinant ICAM-1/Fc or VCAM-1/Fc
fusion proteins (R&D systems) overnight at 4 'C, prior to addition of cells (2-3x106) and
chemokine. A fraction of CD4÷ T cells from C57B1/6 mouse spleens (~20 %, for ease of
automated tracking) were labeled with 2.5 [tM Fura 2-AM (Molecular Probes) for 25 minutes at
37 TC. Similarly, splenic CD4' T cells from GFP mice used for chemokine response longevity
studies were diluted to 20% with C57BL/6 CD4÷ T cells. Fura (for C57B1/6 mice, exc 380 nm,
em 510 nm) or green (for GFP mice, exc 488 nm, em 510 nm) fluorescence and bright-field
images were acquired at 30 s intervals for 40 min on a Zeiss Axiovert 200 3D epifluorescence
microscope equipped with environmental stage (37 'C, 5% CO2) with the aid of Metamorph
software (Universal Imaging, Inc.).
3.2.4 Image Analysis
Cell polarization and migration were analyzed with the aid of Metamorph and Volocity
(Improvision, Inc.) software packages. Data were sharpened with the no-neighbors 2D
deconvolution algorithm in Metamorph to facilitate cell tracking using Volocity. For each field,
26-44 cells were analyzed (depending on fluorescent cell density) based on intensity thresholding
and size exclusion (to rid a small fraction of large cell contaminants); the dead cell population
that developed during longevity experiments was excluded from analysis. A cell was scored as
polarized at a single time-point if its shape factor (4n area/perimeter2) did not exceed 0.85. To
score average population behaviors, polarized cells were defined as those with a shape factor 5
0.85 in L 15% of observed time-points. Migrating cells were defined as polarizing cells with
time-averaged velocities > 4 [tm/min.
3.2.5 T-DC co-cultures
All experiments were performed in 96-well round-bottom plates (BD Falcon). To assay CD69
upregulation, duplicate samples of 2x105 total cells were prepared at an overall T:DC ratio of
1:1. A portion of day-6 DC were matured with lipopolysacharride (LPS, 1 [g/mL, Sigma) and
pulsed with OVA peptide (ISQAVHAAHAEINEAGR, 500 nM, AnaSpec Corporate) for 16 h,
while others were left untouched; mixtures of peptide-loaded (and washed) mature DC (OVA-
mDC) and immature DC (iDC) were then prepared at a 1:20 ratio. OT-II CD4' T cells were also
diluted 1:9 with C57B1/6 CD4' T cells. T cells (with or without PTX pre-treatment) and DC
mixtures were aliquotted in FN-treated wells, briefly centrifuged (1200 rpm, 1-2 min), then
placed in culture in the presence or absence of 1 gg/mL CCL21, which was replenished at 48 h.
CD69 upregulation was analyzed at times ranging from 24-96 h: duplicate samples were pooled,
cells were stained with anti-CD69-FITC, anti-Va2-PE, and anti-CD4-biotin followed by
streptavidin-APC, and finally propidium iodide.
The effect of CCL21 on T cell proliferation was assessed by a CFSE dilution assay, using a
similar co-culture system: OT-II T cells were labeled with 10 pLM CFSE for 10 min and washed
3X prior to mixing with C57B1/6 CD4' T cells at a 1:9 ratio. Triplicate co-cultures of 5x105 total
cells were prepared at an overall T:DC ratio of 9:1 and an iDC:OVA-mDC ratio of 1:1; 1 tg/mL
CCL21 was added at time zero to CCL21-treated cultures. Proliferation in each well was assayed
on day 4 by flow cytometry analysis of cultures stained with anti-Va2-PE, anti-V35-biotin (then
streptavidin-APC), and propidium iodide. All data was collected on a Becton-Dickinson
FACSCalibur using CellQuest software and analyzed with FlowJo software, using antibodies
from Pharmingen.
3.2.6 T cell viability studies
T cells (2x105 in 200 [tL per well) were labeled with CFSE as described above, incubated
with or without 1 [pg/mL CCL21 for 24 h, then stained with propidium iodide and analyzed by
flow cytometry. Equal volumes were run from each sample, in order to determine both the
percentage of live cells in the sample, and the absolute number of live cells in the sample.
3.2.7 DC phenotypic analysis
DCs (~1 x 10 in 1 mL per well) were left untreated or incubated with 1 ptg/mL CCL21 and/or
1 Rg/mL LPS on day 6. The next day, the following antibodies were used for staining (all at 10
ptg/mL unless otherwise noted): CD16/32 blocking antibody, CD80-FITC, I-Ab- PE (2 Rtg/mL),
and CDI I c-biotin followed by streptavidin-APC and propidium iodide (1.25 [tg/mL). Equal
numbers of cells were analyzed per sample.
3.3 Results
3.3.1 CCL21 and CCL 19 induce chemokinesis in resting CD4* T cells
exposed to an adhesive substrate
Many chemokines, including CCL19 and CCL21, are known to trigger polarization in resting T
cells at uniform concentrations (168, 169). We confirmed that both CCL21 (Figure 3-1, A and B)
and CCL 19 (data not shown) elicited pronounced polarization of - 75% of freshly isolated
murine (C57B1/6 strain) CD4÷ T cells within 5 min, whereas the majority of untreated resting
cells were round. In experiments where CD62L+CD441 o, CD62L+CD44hi, and CD62L- CD4 T
cells were separated, all populations responded nearly equally to CCL21 (data not shown). When
T cells were seeded on bare glass with soluble CCL21 and tracked by videomicroscopy, we
observed not only rapid cell polarization, but also that a small fraction of cells (~3%) appeared to
actively migrate (Figure 3-1B). Because polarization and adhesion are two prerequisites for T
cell motility (156, 170), and CCL21 is known to induce adhesion to integrin ligands (111, 171),
we tested whether motility would follow polarization if the cells were exposed to a suitable
adhesive substrate.
CD4' T cells were seeded at relatively high densities (crudely mimicking the dense
cellularity of SLO) on glass substrates coated with recombinant ICAM-1, with or without
chemokine. T cells had low basal adhesion and motility when seeded on ICAM-1-coated
substrates in the absence of chemokine; most cells moved only by convective drift and collisions
with neighboring cells (Figure 3-1 B, and data not shown). In contrast, addition of CCL21
stimulated migration in 60 ±- 5 % of T cells (Figure 3-1B). As illustrated by single-cell migration
paths (Figure 3-1C), CCL21-treated cells migrated substantial distances on ICAM-1 with no
preferred direction, while the majority of cells remained relatively stationary in the absence of
chemokine or slowly convected. Convecting vs. migrating cells were readily distinguished via
single cell velocity time-courses (Figure 3-1 D) and histograms of instantaneous velocities
(Figure 3-1E); migrating T cells had peak speeds of up to 20 mrn/min, while control cells had
smoother velocity profiles with speeds rarely exceeding 10 tpm/min. The time-averaged velocity
of single cells exposed to CCL21 on ICAM-l-coated surfaces (<v> = 5.16 + 2.08 pm/min) was
likewise significantly higher (p , 0.0001) than that observed for cells on ICAM-1 with no
chemokine (Figure 3-IF).
Importantly, chemokinetic migration was dependent on the presence of both chemokine and
adhesive ligand: when the T cell integrin LFA-1 was blocked with an antibody, T cells on
ICAM-1 substrates polarized, but failed to migrate (Figure 3-IG); isotype control antibody had
no effect (data not shown). Treatment of T cells with pertussis toxin (PTX), which inhibits G-
protein-coupled receptor signaling, reduced both polarization and migration (p : 0.05), whereas
the PTX B oligomer (control) had no effect (Figure 3-1G). Blocking LFA-1-ICAM-1
interactions with an anti-LFA-1 antibody or treating the cells with PTX significantly reduced
average cell velocities as well (Figure 3-1F). We tested whether the observed migration was a
result primarily of increased adhesion to ICAM-1 rather than chemokinesis per se, by treating
cells with the phorbol ester PMA, which increases T cell adhesion to ICAM-1 (172). PMA
triggered polarization in a majority of cells, but did not induce migration on ICAM-1 (Figure
3-1G). Thus, CCL21 elicits chemokinesis from CD4+ T cells, with migration dependent upon G-
protein coupled receptor signaling and exposure to an adhesive substrate such as ICAM-1.
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Figure 3-1 CCL21 synergizes with ICAM-1 to promote chemokinesis of freshly-isolated
CD4÷ T cells. (A) Fluorescence (top) and brightfield (bottom) images of C57B1/6 CD4 ÷ T cells
before (left) and 20 min after (right) addition of 1 g/mL CCL21. A fraction of cells (20%) were
labeled with Fura 2-AM for software-assisted tracking. Scale bars 20 ptm. (B) Percent T cells
polarizing and migrating on bare or ICAM-1-coated surfaces, with or without CCL21 addition.
Ave. ± std. dev. shown for 3 independent experiments per condition. [* indicates bracketed
conditions are statistically different (p ! 0.05)] (C) 2D migration paths for 6 representative
control (left) and CCL21-stimulated (right) cells over 20 min are shown; all axes 90 [tm. (D)
Single cell velocity time-courses for 3 of the individual control (left) and CCL21-stimulated
(right) cell tracks shown in (C). (E) Instantaneous velocity distributions on ICAM-1-coated
surfaces without (left) or with (right) CCL21 are shown (n > 75 cells each). (F) Time-averaged
single-cell velocities on ICAM-1 surfaces with or without CCL21 addition and other treatments
as shown; bars indicate the population average velocity. [* indicates conditions statistically
different (p < 0.0001) from +CCL21 sample.] (G) Percent T cells polarizing and migrating on
ICAM-1 coated surfaces after indicated treatments shown for 3 independent experiments per
condition. [* indicates statistically different (p < 0.05) from +CCL21 only case.]
3.3.2 Chemokinesis occurs at physiological CCL21 doses and supports
long-lived cell migration
Naive T cells are estimated to spend 12-18 h in a single lymph node during their homeostatic
recirculation between blood and secondary lymphoid tissues (162). In order for chemokinesis
triggered by CCL21 to be relevant to T cells' search for antigen in lymph nodes, the migratory
response would need to be sustained throughout a similar time period in response to chemokine
doses present in the intact tissues. The concentration of CCL21 in secondary lymphoid organs
has been estimated at -2 and ~10 tg/mL by ELISA and Western blotting of tissue supernatants,
respectively (25, 36, 38). Using videomicroscopy, we found an onset of T cell motility induced
by 10-100 ng/mL CCL21, whereas the percentage of cells polarizing and migrating began to
plateau between 100-1000 ng/mL (Figure 3-2A). (However, the average time that any particular
cell spent polarized and the average single-cell velocity continued to increase up to at least 10
gg/mL - data not shown). Notably, the onset and plateau response in chemokinetic migration
measured here parallels the dose response reported for chemotactic migration triggered by
murine CCL21 (21).
To assess the longevity of the observed chemokinetic response, T cells seeded on ICAM-1
surfaces were tracked by videomicroscopy 20 min after addition of CCL21, and again 24 h later.
Live T cell migration in response to CCL21 did not appear to weaken at all over 1 day (Figure
3-2B-D), whereas only minor basal motility (< 20 %) developed in samples not treated with
CCL21 (Figure 3-2B). When we attempted to wash out the chemokine 24 h after addition (or 1 h;
not shown), cell polarization was significantly reduced (p < 0.0001, Figure 3-2C). Thus, CCL21-
driven responses are sustained at physiological concentrations over time periods consistent with
lymphocyte residence in a given lymph node, and appear to be dependent on the persistent
presence of chemokine.
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Figure 3-2 Polarization and migration responses of CD4' T cells triggered by CCL21 are
sustained for at least 24 h in the presence of chemokine. (A) Average percent cells polarizing
and migrating at given doses of CCL21. (B) Average percent cells migrating at 0 and 24 h in the
presence or absence of chemokine (error bars represent range). (C) Percent time polarized for
individual cells from two pooled longevity and chemokine removal experiments: cells were
observed at 0 h both before and after chemokine addition, 24 h later, and finally after washing.
Horizontal bars denote pop. aves. [* and ** indicate conditions statistically different from
+CCL21 (p s 0.0001) or control (p 5 0.001) samples, respectively.] (D) For a sample treated
with I [g/mL CCL21 at 0 h (left), many polarized cells remain at 24 h (right). Labeled cells
(Fura 2-AM) shown in false color. Scale bars 20 tm.
3.3.3 CCL21 triggers chemokinesis on several adhesion ligands present in
secondary lymphoid tissues
To determine whether CCL21 could synergize with other adhesion ligands present within T cells
areas of secondary lymphoid organs to promote T cell migration, we observed CD4' T cell
motility on VCAM-1 and fibronectin (FN)-coated substrates for comparison to the response
observed on ICAM-I surfaces. T cell polarization induced by CCL21 was statistically identical
on bare glass or in the presence of each adhesion ligand (Figure 3-3A). For all 4 surfaces, the
population time-averaged velocity was increased in the presence of CCL21 (Figure 3-3B). (This
was true even on bare glass where cells were non-adherent, due to increased convection caused
by CCL21-induced polarization.) However, the CCL21-induced increase in mean velocity of T
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cells was significantly greater for cells cultured on ICAM-1, VCAM-1, and FN compared to bare
glass, suggesting that CCL21 can synergize with multiple adhesion ligands to promote T cell
migration (Figure 3-3B, p ! 0.05). The exact velocity profiles of both chemokine-treated and
untreated cells depended on the surface (Figure 3-3C); this is to be expected, as cell migration
rates are controlled by adhesion strength - which likely differs for each ligand at the single
surface-coating densities tested here - as well as potential qualitative differences in the adhesion
receptors involved (173). However, the responses measured here clearly indicate that
chemokinesis induced by CCL21 in concert with an adhesive substrate is not limited to synergy
with ICAM-1 alone.
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Figure 3-3 CCL21 synergizes with several adhesion ligands present in secondary lymphoid
tissues to promote random T cell motility. (A) Percent CD4' T cells polarizing on bare glass,
ICAM-I-, VCAM-I-, or FN-coated substrates with/without CCL21 (B) For each substrate,
percent increase in average cell velocity with chemokine treatment (vs. untreated sample) is
shown. [* indicates statistically different (p < 0.05) from bare glass case.] (A-B) show ave. ± std.
dev for 3 independent experiments. (C) Histograms of time-averaged single cell velocities for
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control and CCL21-stimulated cells on ICAM-1, VCAM-1, FN, and bare glass shown for 3
pooled experiments per condition (n > 75 cells each); arrows indicate population median
velocity. CCL21 was used at 1 pg/mL for all experiments.
3.3.4 CCL21 impacts CD4 ÷ T cell priming under conditions of rare antigen
specific T cell-DC encounters
To determine whether CCL21 could impact nadve T cell priming under conditions modeling the
rarity of Ag-specific encounters in vivo, we prepared T cell-DC co-cultures where both Ag-
specific T cells and peptide-bearing DCs were present at high dilution. We first assayed T cell
activation kinetics via CD69 upregulation, reasoning that chemokinesis triggered by CCL21
might alter the rate of early priming events. Peptide-loaded mature bone marrow-derived DCs
(OVA-mDC) were mixed with immature peptide-free DCs (iDC) at a ratio of 1:20 and plated in
FN-coated round-bottom culture wells. A mixture of OVA peptide-specific transgenic CD4÷ T
cells (OT-II (174)) and CD4÷ T cells from wild-type (C57B11/6) mice (at a 1:9 ratio) was then
added for an overall 1:1 T:DC ratio. Wells received CCL21 (1 [tg/mL) at both 0 and 48 h or were
left untreated, and CD69 upregulation was assessed as a function of time on equal numbers of
live Ag-specific cells (identified as CD4Vat2+PIl" cells, a gating which included some wild-type
cells, Figure 3-4A). As shown for a representative experiment in Figure 3-4B, the fraction of
CD69hi Va2÷ cells was higher for CCL21-treated samples than for untreated controls at all time-
points, by up to 1.5-fold at 48 h.
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Figure 3-4 CCL21 impacts kinetics of naive T cell priming under conditions of rare Ag-
specific T cell-rare Ag-bearing DC encounters. (A-C) Co-cultures comprising 5% OVA-
specific OT-II CD4' T cells, 45% C57B1/6 CD4' T cells, 2.5% OVA-pulsed mature bone
marrow-derived DC (OVA-mDC) and 47.5% immature DC (iDC) with/without CCL21 were
analyzed by flow cytometry at the indicated times. (A) Va2+CD69"' cells from the CD4'PI"o
population were identified as shown by the rectangular gate. (B) Percent of Vca2 T cells that
were also CD69"I shown over time for control (-CCL21), CCL21-treated (+CCL21), PTX-treated
cells and without CCL21, and a control containing 50% T cells and 50% iDC are shown. A and
B are data from 1 representative of 3 independent experiments. (C) % increase in CD69hi
population for CCL21-treated samples (vs. relevant control), comparing PTX-treated (gray) and
untreated (black) samples; data from three independent experiments, pooled. [* indicates
bracketed samples statistically different (p < 0.05).]
To distinguish between effects of CCL21 on T cells and DCs in the co-culture, we also
applied a PTX treatment strategy reported by Lo et al. to block G protein-coupled receptor
signaling in a selected cell population for at least 26 hrs (175). PTX-treated T cells showed
reduced CD69 upregulation compared to untreated T cells in the presence of CCL21, indicating
that the primary effect of CCL21 in these co-cultures was mediated by T cells (Figure 3-4). The
increase in the CD69"' population elicited by CCL21 was significantly greater for untreated
versus PTX-treated co-cultures across multiple experiments (p 0.05, Fig. 4C), and was most
prominent at 48 hrs.
In order to examine the end-point effects of CCL21 on T cell priming, we performed a
CFSE dilution assay to directly observe Ag-specific cell division. For this assay, OT-II T cells
were again diluted 1:9 with polyclonal CD4' T cells, but a more physiological total T:DC ratio of
9:1 was used, and the DC population was equal parts iDC and OVA-mDC. OT-II T cells in the
culture were labeled with CFSE to track cell division by flow cytometry. At 85 h, equal volumes
of total cells were analyzed and the number of live OT-II cells (Vca2*VI35'PIJo) and their CFSE
fluorescence distribution were determined. In control co-cultures where all DCs were immature
cells lacking antigen, no cell division was observed; in contrast, both PTX-treated and untreated
OT-II cells proliferated when OVA-mDC were present (Figure 3-5A and data not shown), with
similar cell division profiles irrespective of CCL21 treatment (2.88 ± 0.03 vs. 2.70 ± 0.02 mean
divisions per cell in the presence or absence of chemokine, respectively, for the no PTX case).
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Figure 3-5 CCL21 impacts naive T cell proliferation under conditions of rare Ag-specific T-
DC encounters. Co-cultures comprising 9% OVA-specific OT-II CD4+ T cells, 81% C57B1/6
CD4' T cells, 5% OVA-mDC and 5% iDC with/without CCL21 were analyzed by flow
cytometry at 85 h. (A) Sample CFSE histograms are shown for control (left, iDC only) and
experimental (right, with OVA-mDC) conditions. (B) OTII cell recovery for all conditions is
shown. Ave ± std. dev. for 3 wells per condition. [* indicates bracketed conditions statistically
different (p < 0.05)] (A-B) are from I representative of 5 experiments.
Equal numbers of OT-II cells were recovered from PTX-treated samples regardless of
CCL21 treatment (Figure 3-5B). However, in both the presence and absence of OVA-mDC, the
addition of CCL21 increased the number of OT-II T cells recovered significantly, by 2.0-fold
and 1.4-fold, respectively (p ~ 0.05, Figure 3-5B). In comparing multiple similar experiments we
found that the fold increase in T cell recovery was consistently greater in the presence of Ag-
bearing DCs than in their absence (2.1 ± 0.4-fold in presence of Ag, 1.4 ± 0.1-fold in absence of
Ag, p < 0.05), thus showing an Ag-specific effect.
The enhanced cell recovery in CCL21-treated co-cultures was not due to a direct survival
signal delivered to resting T cells by chemokine, as purified T cells cultured alone for 24 h with
or without CCL21 were recovered in equal numbers, with an equal percentage of dead cells (as
determined by PI staining, see Figure 3-6). Nor did variations in T cell co-stimulation by DCs
appear to play a role, which we concluded by observing the levels of the co-stimulation marker
CD80 on LPS-matured and untreated DCs exposed to CCL21. As shown in Figure 3-7, there was
a shift in CD80 levels observed for DCs treated with LPS, as is expected upon maturation;
however, intensity data from CCL21-treated cells with or without concurrent LPS treatment
overlap the data for their respective DCs (mature or immature) lacking CCL21 almost exactly.
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Figure 3-6 CCL21 does not alter resting T cell viability. Equal numbers (left) and an equal
percentage (right) of live CD4+ resting T cells were recovered from wells treated or not treated
with CCL21. No other additives were used.
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Figure 3-7 CCL21 does not affect CD80 levels on immature or mature DC. Flow cytometry
analysis was performed on DCs cultured with the following factors: blue line - none, red line -
CCL21 only, green line - LPS only, orange line - both LPS and CCL21. Cells were gated on the
DC marker CD 11 c and PI staining was used to exclude dead cells.
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Altogether, these results suggest that CCL21 signaling can impact the kinetics of early
activation events and the ultimate number of expanded T cells while having a minor impact on
the mean number of cell divisions, under conditions where Ag-specific T cells and peptide-
bearing DCs are present at low frequency.
3.4 Discussion
Fewer than 1 in 1000 naive T cells express receptors specific for any given antigen (9, 176), and
in order for a primary immune response to occur, these scarce Ag-specific T cells must come
into physical contact with rare but strategically-placed DCs (6, 177). Further, during Ag-limited
infections or immunizations, only a fraction of DCs may present the relevant antigen to T cells.
Recent studies have revealed sphingosine-l phosphate receptor down-modulation on entry into
lymph nodes and slow re-expression during trafficking through the lymphoid tissue as a possible
molecular timer influencing naive T cell residence times in lymph nodes (175). Rapid motility
within lymph nodes may thus enable efficient detection of rare antigens prior to default
trafficking of Ag-specific cells out of the organ. Here we tested whether chemokinesis could be
one regulatory mechanism in secondary lymphoid organs for inducing favorable motility during
both T cell priming and homeostatic trafficking.
We first showed, using direct videomicroscopic observation, that the homeostatic chemokine
most abundant in T cell areas of secondary lymphoid organs - CCL21 - causes pronounced T
cell migration in the absence of specific gradients, and that this response is critically dependent
on the presence of appropriate ligands to promote cell adhesion, notably ICAM-1. In secondary
lymphoid tissues where CCL21 (and CCL19) is constitutively produced, T cells are exposed to
VCAM-1 on stromal cells and DCs (178), ICAM-1 on DCs (179) (and potentially stromal cells
(178)), and possibly FN presented by fibroblastic reticular cells or exposed on the surface of a
small fraction of reticular fibers not enveloped by reticular cells (2, 7). We found that all three of
these ligands could support some degree of cell migration. Highly favorable T cell migration on
ICAM-1 may reflect the need for rapid investigation of DC cell bodies. Notably, histological
studies reveal that about 60% of T cells in lymph nodes are in contact with DCs at any given
moment (177).
In order for chemokinesis to be relevant for T cell migration within secondary lymphoid
organs, it should be sustained for the typical cell residence time: 12-18 h in the case of lymph
nodes (162). We found that CCL21-induced chemokinesis is indeed sustained for at least 24 h,
consistent with the finding in the human system that, in contrast to many chemokine/receptor
interactions, CCL21 binding to CCR7 does not trigger receptor downmodulation (180). The
residual cell polarization we observed after washing out chemokine may be due to the high-
affinity nature of CCL21 I-CCR7 binding and possible chemokine sequestration by cell surface
proteoglycans (110, 181), which complicate full separation of the cells from ligand.
Nevertheless, we observed that the long-term chemokinetic response was dependent at least in
part on the continued presence of CCL21.
Based on these findings, we sought to examine whether chemokinesis triggered by CCL21
could impact T cell priming, using a culture system designed to model the infrequency of Ag-
specific T-DC contacts in vivo. We found that addition of CCL21 to T cell-DC co-cultures
enhanced the initial kinetics of CD69 upregulation and led to 2-fold greater numbers of Ag-
specific OTII T cells recovered after 4 days. Because activated/expanded T cells are
constitutively motile (182-185) we might expect that the presence of CCL21 would only alter the
initial number of (otherwise non-motile) naive T cells that would encounter a DC and begin
proliferating. Naive cells that did make contact with DCs and divide (in the presence or absence
of chemokine) would thus proceed at equal rates to begin dividing, assuming equal rates of
further cell division and no differences in cell death (we found similar fractions of apoptotic cells
in cultures with or without CCL21, data not shown). In agreement with this hypothesis, CCL2 I -
treated T cells had similar cell division profiles as control cells - only the recovery of Ag-
specific T cells changed. Surprisingly, we found that addition of CCL21 to peptide-free co-
cultures also increased the recovery of OTII cells, though control experiments revealed no
evidence for a direct survival signal given to T cells by CCL21. This could be due to CCL21-
driven T cell motility increasing Ag-independent T-DC contacts, which promote T cell survival
(186, 187). We found that the increase in T cell recovery was consistently greater in the presence
of Ag-bearing DCs than in their absence, suggesting an Ag-specific effect apart from survival
cues imparted to T cells by immature DCs. However, we also cannot rule out the possibility that
the viability of T cells is enhanced by CCL21 once they are activated.
These results suggested an influence of T cell chemokinesis on priming but were not
definitive, since the receptor for CCL21, CCR7, is expressed by both naive T cells and mature
DCs (188), and CCR7 signaling is known to promote DC motility (189), dendrite extension
(190), and enhance LPS-driven maturation (191). However, flow cytometry analysis of our LPS-
matured DCs exposed to the prokaryotic-derived CCL21 used here showed no evidence of
further maturation, nor were immature DCs matured by CCL21. More importantly, selective
PTX-treatment of T cells alone largely abrogated the positive effects of CCL21 (Figure 3-4B and
D, Figure 3-5B), suggesting that chemokine receptor signaling in T cells was responsible for the
accelerated CD69 upregulation and enhanced proliferation of Ag-specific cells in our co-culture
system. Notably, CD69 upregulation and proliferation of PTX-treated cells were slightly lower
than for untreated T cells even in the absence of exogenously added CCL21, perhaps reflecting a
contribution of other chemokine signals to the T cell response- e.g., CCL19, which is produced
by mature DCs (192), and which has recently been shown by Kaiser et al. to promote T cell
scanning of DCs (158).
Altogether, these findings suggest that the rapid migration of lymphocytes observed within
the parenchyma of secondary lymphoid organs could be supported by chemokine signaling in the
absence of significant concentration gradients. Recent analyses of T cell migration within intact
SLO have so far failed to reveal evidence for chemotaxis during homeostatic lymphocyte
trafficking once T and B cells reach their respective zones, which may reflect a truly random
program for T cell scanning or the action of very local attraction gradients near antigen-
presenting cells such as DCs (39, 116, 159). In either case, the data shown in this chapter suggest
that homeostatic chemokines could function not only to direct lymphocytes to their respective
compartments, but also to regulate the random motility of these cells in lymphoid organs
observed during their constitutive surveillance for antigen. This knowledge can be applied to
artificial immune constructs by modifying them to incorporate CCL21.

4 Providing a cell-supportive microenvironment in inverse
opal scaffolds for lymphoid tissue engineering
4. 1 Introduction
The goal of many immunotherapies is to trigger de novo immune responses or amplify existing
responses (57). Immunotherapies are particularly attractive for cancer treatment: many tumors
display weakly immunogenic antigens that stimulate a partial adaptive immune response, and the
quantity (and type) of the resulting immune cell infiltrate correlates with increased survival in
many cancers (41, 43). Thus, one strategy to activate or enhance immunity is to provide cues that
drive the accumulation of adaptive immune cells at a tumor or infection site. Dendritic cells
(DCs) capture and present foreign antigens to T cells, driving the latter's differentiation into
effectors or memory cells that can eliminate infected or transformed cells. The co-localization of
T cells and DCs at a tumor or infection site should therefore facilitate the uptake of antigen and
priming of a productive immune response. Attracting immune cells to cancer sites has been
achieved by injecting immune cell chemoattractants into tumors (54), antibody targeting of
chemoattractant-inducing cytokines to tumors (52), and transfecting tumor cells to express such
cytokines or chemokines themselves (53, 55) (see also section 1.2). In addition to attracting
immune cells, the chemokine CCL21 is also able to dampen (54, 55) tumor immunosuppressive
signals (44). However, to achieve significant effects, chemoattractant signals must be sustained
by daily injections.
An alternative might be to use a tissue engineering-based approach, by implanting or
injecting a scaffold/matrix to create a defined space for immune cell interactions. As in
traditional tissue engineering strategies, this microenvironment could be populated by co-
delivering specifically selected (e.g., disease-specific) autologous immune cells (193), recruiting
host immune cells in situ from the local circulation, or via a combination of these two
methodologies. The ability to specifically engineer this microenvironment to support the
activation of T cells, localize it to relevant tissue sites (e.g., tumor biopsy sites), and to create
depots of supportive chemokines/cytokines might provide important advantages over the
strategies described above. Because the specific architecture and cell compartmentalization in
secondary lymphoid organs is believed to make immune responses highly efficient (2, 3), a
scaffold providing a defined space and supportive signals for lymphoid tissue neogenesis may
also be superior to vaccination strategies based on the simple injection of purified disease-
specific T cells or dendritic cells.
Notably, many of the cytokines that have been studied for driving site-specific immune cell
accumulation play a role in lymphoid organogenesis (33, 38) and can induce local ectopic
lymphoid tissue neogenesis ('tertiary' lymphoid tissue) (35, 36). In a murine system, Suematsu
et al. used collagen sponges loaded with a cell line expressing the key developmental cytokine
lymphotoxin to induce the local generation of lymphoid tissue within the implant, complete with
organized T cell and B cell areas (119, 120). This study provides a provocative example of what
may be possible with a tissue engineering-based approach; however, the use of transfected cell
lines may not be attractive for clinical application due to safety and cost issues. We have thus
pursued suitable scaffolds and cytokine cues that could be combined to drive local immune cell
accumulation and/or lymphoid tissue induction without the need for genetically engineered cells.
Scaffolds for such lymphoid tissue engineering should provide a mechanically robust,
defined microenvironment for ex vivo cell loading and/or in vivo cell infiltration, as well as
adhesion and motility cues to support cell migration and interactions. As described in Chapter 2,
we and others have demonstrated the use of colloidal crystal templating to create macroporous
'inverse opal' hydrogels, which are composed of ordered, interconnected arrays of pores formed
on the tens of microns length scale (152, 153, 194). We envisioned this macroporous network as
an idealized surrogate for the reticular network in the T cell areas of secondary lymphoid organs,
a matrix composed of collagen fibers spaced 5-30 [tm apart (2, 3) and coated with basement
membrane proteins (5) and cells.
In the present studies, we tested the ability of these inverse opal hydrogels to support the
migration of primary T cells and dendritic cells, and explored strategies to provide motility-
inducing cues within these structures. Because the frequency of antigen-specific T cells is very
low (as few as 1 in 200,000 T cells in primary immune responses (9, 176)), T cell motility must
be robust for efficient antigen surveillance. As described in Chapter 3, T cell migration is
modulated by the cells' ability to adhere to their surroundings and by the presence of motility-
inducing chemokines (170, 195, 196). Thus, we first tested T cell loading and migration within
crosslinked poly(ethylene glycol) (PEG) inverse opal scaffolds surface-functionalized with the
short adhesion peptide Arg-Gly-Asp-Ser-Pro (RGDSP) (see Figure 4-1A and B). Though RGD
peptides supported the attachment and migration of an activated T cell clone through the matrix,
we found that most primary T cells adhered poorly to RGD-functionalized gels. This finding
may reflect the relatively low level of P31 integrins expressed by T cells (197) and the fact that
integrins are known to bind RGD peptides with at least 10-fold lower affinities than complete
adhesion proteins such as fibronectin (198).
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Figure 4-1 Strategies for preparing adhesive scaffolds. (A-D) depict a small portion of a
macroporous PEG scaffold. (A) Schematic indicating scaffold parts. (B) Schematic of peptide
labeling strategy: short adhesive peptides such as RGD were attached to cross-linked PEG
scaffolds by PEG tethers. Red dots represent the co-polymerization of tethered RGD throughout
the gel. (C) Schematic of protein attachment strategy: whole proteins (green globules) were
attached specifically to scaffold surfaces by binding to functionalized PEG tethers after scaffold
fabrication (functional bridging groups not shown). (D) Schematic of composite scaffold
strategy: collagen gel was infused into PEG scaffolds after fabrication. Schematics not to scale.
To enhance T cell adhesion, we next functionalized scaffold surfaces with full-length
adhesion proteins instead (Figure 4-1C). In particular, we tested intercellular adhesion molecule-
1 (ICAM-1), an adhesion receptor expressed by lymph node fibroblasts and dendritic cells (178,
179) that normally line the ECM of lymphoid tissues (3, 6), and fibronectin, an extracellular
matrix protein that may be presented to T cells by reticular fibroblasts (5). T cells express the
cognate receptors LFA-1 for ICAM-1 (170) and VLA-4 and VLA-5 for fibronectin (199).
However, we found that T cells adhered only modestly to ICAM-coated scaffolds (and not at all
to those coated with fibronectin), even in the presence of the adhesion- and migration-promoting
chemokine CCL21. The cells exhibited a relatively poor ability to migrate from pore to pore
within the 3D scaffold structure, irrespective of pore sizes.
This prompted us to evaluate a third strategy, this time forming a composite scaffold in
which a fibrillar collagen matrix was polymerized in the internal voidspace of a PEG inverse
opal hydrogel (Figure 4-1D). By this approach, we sought to combine collagen gels' ability to
support rapid amoeboid migration of T cells (200-202) with the mechanical robustness and
chemical flexibility of inverse opal synthetic gels. In these composite structures, T lymphocyte
and DC loading into scaffolds was enhanced, and further, T cells were capable of rapid pore-to-
pore migration. Finally, we implemented a strategy using heparin-conjugated PEG scaffolds to
bind the chemokine CCL21 on the walls of the inverse opal supporting structures, as a potential
means to deliver lymphoid tissue induction/motility signals within the composite scaffolds.
These results demonstrate the successful fabrication of a scaffold supportive of lymphocyte
migration, which could be further developed for use in cancer immunotherapy or to study factors
controlling de novo formation of lymphoid tissue at ectopic sites.
The cellular environment in the lymph node is complex, even within the T zone alone.
Because of their central role in the immune response and highly dynamic behavior, we were
especially interested in T cells. However, in addition to our work with T cells, we also studied
the behavior of dendritic cells and lymphoid stromal fibroblasts in lymphoid scaffolds, and this
work will also be described in the proceeding chapter.
4.2 Materials and Methods
4.2.1 Scaffold chemistry and fabrication
Inverse opal scaffolds were prepared as described in sections 2.2.1- 2.2.4. For whole protein
attachment, biotin-PEG-monoacrylate (biotin-PEGA) was included in the hydrogel precursor
solution at 1:500 biotin-PEGA:PEGDMA by moles. Biotin-PEGA was prepared by mixing 1:1
moles EZ-link biocytin (Pierce) with acryloyl-PEG-NHS (Nektar Therapeutics) for 2.5 h in 0.1
M sodium bicarbonate buffer (pH 8.3), followed by dialysis for lh (500 MW cutoff, Spectrum
Laboratories, Inc.), filtering and lyophilization. Like peptide-PEGA, biotin-PEGA was stored at
-20 TC in ~40 mg/mL aliquots.
4.2.2 NR6 fibroblast adhesion to PEG-RGD gels and scaffold
Adhesion of mouse fibroblasts (NR6 (203), a gift from Dr. Douglas Lauffenburger) to PEG gels
modified with tethered RGD peptides was confirmed after the method of Hern and Hubbell
(204). Thin solid gel films (22x22 mm 2, -200 ltm thick) were prepared by casting 100 pLL of
hydrogel precursor solution between glass slides and irradiating with a UV lamp for 90 seconds.
Films were moved to 6-well polystyrene culture plates, pinned flat by sterile aluminum rings,
sterilized with 70% ethanol, and exchanged into sterile complete RPMI culture medium. NR6
cells (5 x 103) were seeded on films in RPMI with or without 10% FCS, and incubated at 37"C
5% CO2 for up to 12 hours. Per condition, three random fields were observed, and the number of
both round and spread cells was recorded.
NR6 cells were also observed within PEG-RGD scaffolds. Fibroblasts (~xl106 per scaffold)
were labeled with PKH26 red membrane dye (Sigma) according to the manufacturer's protocol,
then loaded into scaffolds. Cells were incubated for 6-8 h, then fixed and stained with DAPI
nuclear dye (Invitrogen) prior to observation.
4.2.3 T cell migration in PEG-RGD scaffolds
Primary CD4' T lymphocytes were isolated from the lymph nodes of OT-II mice and activated
by exposure to peptide on the surface of gamma-irradiated antigen-presenting cells. These cells,
or cells from the D 10 CD4' T cell clone, were loaded into scaffolds by pipetting (106 cells in 20
[pL with shaking for 15 minutes at 100 rpm). Cell-scaffold constructs were observed in time-
lapse by optical microscopy.
4.2.4 Protein conjugation to biotinylated scaffolds
Fibronectin from bovine plasma (Sigma) was biotinylated using sulfosuccinimidyl-6'-
(biotinamido)-6-hexanamido hexanoate (Pierce) per the manufacturer's instructions.
Recombinant ICAM-1 (R&D Systems) was biotinylated using the Biotin-XX Microscale Protein
Labeling Kit (Invitrogen) according to the manufacturer's instructions. For protein attachment,
biotinylated scaffolds were sequentially incubated for 12-24 h at 4 TC with shaking in the
following solutions: (1) 1 mL of I VLg/mL streptavidin (SAv) or SAv-Alexa-647 (Invitrogen) in
pH 7.4 phosphate buffered saline (PBS), (2) 1.5 mL PBS (2-3 exchanges), (3) 0.5 mL of 10
tg/mL biotinylated protein in PBS. Prior to use in cell motility or fluorescent visualization
experiments, scaffolds were washed once per hour for 4-6 h in PBS.
4.2.5 Scaffold immunostaining
Attachment of adhesion proteins and chemokines was confirmed by immunostaining of scaffolds
using the following antibodies: 10 [pg/mL FITC-conjugated anti-ICAM-l clone 3E2
(Pharmingen), 1 pg/mL anti-fibronectin clone 10 (Pharmingen) followed by 2 [Lg/mL PE-
conjugated anti-mouse IgG, (Invitrogen), or 10 [tg/mL anti-CCL21 clone 59106 (R&D Systems)
followed by 10 lxg/mL Alexa-546-conjugated anti-rat IgG (Invitrogen). Antibody staining and
wash steps (3 quick rinses, then soak) were performed for 12 h at 4°C with shaking. Finally,
scaffolds were observed on a Zeiss Axiovert 200 epifluorescence or on a Zeiss LSM 510
confocal microscope.
4.2.6 Cell preparation and labeling for protein and composite scaffolds
All animal studies were approved by the MIT Committee on Animal Care, and carried out in
accordance with federal, state, and local regulations. Mice were obtained from Jackson
Laboratory. CD4' T cells were isolated from spleens of 6-12 wk-old male BALB/c mice by
magnetic bead negative selection: splenocytes were treated with a cocktail of biotinylated
antibodies (1 [tg/mL each anti-CD8a, anti-CD1 l b, anti-B220, and anti-NK 1.1) after erythrocyte
lysis with ammonium chloride, tagged with anti-biotin magnetic beads (Miltenyi Biotech) and
sorted on a MidiMACS column according to the manufacturer's instructions (Miltenyi Biotech).
T cell blasts were prepared by culturing the isolated cells in tissue culture wells previously
coated with 10 [tg/mL anti-CD3 and anti-CD28 (for 90 min at 37 'C) in complete RPMI medium
(RPMI 1640 containing 10% fetal calf serum, 2 mM L-glut, 50 [tM 2-mercaptoethanol, 10 mM
HEPES, 100 U/mL penicillin, and 100 [tg/mL streptomycin). The activated cells were split 1:2
and treated with 5 ng/mL IL-2 after 48 h. Cells were >96% CD4' at both day 3 and day 6 (as
determined by flow cytometry), and were used on day 4-5. A fraction of T cells (30% for
migration experiments, 100% for loading experiments) were labeled with 0.5 [LM
carboxymethylfluorescein diacetate (CMFDA) or 2.5 [tM Fura-2 AM according to the
manufacturer's instructions (Invitrogen).
Dendritic cells were prepared following a modification of the procedure of Inaba (167) by
extracting bone marrow from the femur and tibia of BALB/c mice and culturing the recovered
cells in complete RPMI supplemented every two days with 5 ng/mL GM-CSF (Peprotech). Cells
were typically used on day 6, following 16 h treatment with 1 [tg/mL lipopolysaccharide (LPS)
to trigger maturation (Sigma). In some experiments, DCs were prepared from C57B1/6 mice
expressing enhanced green fluorescent protein in all cells (EGFP mice).
BLS4 fibroblasts were a generous gift from Dr. Tomoya Katakai. Cells were cultured in
RPMI 1640 medium, passaged regularly, and labeled with DiI dye according to the
manufacturer's protocol (Invitrogen) one day prior to use. Cells were treated with EDTA and
trypsin to separate them from each other and the culture surface, then loaded in scaffolds in the
usual fashion (- 500,000 cells per scaffold).
4.2.7 Cell migration studies in protein and composite scaffolds
Excess liquid was removed from inverse opal gels by aspiration and a suspension of T cells or
dendritic cells was pipetted onto the scaffold 10-15 [iL at a time for 2-3 total additions. After
each addition, the suspension was incubated 3 min on the gel and then centrifuged into the
scaffold on a well plate carrier for 1 min at 800 rpm. Cells were loaded at 5x10 8 cells/mL in
medium or 2x10 8 cells/mL in bovine type I collagen (2.2 mg/mL, Inamed PureCol), containing 4
[g/mL CCL21 for scaffold experiments, and 2 [tg/mL for experiments in collagen alone. Cell-
loaded scaffolds were observed on a Zeiss Axiovert 200 epifluorescence microscope equipped
with a humidified environmental chamber (37 TC, 5% CO2) and images were collected with a
digital CCD camera (CoolSnap HQ, Photometrics) using Metamorph software (Molecular
Devices, Inc.). To track single-cell migration, time-lapse images were collected for 40 min in 30
s intervals using a 40x oil immersion 1.3 N.A. objective. At each interval, a single fluorescence
plane and a 10-plane z-stack of brightfield images collected through a total depth of 20 ptm were
collected in rapid succession using a high-speed pieozoelectric objective motor (Physik
Instrumente).
4.2.8 Cell adhesion studies in protein and composite scaffolds
BLS4 fibroblast cells (0.5-2.5x107cells/mL) or dendritic cells (1-5x108 cell/mL) were loaded into
scaffolds using the same procedure described for T cells (see previous section). However, BLS4
were kept in minimal amounts of medium (<100 [tL) for 20-60 minutes to allow them to partially
attach prior to addition of a larger pool of fresh warm medium (250-400 [tL). Cell-scaffold
constructs were observed after 0-24 h on an epifluorescence or confocal microscope maintained
at 37 oC.
4.2.9 Migration analysis
Maximum projections of brightfield image stacks were prepared in Metamorph software.
Individual cells were traced in brightfield or fluorescence images and tracked using Volocity
software (Improvision, Inc.). For quantitative measurements, 15 cells were tracked for each of 2-
3 independent experiments. Statistical significance of measured differences in migration
parameters was determined using one-way ANOVA, followed by Bonferroni's multiple
comparison test for all pairs of samples, and Dunnett's test for all treated samples vs. controls
(GraphPad Prism software).
4.2.10 Scaffold cross-section observation
Cell-loaded scaffolds were fixed in 4% paraformaldehyde (PFA) at 4 TC overnight, cut with a
razor, and observed on a Zeiss LSM 510 confocal microscope using a 40x water immersion 0.8
N.A. objective. Alternatively, PFA-fixed scaffolds were dehydrated in ethanol and prepared for
scanning electron microscopy as described in section 2.2.5.
4.2.11 Chemokine adsorption to scaffolds
Streptavidin-conjugated scaffolds were incubated with 0.5 mg/mL aqueous biotinylated heparin
(Sigma, average MW 15 kDa), then washed in deionized water for 12 h each. Recombinant
CCL21 (R&D Systems) was reconstituted in PBS with 0.1% bovine serum albumin (BSA) at
100 Rig/mL, then diluted in water just prior to use (5-10 [tg/mL). Heparin scaffolds were
incubated in 0.3 mL of the diluted solution for 12-16 hrs at 4°C, followed by washing for 4 or 24
hrs with PBS/1% BSA depending on the subsequent assay.
4.3 Results
4.3.1 Integration of cells and porous hydrogel scaffolds
In the course of integrating cells with our newly developed porous scaffold, we pursued several
cell loading strategies. These were modified over time depending on the properties of the current
scaffold as it went through several stages of development, as well as depending on the cell type
to be added.
The two main strategies we studied were pipetting of cells onto the scaffold and injection of
cells into the scaffold. Either of these could be further modified by a centrifugation step (meant
to improve cell loading in the center of the construct) or by an incubation and/or shaking step
(also meant to improve uniformity of loading, and give time for adhesive cells to attach prior to
the construct being moved to the observation dish). Injection by needle had the drawback of
damaging the scaffold, difficulty in attaining reproducibility of cell entry and distribution, and
the possibility of shear stresses harming the cells. Injection also appeared to work best when
using scaffolds that were covalently attached to slides modified with silane-acrylates and a thin
film of non-porous PEG; this way cells could not escape through the bottom of the porous gel,
and were forced back up into the scaffold. However, attachment of scaffolds to glass slides
reduced the surface area available for mass transport, and thus required harsh organic solvents
(dichloromethane) to fully remove the templating microspheres.
Ultimately, we settled on the following basic procedure: 1) cells are suspended at high
concentration in a small volume of medium (or collagen); 2) this suspension is pipetted on top of
the scaffold, and incubated for a few minutes at 4 or 37 'C; 3) the scaffold-cell construct is
briefly centrifuged to improve uniformity of cell loading; 4) the construct is placed in a pool of
fresh medium or collagen. Although cell distribution continued to vary somewhat across
different fields of the scaffolds, and from scaffold to scaffold, this method was comparable to
injection in final result without any of the drawbacks. In the main, our cell loading studies
revealed that small, non-adhesive cells such as T lymphocytes require very high cell
concentrations (>100M cells/mL) for sufficient loading within a macroporous scaffold, due to
poor loading efficiency. Cell losses due to flow over the top and sides of the scaffold, as well as
potentially from the surface pores, were the cause of this low efficiency. For large cells such as
fibroblasts, a (100-1000)-fold lower cell concentration could be used.
An example of uniform cell loading is shown in the low-magnification scanning electron
micrograph below of dendritic cells in a scaffold with a 40 ýtm void size (Figure 4-2). This
protein-coated scaffold allowed some attachment of DCs, as shown in the higher magnification
view. Examples of fibroblast cell loading will be shown in sections 4.3.3.5 and 4.3.4.5. We were
most interested in T cell loading in scaffolds, as well as most challenged by it, due to the poor
adhesiveness of T cells. As described in section 4.3.4, we found that the use of collagen gel
within the synthetic polymer scaffold dramatically improved cell loading and retention.
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Figure 4-2 Example of cell loading in protein-coated scaffolds. (A) Scanning electron
micrograph demonstrating dendritic cell loading across a large section of a protein-coated
scaffold surface (original magnification 100x). (B) Closer view of cells attached to walls of
scaffold (original magnification 800x).
4.3.2 PEG scaffolds with tethered adhesion peptides
PEG networks are readily functionalized with short peptides that support cell adhesion via
specific integrin cell surface receptors (72, 77, 125). Given the simplicity of this approach, we
began our studies by synthesizing PEG monoacrylates conjugated with the adhesion peptide
(135) GWGRGDSP (RGD-PEGA), and tested the response of several cell types to these gels.
We first demonstrated that the RGD tethered to our PEG scaffolds remained functional after
the fabrication process, which includes a long treatment in acetic acid. Since lymphoid stromal
cells were not available at the outset of this thesis, we initially studied the response of generic
fibroblasts to peptide-containing bulk gels and scaffolds. Specific adhesion of mouse fibroblasts
expressing aP33 and tas3p integrins (NR6, (205)) to PEG gels modified with tethered RGD
A
peptides was confirmed after the method of Hern and Hubbell (204). Briefly, NR6 cells were
seeded onto bulk gel films in cell culture medium with or without 10% fetal calf serum. The gels
had been previously soaked in acetic acid and PBS to mimic the templated scaffold processing.
As shown in Figure 4-3, 91.2 + 1.8 % of cells spread on the RGDSP-containing gels by 12 hrs,
while less than 1% of cells spread on control gels containing RDGSP in the presence of serum.
Adhesion was well maintained under serum-free conditions (76.7 ± 5.7%), and did not occur in
the presence of competitive soluble RGD ligand at short times.
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Figure 4-3 Fibroblasts spread on RGD-modified bulk hydrogels. (A) Brightfield images of
NR6 fibroblasts spread on RGD-modified hydrogel films. (B) Brightfield images of films
presenting RDG, on which fibroblasts were primarily rounded and clumped up. (C) Quantitative
analysis of cell spreading on both films, with controls.
When we placed these fibroblasts in RGD-modified scaffolds, they were able to attach,
spread, and remain viable over at least several days when cultured within scaffolds in vitro
(Figure 4-4). We next loaded the RGD-functionalized scaffolds with a more motile cell type of
interest to us - T cells. We used both a constitutively migratory T cell clone and activated
primary T cells isolated from lymph nodes of OT-II mice, in order to address two issues. We
aimed to discover both whether the scaffold architecture was open enough to sustain migration
by moving cells and whether the scaffold adhesion peptides were relevant for primary T cells.
We found that the connected cellular structure of templated gels provided functional pathways
for cell migration within the scaffold: cells could readily traverse the interconnecting pores
throughout the matrices in three dimensions (illustrated by time-lapse images shown in Figure
4-5). However, a majority of primary cells did not travel very far and seemed to readily detach
from the walls of the structure, indicating that the RGD peptide may provide poor support for
adhesion of primary T cells.
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AFigure 4-4 Cell attachment in templated PEG-peptide hydrogels. Overlaid brightfield optical
and fluorescence micrographs of stained NR6 fibroblasts spread on RGD-functionalized PEG
scaffolds with 40 (A) and 60 (B) ýtm void sizes, after 24 hrs (scale bars 50 [tm). Fluorescence
staining of cells within scaffold: red, PKH26 membrane dye, blue, DAPI nuclear stain.
Figure 4-5 Cell movement through templated PEG-peptide hydrogels. (A-B) Time-lapse
brightfield optical microscopy images of T lymphocytes migrating through throat pores in
scaffolds. Primary CD4' T cells isolated from OT-II mice (A) and CD4' T cells (DI0 clone) (B)
are shown migrating in scaffolds with 20 and 30 mrn voids, respectively. Times are elapsed
min:sec; the cell of interest in each case has been identified with a false-color overlay.
4.3.3 PEG scaffolds surface-functionalized with whole adhesion proteins
Due to the limited response of primary T cells to peptide-functionalized scaffolds, we developed
a method to coat scaffolds with whole adhesion proteins instead. Peptides typically consist of a
single recognized epitope for binding, and thus provide incomplete adhesion signals to cells
compared to proteins, which have multiple epitopes arranged in conformations ideally suited to
binding. Despite the superior binding affinity of proteins compared to peptides, when we loaded
T cells into scaffolds coated with intact ECM proteins such as fibronectin, we found no
improvement in T cell motility. In contrast, scaffolds coated with ICAM-1 (normally a cell-cell
adhesion protein) prompted robust migration in a fraction of T cells. We also observed the
behavior of dendritic cells and stromal fibroblasts in protein-coated scaffolds, because of the
importance of these cells in immune responses and lymph node structure, respectively. Both cell
types formed adherent networks in the scaffolds, and DCs were able to migrate along scaffold
walls. These experiments are elaborated in sections 4.3.3.1 - 4.3.3.5 below.
4.3.3.1 Functionalization of inverse opal hydrogels with lymphoid tissue-
associated adhesion proteins
In Chapter 2 we reported a strategy for preparing macroporous hydrogel scaffolds by colloidal
crystal templating, which could be functionalized with covalently tethered adhesion peptides
incorporated during polymerization of the gel matrix (see Figure 2-1, and (194)). Due to the poor
adhesion of most primary T cells to RGD-functionalized gels (as described in the previous
section), we developed an alternative strategy to support T cell attachment and migration:
conjugating full-length adhesion proteins to all of the internal and external free surfaces of
porous scaffolds post-fabrication (see Figure 4-6). The method we developed to attach protein to
scaffolds utilized biotin-streptavidin binding, which is one of the strongest naturally occurring
non-covalent bonds in biological systems (with a dissociation constant KD close to 10"- M,
(206)). Biotin was conjugated to the scaffold by first reacting biocytin (biotin-lysine, which has a
single available amine group) with NHS-PEG-monoacrylate (Figure 4-7), then co-polymerizing
the biotin-PEG-acrylate with PEGDMA as before (Figure 4-6). Finally, protein was conjugated
to the resulting surface-accessible biotin groups by incubating templated scaffolds in a
streptavidin solution followed by washing and binding of biotinylated ICAM- I or fibronectin.
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Figure 4-6 Schematic demonstrating method for protein attachment to hydrogel scaffolds.
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Figure 4-7 Schematic of biotin-PEG-acrylate preparation. NHS is N-hydroxysuccinimide
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Inverse opal PEG scaffolds synthesized with 0.2 mole % biotin-PEG-acrylate (99.8 % PEG-
dimethacrylate) avidly bound streptavidin on all of the interior surfaces of the 3D macroporous
structure, as evidenced by confocal fluorescence images of biotinylated scaffolds following
exposure to fluorescent streptavidin solutions and washing to remove unbound protein (Figure
4-8A). Confocal optical sectioning of scaffolds revealed that protein binding was largely
confined to the surfaces of the scaffold pores and did not penetrate throughout the interior of
scaffold struts, suggesting that the mesh size of the gel is too small for rapid diffusion of
streptavidin into the PEG network. This is particularly apparent on a strut widened due to a
template defect, as indicated by the arrow in Figure 4-8A, which highlights the lack of labeling
on the interior of the 'solid' gel strut.
Once we had successfully prepared streptavidin-conjugated scaffolds, we biotinylated
proteins at a fraction of their free amine groups by succinimidyl ester chemistry. The success and
degree of the protein biotinylation reaction were demonstrated by measurement of biotin groups
on the adhesion proteins: 10 biotin groups per fibronectin were observed by the HABA assay,
while 4-6 biotin groups per ICAM-1 were observed by a FRET-based assay that requires only
miniscule amounts of protein (see Appendix E.2).
To demonstrate specific coupling of these adhesion proteins to scaffolds, and to assure that
protein incubated with the scaffold after the streptavidin conjugation step would remain attached,
we performed immunostaining. Streptavidin-coated gels were incubated with biotinylated
proteins, washed, and then stained with appropriate primary and secondary antibodies against
either fibronectin or ICAM-1. Both proteins were robustly detected on the scaffold surfaces
(Figure 4-8, B and C). The image section shown for ICAM-1 is slightly deeper into the scaffold
than the section shown for fibronectin, and demonstrates that the proteins penetrate beyond the
first layer of the scaffold. Thus, this conjugation strategy allows adhesion proteins to be coupled
to the internal surfaces throughout inverse opal hydrogel scaffolds.
BC
Figure 4-8 Functionalization of macroporous hydrogels with whole proteins. (A) Confocal
images of a biotinylated scaffold (main) and a control non-biotinylated scaffold (inset) exposed
to fluorescent streptavidin under the same conditions. Scale bar 41 ýtm. (B-C) Biotinylated
proteins attached to streptavidin-conjugated scaffolds were detected by immunostaining. (B)
Attachment of fibronectin is shown as obtained from confocal microscopy following
immunostaining with an unlabeled rat anti-fibronectin and a phycoerythrin-conjugated anti-rat
antibody (scale bar 41 ýtm). (C) Staining of ICAM-1 attached to a scaffold is shown in
epifluorescence using a FITC-conjugated anti-ICAM-1 (scale bar 48 Ltm).
4.3.3.2 T cell migration in protein-coated scaffolds
We next characterized the migration of T cells within protein-coated and unmodified scaffolds.
In these studies, we utilized murine primary T cells primed in vitro by antibodies to CD3 and
CD28. Such activated cells may be expanded in great numbers from a single animal, and also are
larger and constitutively more migratory than naive T cells, making them a good candidate for
screening the activity of different adhesion proteins coated on scaffolds. Although as a
chemoattractant the lymphoid tissue chemokine CCL21 is known to be particularly potent for
naive T cells (21), with regard to chemokinesis we observed similar effects of CCL21 on
activated T cells as those described in Chapter 3 for naive T cells. Thus, we added CCL21 (at ~ 4
[tg/mL) to promote cell motility within scaffolds loaded with fluorescently labeled T cell blasts.
Cell migration was recorded by time-lapse brightfield and fluorescence videomicroscopy and
analyzed at the single-cell level.
Unmodified PEG scaffolds with a 40 [im void size supported no T cell attachment and T
cells were unable to migrate between pores of these structures (Figure 4-9A). T cells remained
equally non-motile in fibronectin-coated scaffolds, even if present at high cell densities that
forced many cells into contact with the walls. In contrast, ICAM-1 coated scaffolds supported
avid migration for ~30% of loaded T cells even at low cell densities, as shown by representative
cell migration paths (Figure 4-9B), and further evidenced by quantitative comparisons between
cell motility in each of the scaffold conditions (Figure 4-9, C-F). In uncoated scaffolds, the
average cell velocity was 4.3 pm/min, a somewhat high resting value due to jostling of the
CCL21-stimulated T cells as they extended lamellipodia; however, no cells neared the typical
~10 pLm/min values observed in vivo (116, 207). This average increased to ~ 6.1 pm/min for cells
in ICAM-I coated scaffolds, with several cells migrating at 7-8 plm/min and reaching maximum
displacements of 40-60 pm in 15 min. However, many cells circled within their initial voidspace
without traversing throat pores, as evidenced by the relatively high turning angles for all
samples. The confinement ratio, defined as the end displacement divided by total distance
traveled, also remained low (indicating significant confinement of the cell path) irrespective of
the presence of fibronectin or ICAM-1. Although statistically significant changes in motility
were seen for T cells in ICAM- -coated scaffolds vs. unmodified scaffolds in all four parameters
examined, the population behavior of T cells crawling in ICAM-1 coated scaffolds did not
approach the rapid migration and high confinement ratios (low confinement) observed for T cell
migration in vivo.
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Figure 4-9 A fraction of T cells migrate in ICAM-1 conjugated scaffolds. (A-B) Brightfield
images with overlaid migration paths of several representative T cells in a control scaffold (A) or
ICAM-1 coated scaffold (B) over 15 min. Scale bars 48 Gnm. (C- F) Time-averaged migration
properties of individual T cells in scaffolds, namely velocity (C), maximum displacement (D),
turning angle (E), and confinement ratio (F). Each cell was analyzed for a 15 min timecourse; 15
cells from each of 2 independent experiments were analyzed. ** indicates p < 0.01 compared to
no protein sample.
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4.3.3.3 Interaction of dendritic cells with protein-coated scaffolds
Dendritic cells present antigen to naive T cells in order to activate them, thus playing a major
role in the primary immune response. Intravital imaging has shown that DCs are present in the
lymph node primarily as stationary networks, with newly antigen-loaded DCs that enter from the
periphery at first maintaining moderate cell velocities, and then eventually joining the network.
Despite this immobility, due to their long dendrites and the way they are organized on the lymph
node fibers (17), DCs are readily able to contact many T cells; in fact, about 60% of T cells in
lymph nodes are in contact with a DC at any give time (177). We thus briefly studied the
behavior of dendritic cells alone in protein-coated scaffolds, to see if we could recreate DC
networks in vitro.
We found that the morphology and migratory behavior of DCs on our scaffolds was highly
heterogeneous, depending on their maturation state as well as on biochemical signals presented
by the scaffold. DC networks similar to those seen in vivo were sometimes observed on scaffolds
coated with the ECM proteins fibronectin and/or laminin, as shown in Figure 4-10. As in vivo, a
fraction of DCs migrated rather than remaining stationary (see Figure 4-11). However, this
spreading and/or migratory behavior was not observed in all experiments utilizing DCs. Bone
marrow-derived DCs are a heterogeneous group of cells, so it is not surprising that the fraction of
adherent or migratory cells might vary from batch to batch. Moreover, the tendency of DCs to
spread out and/or migrate is influenced by their maturation state (5), and merely recovering cells
by pipetting (as well as manipulating them to introduce fluorescent labeling) can cause some
degree of maturation (208). Determining the exact conditions necessary and sufficient for DC
network formation and/or crawling, perhaps by performing parallel analyses of DC spreading by
microscopy and DC maturation state by flow cytometry, is an area ripe for further study.
A
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Figure 4-10 Dendritic cell attachment to protein-coated scaffolds. Overlays of brightfield and
confocal fluorescence images are shown. Day 5 immature DCs were stained with CMFDA prior
to loading in scaffolds. (A-B) DCs in scaffolds without protein remain primarily round after 2 h.
(C-D) In fibronectin-coated scaffolds, -50-70% of DCs are spread along the walls. Cells are
shown at 40x magnification (A and C, scale bars 41 [tm) and 20x magnification (B and D, scale
bars 80 [tm).
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Figure 4-11 Dendritic cell crawling on protein-coated scaffolds. A dendritic cell is shown
crawling along the wall of a laminin-coated scaffold pore. The DCs were derived from a
transgenic mouse expressing enhanced green fluorescent protein in all of its cells and did not
require external labeling.
4.3.3.4 Effect of CCL21 on naive T cells in scaffolds with and without DCs
Having systematically studied the impact of homeostatic chemokines in a minimal, monolayer
environment (see Chapter 3), we initiated some studies of CCL21-stimulated naive T cells in our
lymphoid tissue scaffolds, with and without DCs present. As on glass substrates, T cells exposed
to CCL21 in lymphoid scaffolds exhibited striking morphology changes (see Figure 4-12).
However, in medium pore sizes (40 Itm) and in the absence of DCs, T cells did not migrate.
Figure 4-12 CCL21 stimulation of naive T cells in scaffolds. Naive T cells were added to
fibronectin-conjugated scaffolds in the absence (A-B) or presence (C-D) of 1 [tg/mL of CCL2 1.
For improved visualization, -50% of cells were labeled with fura-2AM dye. Brightfield (A and
C) and fluorescence (B and D) images of the same two fields are shown, and an increase in cell
polarization in the samples treated with CCL21 is apparent. Scale bars 25 [tm. This data is
representative of at least five experiments.
In contrast to the inability of na'ive T cells to migrate on protein-coated scaffolds, when DCs
were added at a high ratio (-2:1 of DC:T cells) under conditions where DCs adhered to the
scaffold walls, a fraction of T cells were able to migrate vigorously in the presence of CCL21.
Figure 4-13 shows the path of one such naive T cell traveling on a DC body, which traverses the
entire pore diameter (40 [tm) in ~3.5 min. Other T cells in the same experiment were able to
cross throat pores that were straddled by DCs. We saw similar results with activated T cells, and
Table 4-1 shows the effect of DCs on single-cell migration parameters seen for both naive and
activated T cells. In the presence of DCs, maximum values in the cell population for maximum
displacements, confinement ratios, and velocities all increase, while minimum values stay the
same or slightly increase as well. Activated T cells are clearly more migratory than naive T cells,
but in these experiments only a small fraction of cells were able to migrate on DCs whether the
cells were activated or not.
In conclusion, the presence of supporting cells (their type, number, and ratio) is one
parameter that can substantially influences the migration of T cells. However, due to our interest
in co-attracting (rather than sequentially attracting) any desired cell types in the ultimate
application (tissue engineering immunotherapy), as well for simplicity, the majority of our
studies focused on inducing migration in one cell type at a time rather than studying cell
interactions within the scaffolds.
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Figure 4-13 Naive T cell migration on DC 'carpets' in scaffolds. Nai've T cells in the presence
of both DCs and CCL21 were able to crawl along DC bodies within the scaffold structure, but
were not able to migrate in scaffolds lacking DCs. An example of such migration is shown
above, with T cells false-colored in red and DCs in green. Elapsed times are min:sec.
Table 4-1 Effect of DCs on migration parameter ranges for T cells.laI
Sample[Lb Velocity Maximum Confinement
(p[m/min) Displacement (pm) Ratio
To - DCs 1.2 - 3.4 0.0 -17 0.07 - 0.34
To + DCs 0.56 - 5.5 2.3 - 25 0.08 - 0.55
Tb - DCs 2.5-4.4 8.9- 18 0.07-0.15
Tb + DCs 3.5 - 7.9 11.6 - 57 0.10 - 0.76
[a] Migration parameters were determined for single cells, and the ranges of values observed in the entire population
are shown.
[b] T,, are naive T cells, and Tb are activated T cell blasts.
4.3.3.5 Lymphoid fibroblasts form networks in protein-coated scaffolds
Fibroblastic reticular cells (FRCs) surround the fibrous ECM scaffolding of the lymph node T
zone, produce chemokines that act on lymphocytes (such as CCL21, (24)), and have long been
inferred to influence T cell migration (2). In 2004, Katakai et al. derived a stromal cell line that
expresses ER-TR7, one of the few proteins known to be produced specifically by FRCs in the
lymph node T zone (178). Using this model cell line, Katakai showed that lymphocytes (and to a
lesser extent inflammatory factors such as TNF-ac and LT-13) promote ECM secretion by FRCs.
Stromal cells in turn are known to improve T lymphocyte viability in vitro (209). FRCs also help
maintain appropriate architecture in the lymph node via cell-matrix and cell-cell interactions,
forming an interconnected living network in the T zone (4). Quite recently, the first dynamic in
vivo demonstration that T cells in the lymph node preferentially crawl on FRCs was published
(4). Due to their structural and functional importance in the lymph node, it would be desirable to
have FRCs present in a tissue engineering construct for immunotherapy. We therefore briefly
studied the response of lymphoid fibroblasts to the protein-coated version of scaffolds.
Using the FRC cell line derived in Katakai's group, we first studied whether a stromal cell
network could self-assemble in our model lymphoid scaffolds. FRCs were initially round after
being loaded into scaffolds, but over time spread and connected with other cells to form a
network (see Figure 4-14, A-F). Network formation occurred only in the presence of the
extracellular matrix protein fibronectin at short times. At longer times, some network formation
could occur even in scaffolds lacking protein, perhaps due to the non-specific adsorption of
serum proteins to the negatively charged groups (from the free carboxyl groups on biocytin) in
the scaffold or due to ECM produced in situ by FRCs. It especially occurred in places where
cells were nearby enough to contact each other. Unlike dendritic cells, which primarily lined the
gel matrix walls, FRCs primarily extended processes that penetrated through interconnected
pores; thus, the scaffold 'templates' the FRCs into an additional close-packed circular layer,
which is offset from the porous gel template above and below those cells (Figure 4-14, C-F,
Figure 4-15). This dictation of a regular cellular architecture by the ordered macroporosity is a
unique feature of our system, and may find use in other tissue engineering applications.
In further contrast to DCs, this lymphoid fibroblast cell line appeared to have no influence on
T cell migration in the co-loading studies that we performed (data not shown). However, it is
possible that in an in vivo environment the fibroblasts might be exposed to factors that would
upregulate adhesion molecules or otherwise influence their interaction with T cells. In support of
this hypothesis, Bajenoff et al. recently showed in vivo that T cell migration within lymph nodes
primarily occurs along FRCs (4). Thus, it is potentially useful to be able to support FRC
networks in scaffolds for lymphoid tissue engineering applications.
CE
Figure 4-14 Effect of fibronectin on lymphoid stromal cell network formation in scaffolds.
Cells from the BLS4 line were labeled with Dil fluorescent dye and loaded into unmodified (A,
C, E) and protein-coated (B, D, F) scaffolds. (A-B) Brightfield images of cells just after loading.
All cells are round at this time. (C-F) Brightfield (C-D) and red fluorescence (E-F) images after 9
h of cell incubation in scaffolds. Cells in the scaffolds without protein are slightly enlarged but
do not extend many processes, while cells in the fibronectin-conjugated scaffold are forming
multi-cell networks. Arrows indicate cell spreading through throat pores and multi-cell junctions.
Areas of comparable cell density are shown. Scale bars 50 ptm.
BFigure 4-15 Formation of large-area, 3D stromal cell networks 
in fibronectin-coated
scaffolds. (A) Brightfield image is shown from a porous layer near the scaffold surface, 
16 h
after seeding fibroblasts. Arrows indicate cell spreading through throat 
pores. Scale bar 41 [tm.
(C) A 3D view (-35 [tm thick) of an extended FRC network made by computational
reconstruction. Fibroblasts were labeled with Dil red fluorescent 
dye and observed at 14 h.
4.3.4 Polymer-collagen composite scaffolds for improved cell support
Protein-coated scaffolds were a great improvement over peptide-containing scaffolds in
promoting T cell motility, and also induced interesting networking behaviors by dendritic cells
and lymphoid fibroblasts. More specifically, ICAM-1 presentation caused moderate migration in
~ 30% of T cells, while attachment of ECM proteins such as fibronectin and laminin promoted
DC and FRC adhesion. However, as a therapeutic construct these scaffolds might be limited, as
under no conditions that we tested (varying ligand, cell composition, and also pore size - not
shown) did T cells migrate as rapidly as they are known to do in vivo. We reasoned that we could
improve T cell migration, as well as cell retention, by loading collagen-cell suspensions within
porous polymer scaffolds and then allowing the collagen to form a fibrillar gel. In this case, the
polymer remains as a support with mechanical properties superior to collagen, allowing it to be
implanted as a stable construct in tissue engineering applications. It also may be exploited for
delivery of soluble factors, as will be described in section 4.3.5. Meanwhile, the collagen
provides an excellent substrate for cell migration. As we did for the protein-coated scaffolds
described in the previous section, we focused on T cell migration within composite scaffolds, but
also briefly studied dendritic cell and fibroblast responses.
4.3.4. 1 Fabrication of collagen-infused inverse opal scaffold
Though T cell migration was enhanced in ICAM-l-coated scaffolds relative to unmodified gel
surfaces or fibronectin-coated structures, the majority of T cells exhibited low total displacement
and remained confined to individual pores of the matrix for times exceeding 15 min. In contrast,
T cells migrating through lymph nodes in vivo often travel 70-100 [tm away from their origin
within similar time spans (116). The videomicroscopy data from our experiments suggested to us
that lymphocytes adhered weakly to the walls of the matrix and were easily dislodged by random
contacts with neighboring cells or convective currents. To address these limitations we examined
an alternative approach, in which we formed a composite matrix of PEG inverse opal hydrogels
infused with a fibrillar collagen gel (Figure 4-16A). In this strategy, the inverse opal gel provides
mechanical support (194) (and as shown later, the ability to reversibly bind chemokines) while a
collagen matrix filling the voidspace of the inverse opal structure provides a physical meshwork
that supports T cell migration (201, 202). To create the composites, cells suspended in collagen
solution were pipetted onto PEG scaffolds rid of excess liquid, which imbibed the solution over
periods of a few minutes at 4°C. Collagen fibrillogenesis and cell equilibration were then
achieved by incubating the infused scaffolds at 370 C for 60 min.
The successful formation of the composite matrix was demonstrated by combined confocal
reflectance (210) and fluorescence microscopy. The scaffold was visualized by conjugation of
fluorescent streptavidin to its surfaces, while reflected light in the green and red part of the
spectrum was used to visualize the collagen fibers polymerized in the scaffold voidspace (Figure
4-16B). The composite scaffold gave more reproducible results for cell loading and subsequent
cell behavior, and allowed us to perform systematic studies of how architecture affects T cell
migration. These studies are described in the following section.
collagen
solution
Figure 4-16 Fabrication of composite polymer-collagen scaffolds. (A) Schematic of
composite scaffold fabrication. (B) Successful formation of composite was visualized by
combined confocal reflectance (for collagen) and fluorescence (for scaffold labeled with
fluorescent streptavidin) imaging. Collagen fibers are shown in green and red, scaffold is
shown in blue. Scale bar 41 ptm.
4.3.4.2 T cells migrate avidly in collagen composite scaffolds
Before examining T cell migration in inverse opal composite scaffolds, we first characterized T
cell blast migration in neat 2.2 mg/mL collagen gels (i.e., in the absence of a supporting inverse
opal structure) with or without the addition of the motility-stimulating chemokine CCL21, to
provide a basis for comparison with the inverse opal composite matrices. As on 2D adhesive
substrates, we found that CCL21 treatment (at 2 itg/mL) of T cell blasts in 3D collagen also
substantially increased their migration (Figure 4-17). Because activated T cells are more
constitutively migratory than naive T cells (156, 182, 183), a fraction migrated through collagen
with in vivo-like characteristics even in the absence of CCL21. However, this fraction of highly
motile cells was greatly increased by addition of CCL21 to the collagen gels, resulting in
migration parameters similar to those seen in vivo (see also section 4.4), such as an average
velocity of 8.9 im/min (vs. 3.6 mrn/min for the control), and an average turning angle of 530 (vs.
850 for the control).
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Figure 4-17 The chemokine CCL21 enhances motility of primed T cells in 3D collagen gels.
A-D) Time-averaged properties for individual T cell blasts migrating in collagen are shown for
cells treated with or without 2 lpg/mL CCL21, namely velocity (A), maximum displacement (B),
turning angle (C), and confinement ratio (D). Each cell was analyzed for a 15 min timecourse; 15
cells from each of 2 independent experiments were analyzed. *** indicates significant
difference at p < 0.0001.
The same concentration of collagen was next infused into macroporous PEG gels. T cells in
the resulting composite scaffolds exhibited increased motility compared to those in ICAM-1-
coated scaffolds with the same (40 ltm) void diameter (compare Figure 4-9 and Figure 4-18). For
example, mean maximum displacements were increased by 50%. In this setting, we expected that
lymphocyte displacement and migration parameters would be influenced by the inverse opal void
size. Larger pore sizes give more space for cells to travel before encountering a wall that could
halt their migration or reduce its circuit, while small throat pores on the order of cell size could
prevent transit of cells through the portals entirely (throat pore diameter is ~ 25% of nominal
pore diameter, see section 2.3.2). Indeed, when T cell migration was quantified for composite
scaffolds formed using inverse opals with different void diameters, we found that T cell
trafficking pore-to-pore within scaffolds increased as the void diameter increased (Figure 4-18).
Cells were rarely able to transit between voids in 20 tm scaffolds, exhibited moderate
displacements in 40 [tm scaffolds, and migrated avidly through 80 ýtm pore scaffolds. Cell tracks
(Figure 4-18, A and B) show this phenomenon qualitatively. While paths in the 80 ýtm scaffold
were rarely obstructed, circular paths were evident in the 40 [tm scaffolds, where it appears as
though cells were being guided by contact with the PEG gel pore walls. Scaffolds with 80 ptm
void diameters were statistically identical to collagen alone as a substrate for cell migration in
terms of cells' maximum displacement and confinement ratios (Figure 4-18, C-F), and ranges of
values were similar for all parameters but turning angle, in which there was clearly a confined
population in the 80 [tm scaffold that was absent in pure collagen, with angles > 90'.
Interestingly, migration in 40 ýtm scaffolds was statistically different from that in 80 tm
scaffolds (p < 0.05) for all parameters except velocity. This suggests that just as vigorously
moving cells can nevertheless be differentially confined by the surrounding architecture.
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Figure 4-18 T cell migration in composite scaffolds is robust and is affected by pore size. A-
B) Stills demonstrate migration paths of several T cells (in false color) in scaffolds with a main
pore diameter of 80 [tm (A) or 40 [tm (B). C-F) Time-averaged properties for individual T cells
are shown as a function of scaffold pore size (20, 40, or 80 tm) and in pure collagen. Shown are
velocity (C, [tm/min), maximum displacement (D, tm), turning angle (E, degree), and
Pure
collagen
%a
confinement ratio (F, ratio of end displacement to total distance traveled). Each cell was
analyzed for a 15 min timecourse; 15 cells from each of 2 (collagen) or 3 (scaffold) independent
experiments were analyzed. Significant differences compared to collagen alone are indicated (**
p < 0.01 by Dunnett and Bonferroni, * p < 0.05 by both tests, (*) p< 0.05 by Dunnett but > 0.05
by Bonferroni). Scale bars 24 pm.
In order to determine to what extent cell migration was random under the different
conditions, we examined mean displacements for individual cells, plotted as a function of the
square root of elapsed time. A linear relationship between mean displacement and root time
indicates random cell migration, whereas a linear region followed by a plateau indicates
confined migration, and a linear region followed by positive curvature indicates directed
migration such as chemotaxis (39). (Note that the linear region is usually preceded by a brief
non-linear regime due to the initial persistance of a cell in a given direction). The slope of the
linear region indicates the relative motility of a given cell, with a motility coefficient defined
analogously to a diffusion coefficient (slope2/4 for migration in two dimensions). As shown in
Figure 4-19A, most cells migrating in pure collagen moved randomly and exhibited a range of
motility coefficients (i.e., slopes), but a few non-motile or circling cells were apparent (as curves
with plateaus or dips). Cells behaved similarly in composite scaffolds with an 80 pm pore size
(plots were mostly linear or with slight plateaus), and motility coefficients were statistically
identical to the case of pure collagen (see Figure 4-19B and D). In agreement with the previous
data analyses, in composite scaffolds with 40 [tm pores (Figure 4-19C) many cell migration plots
exhibited plateaus or dips, and cell motility coefficients were significantly lower. Thus, as
scaffold pore size increased, cell migration became less obstructed and was primarily Brownian.
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Figure 4-19 T cell migration is largely random in composite scaffolds with high pore size.
(A-C) Mean displacement plots are shown for cells moving in pure collagen (A), in composite
scaffolds with 80 ptm pores (B), and in composite scaffolds with 40 [tm pores (C). One
representative experiment (15 cells) is shown per condition. (D) Motility coefficients extracted
from mean displacement plots are shown for the three cases. Data was analyzed from two
representative experiments (30 cells) for the pure collagen and 80 [tm conditions, and from one
experiment for the 40 itm condition.
4.3.4.3 Full-thickness cell loading in composite scaffolds
While carrying out the migration studies just described, we discovered that cell loading in the
composite collagen-infused structures appeared to be enhanced relative to loading of cells in
inverse opal scaffolds that had been coated with adhesion proteins. Although observation of the
outermost layers of gels by microscopy indicated that high cell density could be achieved in
large areas of both protein-conjugated inverse opal gels and inverse opal-collagen composite
gels, collagen-infused scaffolds were more uniformly filled with cells. We examined the extent
of T cell loading in 3D by confocal imaging of thin sections cut through 1 mm-thick inverse
opal-collagen composite scaffolds with 80 [tm void diameters. This revealed T cell loading
throughout the 1.2 mm thick scaffold cross-section (Figure 4-20). Similar experiments with
mature dendritic cells showed that these larger cells could also be fully loaded through a scaffold
with 80 [tm pores as well. Figure 4-21 shows the center portions of two separate scaffold cross-
sections, both of which have several DC clusters present. (This is clear in the brightfield images,
although fixed DCs did not retain fluorescent dye well.) Both scaffolds also are brightly labeled
with streptavidin all the way through, providing further confirmation of uniform protein
conjugation throughout the scaffolds. In therapeutic strategies utilizing cells pre-loaded into
scaffolds, full-thickness loading of cells, as well as full penetration of any delivered protein
solutions, would be desirable for rapid and complete tissue formation.
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Figure 4-20 Full-thickness loading of T cells in inverse opal-collagen composite scaffolds. T
cells suspended in collagen were infused into an 80 [tm void diameter biotinylated PEG inverse
opal scaffold. Cells were labeled with CMFDA to aid visualization by fluorescence, and the
scaffold surfaces were visualized by coating with Alexa 647-conjugated streptavidin. Thin
sections through the entire 1.2 mm-thick scaffold were cut and imaged en face by (A) brightfield
and (B) confocal fluorescence microscopy. T cells are green and streptavidin red in the
fluorescence overlay. Scale bars 41 [tm.
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Figure 4-21 Full-thickness loading of DCs in inverse opal-collagen composite scaffolds.
Dendritic cells suspended in collagen were infused into an 80 Ltm void diameter biotinylated
PEG inverse opal scaffold. Cells were labeled with CMFDA (green) to aid visualization by
fluorescence, and the scaffold surfaces were visualized by coating with Alexa 647-conjugated
streptavidin (red). Thin sections through the entire 1.2 mm-thick scaffold were cut and imaged en
face by (A, C) brightfield and (B, D) confocal fluorescence microscopy.
4.3.4.4 Dendritic cell behavior in composite scaffolds
We next investigated whether our inverse opal-collagen composite scaffolds could support
migration of DCs, because of their importance in the immune response. DCs were loaded in
composite scaffolds similarly to T cells and observed in time-lapse. Heterogeneous behavior was
observed under the conditions tested, with some DCs migrating, others appearing to attach to the
PEG scaffold walls, and yet others remaining relatively stationary in collagen away from the
polymer scaffold walls. Much dendrite activity was seen in these LPS-matured cells. Migratory
cells readily moved through pores in scaffolds with void sizes as small as 40 [tm (10 tm throat
pores), as shown in Figure 4-22. Thus, DCs can also traverse pores of the matrix to enter the gel
or interact with T cells.
Figure 4-22 Migration of dendritic cells pore-to-pore in inverse opal-collagen composite
scaffolds. Time-lapse brightfield images illustrate a dendritic cell (marked in false color)
moving through a throat pore between voids in a 40 [tm void size inverse opal-collagen
composite scaffold. Scale bars 10 tm. Times shown are elapsed min:sec.
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4.3.4.5 Lymphoid fibroblasts form networks in composite scaffolds
We tested this final iteration of artificial lymphoid constructs for their ability to support the
formation of stromal cell networks. We again found that fibroblastic reticular cells from the
BLS4 cell line could form networks in the scaffolds by extending processes through the scaffold
throat pores. Uniformity of cell density was somewhat harder to control than for T cells, due to
the fact that BLS4 stick to each other in culture even after brief trypsinization. Extended EDTA
treatment can be used to separate individual cells better, but if done for too long then viability
can suffer. However, parts of the cell networks were viable for at least four days, and networking
behavior was observed in both 80 and 40 [tm void size scaffolds (see Figure 4-23).
A
C
Figure 4-23 Lymphoid fibroblasts form networks in composite scaffolds. (A-C) are
brightfield images with 50 tm scale bars. Arrows indicate cell spreading through throat pores.
(A) BLS4 networks formed in composite scaffolds with an 80 [tm void size by 22 hours. (B)
Portions of the network remained viable for up to 4 days. (C) 40 tm scaffolds infused with
collagen also were able to support some degree of BLS4 network formation (shown at 11 h).
4.3.5 Providing CCL21 chemokine directly from composite scaffolds
As discussed in section 1.1.3 and Chapter 3, the chemokine CCL21 provides critical signals for
chemoattraction of lymphocytes and DCs to specific tissue sites (21, 38, 211, 212) and also
supports random migration of T cells in the absence of specific gradients (158, 196). While our
studies show a useful role for this chemokine in supporting cell migration within PEG-collagen
composite gels, soluble CCL21 added to the scaffold would be expected to rapidly diffuse away
in vivo. In order to support both chemotaxis of host cells into the structure and chemokinesis of
cells interacting within the scaffold, we anticipate that sustained delivery of CCL21 would be
desirable. To this end, we tested a strategy for reversibly binding CCL21 to the surfaces of
inverse opal PEG gels, in order to provide a depot that would sustain levels of chemokine in the
composite scaffold over an extended time period.
To mimic the native interaction between basic chemokines such as CCL21 and
polysacharrides such as heparin (see Figure 4-24), we exploited the biotin functional groups in
the inverse opal scaffolds to bind biotinylated heparin to the scaffold surfaces via a streptavidin
bridge. The heparin could in turn bind CCL21. Successful binding of biotinylated heparin to
streptavidin-coated inverse opal PEG gels was indirectly confirmed by staining of gels with the
cationic dye Toluidene blue (see Figure 4-25). Although non-heparinized scaffolds were faintly
stained due to the free carboxyl groups in the biotin-lysine, only scaffolds that were sequentially
incubated in both streptavidin and biotin-heparin were stained dark blue-purple.
Figure 4-24 Schematic of heparin-chemokine interaction. Adapted from (213). A fragment of
heparin (circled) is shown using a ball-and-stick model, and the chemokine (CXCL12) is shown
using a ribbon diagram. The type and positions of basic residues on the protein that interact
directly with acidic groups on the heparin are indicated.
A C
Figure 4-25 Biotinylated heparin binds to streptavidin-coated scaffolds. Scaffolds were
stained with the cationic dye Toluidene blue to detect bound anionic heparin. While scaffolds
incubated only with streptavidin (A) or only with biotin-heparin (B) stained faint blue, scaffolds
that received both treatments (C) became a deep purple color.
To confirm that heparin-modified PEG gels would bind CCL21, scaffolds were incubated
with chemokine, washed for 24 h, and then immunostained with anti-CCL21 and secondary
fluorescent antibodies. Punctate spots of chemokine were clearly visible on the scaffold surfaces
via confocal microscopy (Figure 4-26), while a control scaffold that received no chemokine was
completely free of background staining (data not shown). Because CCL21 binding to heparin is
reversible (with a dissociation constant K,) of -5 nM for the human protein, (112)), we expected
that scaffold-bound chemokine would become available to cells loaded in composite scaffolds
over time. To test the functionality of chemokine loaded on the PEG gel surfaces of inverse opal-
collagen composite scaffolds, we assayed the motility of naive CD4' T cells loaded into
composite scaffolds with or without surface-bound CCL21. As discussed in Chapter 3, naive T
cells have low basal motility; they have almost no motility in collagen in the absence of CCL21
under the conditions that we use. Thus, their motility provides a sensitive in situ assay for the
presence of chemokine. Scaffolds loaded with chemokine were thoroughly washed (12x in 4 h)
to rid free CCL21 and then loaded with cells suspended in collagen. Within 0.5 h, a fraction of
the naive T cells became motile in CCL2 l-loaded scaffolds, while none did in the control
sample; this difference became more pronounced with time. We quantified cell migration at 5-6
h, as shown in Figure 4-26B-D; a fraction of the T cells were highly migratory in CCL21 -loaded
scaffolds, while essentially zero motility was observed in controls.
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Figure 4-26 Chemokine released from scaffolds remains functional. (A) Immunofluorescence
staining of CCL21 in an 80 jtm void size scaffold. B-D) Time-averaged properties for individual
naive T cells migrating in composite scaffolds with or without heparin-immobilized CCL21 are
shown, namely velocity (B), maximum displacement (C), and turning angle (D). Each cell was
analyzed for a 10 min time course; 15 cells from each of 1 (control) or 2 (chemokine)
independent experiments were analyzed. *** indicates significant difference at p < 0.0001.
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These results suggest that the inverse opal gel can serve not only to provide mechanical
support for the infused collagen matrix, but also act as a chemokine-binding depot to sustain the
delivery of chemokines or other cytokines relevant to promoting a lymphoid tissue-like
microenvironment.
4.4 Discussion
Boosting the adaptive immune response is a major goal of immunotherapy, particularly for the
treatment of cancer (57). Thus far such therapies have primarily focused on the injection of cells
or cytokines to increase infiltration of adaptive immune cells (or their activation) at tumor sites.
Cytokine therapies have the disadvantage of requiring repeated dosing, while direct injections of
cells without control over their microenvironment may cause inefficient or incomplete induction
of immune responses. As an alternative approach, two strategies can be envisioned for using a
synthetic scaffold to drive the local accumulation of adaptive immune cells involved in T cell
priming. In an 'adoptive transfer' strategy, autologous T cells and dendritic cells could be
isolated from peripheral blood or derived from peripheral blood monocytes, respectively (193).
These cells could then be loaded ex vivo into scaffolds for implantation at a tumor site (e.g.,
during solid tumor resection), or alternatively, at a site well removed from the
immunosuppressive tumor microenvironment. In an 'in vivo assembly' strategy, scaffolds loaded
with chemoattractants normally present in secondary lymphoid organs would chemoattract nai've
lymphocytes and DCs from the local blood supply. Attracting rather than merely injecting DCs
may be particularly important, as the presence of native DC at the tumor site improves tumor
eradication even when utilizing cancer vaccines with transferred cells (214). While the second
approach likely represents a greater technical challenge, it would of course simplify clinical
application.
Here we have described the development and in vitro testing of a scaffold that could support
either strategy of lymphoid or lymphoid-like tissue induction. In Chapter 2, we showed that an
inverse opal structure allows gels with highly interconnected pores to be formed without the
extreme deterioration in mechanical properties typical of random porogen methods, which
require very high degrees of total porosity to achieve high interconnectivity of pores (194). Thus,
in the inverse opal-collagen composite strategy examined here, the macroporous PEG structure
provides mechanical support and ease of handling for implantation, while the softer collagen
matrix within the pores supports rapid T cell migration. As shown in Figure 4-26, the scaffold
can also act as a platform to depot chemokine for stimulating immune cell chemotaxis and
chemokinesis.
We initially tested the feasibility of using a macroporous PEG scaffold modified at its
surfaces with adhesion ligands (rather than infused with a collagen gel) as a support for cell
migration. We compared scaffolds coated with ICAM-1 and fibronectin, two ligands present in
secondary lymphoid organs. Although scaffolds presenting the key integrin ligand ICAM-1
significantly increased T cell velocity and displacement compared to scaffolds lacking protein,
only a fraction of T cells rapidly migrated, and even those were not as motile as cells that have
been observed in vivo. Meanwhile, the peptide RGD and whole fibronectin had no effect on T
cell motility at all. These results may have been due to a variety of factors, including low T cell
integrin expression, insufficient density of T cell packing in the scaffolds, inappropriate stiffness
of the substrate, or simply too low ligand density. We recognized that we would have to modify,
perhaps radically, our approach to attaining rapid T cell migration in vitro. However, first we
examined two other cell types of interest - DCs and FRCs - for insight as to how these protein-
coated scaffolds were functioning.
The critical partner involved in triggering T cell mediated immune responses is the dendritic
cell, a professional antigen presenting cell which activates and differentiates T cells into effector
or memory cells capable of directly or indirectly attacking tumors and infected cells. DCs also
likely play an interactive role in lymphoid tissue development through various feedback
mechanisms in concert with T cells (36, 215, 216), making their presence important for the
potential development of lymphoid neotissues. We found that dendritic cells cultured alone in
scaffolds were able to spread and crawl on scaffold surfaces coated with fibronectin and/or
laminin. Interestingly, in the presence of DCs and fibronectin, we saw that a fraction of T cells
could migrate along the DC bodies about as well as on ICAM-1-coated scaffolds (see Table 4-1).
However, even if this migration could be optimized (e.g., by changing relative cell ratios), we are
potentially interested in co-attracting and co-infiltrating these cells into the scaffold, rather than
relying on the infiltration of DCs first, followed by T cells. This may be an unlikely order of
events in vivo, as evidenced by studies comparing the effects of ectopic expression of CCL21 in
RAG-/- mice (which lack mature T and B cells) versus wild-type mice. In wild-type mice, DCs
are recruited to the ectopic site of chemokine release, but this does not occur in RAG knockout
mice, indicating a co-requisite role for T cells (36). Sequential cell addition in vitro might be
more feasible than sequential attraction in vivo, but only if consistent conditions for DC
spreading along the scaffold (rather than filling the pores) can be determined; otherwise it may
be difficult to load T cells uniformly throughout the structure, due to pore blockage by DCs.
To complete our studies in protein-coated scaffolds, we observed the behavior of stromal
fibroblasts in these structures, and found that they spread and connected to form intricate 3D
networks. Unlike the case of DC networks, the presence of fibroblasts did not appear to influence
T cell migration favorably (nor unfavorably). Thus, we found that varying the type of adhesion
ligand presented on the scaffold or adding accessory cells affected T cell migration in only a
minimal fashion in these inverse opal structures. Although there was a vast potential parameter
space to explore in these factors alone (ligand concentration, cell density and ratios, etc.), we
were concerned about heterogeneity of parameter values across the scaffold and thus
reproducibility of experiments. Because relatively uniform T cell mobility is critical for antigen
surveillance, we looked for alternative means to promote T cell migration within these structures.
Prior studies by Friedl et al. have shown that T cells migrate in collagen gels by an integrin-
independent 'amoeboid' mechanism (200). This prompted us to test the infusion of inverse opal
structures with collagen. In the presence of soluble CCL21, T cell migration in neat collagen gels
quantitatively approached behavior recorded in vivo, including an average velocity of ~ 9
ýnm/min (10-11 tnm/min in vivo (116, 207)), an average turning angle of 530 (63' in vivo(207)),
and an average confinement ratio of 0.50 (0.56 in vivo (207), 0.48 for CD8' T cells (217)).
Similar values (8-9 ýxm/min velocity) were also obtained by Gunzer et al. for T cells co-cultured
for 2 days in collagen with dendritic cells (202), which are known to secrete a number of
chemokines active on T cells (192).
In collagen-infused composite scaffolds, T cell migration was improved compared to protein-
coated scaffolds, and was dependent on the pore size of the inverse opal polymer structure. The
increased migration response reflected the ability of the cells to move effectively throughout the
3D voidspace of the PEG gels supported by the collagen fiber network, without requiring contact
with the PEG gel walls to adhere and migrate. Cell migration was enhanced at larger pore sizes,
and for inverse opal structures with 80 [tm void diameters, T cells were able to travel almost as
freely as in neat collagen gels. Notably, because the modulus of porous materials scales with
porosity, and porosity is equivalent in the inverse opal structures regardless of void diameters,
the mechanical properties of the inverse opal gels are not decreased by increasing the void
diameters (194, 218).
Due to the increased viscosity of collagen compared to culture medium, cell loading and
retention for both T cells and dendritic cells was excellent in composite scaffolds, particularly in
the very open 80 mrn structures. Such full-thickness loading would be key for a therapeutic
approach in which cells are expanded/activated ex vivo and then transferred back to a patient in
scaffolds to drive an immune response. Others have used alginate or collagen-infused composite
polymeric scaffolds to similarly achieve good cell retention and suitable mechanical properties in
the same construct (219, 220).
As we had done for the protein-coated scaffolds, we tested DC and stromal fibroblast
behavior in the composite scaffolds as well. Fewer DCs were associated with the walls of the
inverse opal in the composite than in the protein-coated scaffolds, due to the presence of an
adhesive substrate (collagen) within the pores as well. DCs are known to migrate through
collagen, and we found that DCs in our composite structures could readily move through the
collagen across PEG-outlined throat pores as small as 10 trn (void size 40 rLm). Stromal
fibroblasts of the BLS4 cell line were able to form networks in the collagen-infused structures as
they did in the protein-coated scaffolds. Thus, we developed a scaffold that supported DC and
rapid T cell migration, and could potentially be used in concert with stromal cells as well.
Finally, we tested a strategy for binding chemokine to the PEG surfaces of the composite
scaffolds, to provide a chemokine depot that might support both chemotaxis of host cells into the
structure and chemokinesis of cells interacting within the scaffold. We focused on the chemokine
CCL21, which provides critical signals for immune cell homing to secondary lymphoid organs
(21, 211) and also supports random migration of T cells in the absence of specific gradients (158,
196). Various methods have been used to incorporate growth factors and other biological
signaling molecules in tissue engineering scaffolds (see section 1.3.4, (97)). One promising
strategy for retaining long-term release and functionality is the use of heparin, which binds many
cytokines. Heparin has been covalently attached to PEG scaffolds via methacrylation (104), to
PLGA scaffolds (105) via carbodiimide chemistry, and by noncovalent interactions with PEG
networks (106, 107); it has typically been used to release cytokines such as basic fibroblast
growth factor (104-106). In our system we used biotin-streptavidin non-covalent interactions to
attach heparin to PEG scaffolds. Heparin-conjugated scaffolds bound CCL21, and the functional
release of this factor in composite scaffolds was demonstrated by the induction of naive T cell
motility within the composite gel. Future studies will be required to determine the limits to the
amount of chemokine that can be delivered in this manner and whether slow release of
chemokine from inverse opal surfaces can drive chemotaxis of lymphocytes or dendritic cells
from the local bloodstream to enter the scaffold structure.
In conclusion, we have demonstrated a composite inverse opal-collagen hydrogel as a
scaffold that can support the loading and robust migration of immune cells, as a first step toward
in vivo engineering of T cell-mediated immune responses within a supporting synthetic
microenvironment. For these in vitro studies we used nondegradable PEG gels; however, this
system is readily modified to incorporate enzyme-sensitive peptides to tailor degradability (76).
As stated previously, the poly(ethylene glycol) inverse opal component of this composite
provides mechanical support and sites to deliver supporting factors such as chemokines or other
cytokines, while the infused fibrillar collagen provides a matrix for rapid lymphocyte motility.
This general approach may be broadly useful as a strategy to combine the favorable properties of
synthetic and biopolymeric hydrogels and allow each component to compensate for deficiencies
in the properties of its partner.

5 Summary and Future Considerations
In this work, we designed, fabricated, and tested a novel macroporous hydrogel scaffold for
lymphoid tissue engineering applications. Such a scaffold could be used for in vitro investigation
of factors that modulate immune cell behaviors such as motility, and potentially developed as a
construct for cancer immunotherapy. The de novo formation of lymphoid tissue at tumor sites
has been shown to treat cancer in several animal models; previous research has utilized cytokine
injection or antibody targeting of cytokines to tumors to attract immune cells and induce tissue
formation (52-55). We propose that an implantable scaffold providing signals supportive of
immune cell motility and lymphoid organ development could be used to induce lymphoid tissue
formation at tumor sites, with distinct advantages over previous systems. First, a site-specific
controlled release system for cytokines would be preferable to systemic injections, due to the
frequency and potential toxicity of the latter method. Further, providing a defined space for cell
interactions and neotissue development would likely promote more efficient immune cell
compartmentalization and subsequent interactions than an injection of cytokines and/or cells
alone. As a first step in development of a scaffold system suitable for clinical use, we performed
in vitro studies of cell behavior in several iterations of scaffolds.
We were particularly interested in examining the migratory response of T cells in scaffold
microenvironments with different architectures and biochemical signal presentation. Due to the
low frequency of naYve T cells specific for any given antigen, their rapid, unobstructed migration
is important for their ability to contact DCs bearing cognate antigen, which will initiate an
immune response. We thus studied how different adhesion proteins, chemokines, underlying
materials and pore sizes affected T cell migration. These studies were undertaken both to explore
motility signals in a fundamental way, and in order to design a construct that could potentially be
used for immunotherapy. The final design for this lymphoid scaffold was a PEG hydrogel with
hexagonally close-packed arrays of interconnected pores (an 'inverse opal'), infused with a
fibrillar collagen gel. The macroporous PEG provided relative mechanical stability (both
compared to collagen and compared to scaffolds created with stochastic rather than ordered
porogen methods), while the collagen provided a favorable matrix for T cell migration. Although
smaller pores sizes physically constricted T cell migration paths, when an 80 [tm pore size was
used for the inverse opal, T cell migration was nearly identical to that in pure collagen. We also
developed a preliminary method to deliver the chemokine CCL21 (which induces motility in
several immune cell sub-sets, and also influences lymphoid organ development) from the surface
of the PEG gel, for the purpose of attracting, organizing, and maintaining the motility of immune
cells. In surface studies performed outside scaffolds, we showed that the chemokine CCL21 can
promote T cell chemokinesis, i.e., motility in the absence of a concentration gradient. We then
demonstrated that 3D scaffolds delivering CCL21 via surface-bound heparin could also induce
naive T cell chemokinesis within composite scaffolds. In the future, the maintenance and scale of
CCL21 chemotaxis activity should also be demonstrated in the scaffolds, by attracting T cells
and dendritic cells from a nearby chemokine-free tissue mimic such as collagen gel.
In early studies, we found that PEG gels coated with peptides or even whole adhesion
proteins (in the absence of interstitial collagen gel) were not suitable as a microenvironment for
T cell migration. The only protein we tested that was able to support any migration was ICAM-1,
but it only did so for about 30% of cells, with an average velocity about ~30% lower than that
seen in vivo. Cells were easily bumped off the walls by the movement of nearby cells or
convective currents in the medium. It is possible that if cells were packed to very high density in
scaffolds (similarly to their dense packing in native secondary lymphoid organs) with pore
diameters on the order of cell size, then the high surface area of protein might support cell
migration, with a minimal effect of convection even in the absence of a collagen gel. However,
scaffolds with small pores (e.g., 20 1km, with throat pores on the order of cell size at 5 [tm) are by
nature more difficult to load uniformly and to a high density with cells. One possibility for the
future is to create thermoresponsive hydrogel scaffolds using polymers such as NIPAM (N-
isopropylacrylamide). These could be loaded with cells at 4 OC in a large pore state, then
transferred to 37 TC to shrink the pores around the cells. Initial experiments in our lab have
shown that at least a 20-30% decrease in gel size is possible.
Another materials parameter worth exploring is the composition of the interstitial gel.
Alginate, hyaluronic acid, fibrin, or the basement-membrane extract MatrigelTM might be
biopolymers worth testing as alternatives to collagen. An ideal gel would not only support cell
migration, but might also interact with CCL21 so as to slow but not completely halt its diffusion
out of the scaffold. This may be one way to lengthen the time for CCL21 release, as long-term
release may be needed to attract enough relevant immune cells in clinical application.
Besides experimentation with the biopolymer component as a diffusion barrier, further work
should in general be performed to improve the chemokine delivery system and test its limits.
Having already developed a method using biotin-streptavidin interactions for attachment of
arbitrary adhesion proteins, we used this same method for attachment of biotinylated heparin,
which was subsequently used to sequester chemokines. Noncovalent binding strategies are
attractive because they do not require any (potentially destructive) modification of the attached
protein. However, it may be more efficient to attach heparin to the scaffold in one rather than
two steps, perhaps by including heparin-binding peptides in the PEG matrix as some other
researchers have done (106, 108). The additional protection and de-protection steps necessitated
by the lysine groups in the peptide might render this method ultimately labor-equivalent,
however. It is also possible that loading chemokine-containing microspheres into scaffolds may
be preferable to surface attachment, for two reasons. One is that the amount of chemokine
loading would be more readily controlled by this method, simply by changing the number of
microspheres added. Ultimately there would be a limit to the amount of chemokine that could be
added, if the microspheres interfered with cell interactions within the structure. However,
whereas with surface attachment there may be a need to saturate one porous layer of the polymer
before the chemokine can diffuse further into the scaffold, this is not a concern with a
microsphere system. Even more importantly, unlike with the multiple incubation steps required
for our surface attachment method, microspheres could be quickly prepared and used to add
chemokine just before use of the scaffold (or better still, lyophilized and stored for a period of
months), allowing more flexibility in preparation. Clinically, this would seem to be the most
feasible method. One other interesting approach might be to isolate CCL21-producing cells in
polymer microspheres or vesicles that cannot be penetrated by large immune complexes, but that
do let nutrients and small proteins such as chemokines pass. This would allow for unlimited
production of CCL21, while avoiding some of the risks of using transfected cells that directly
contact the blood or tissues.
As described above for the chemokine delivery aspect, but also more generally, the system
that we designed requires perhaps an overly complex and time-consuming process. Initially we
were interested in mimicking the lymph node T zone to as great a degree as possible. However,
our many-step process suffers from reproducibility issues, while still not approaching the
complexity of the real biological system. Now that we are focused on a goal of immunotherapy,
a simpler system could perhaps be designed. For example, an injectable rather than implantable
polymer may be preferable in such a case, due to the gain in clinical simplicity. Cells and
chemokines could both be readily suspended in such gels. However, chemokine may be depleted
more quickly using this simple mixing (versus attachment) strategy, even if free heparin is also
included to maintain chemokine activity. Further, if a natural gel such as collagen were used
alone, we would lose the improvements in construct mechanical properties provided by the
polymer, and its degradation rate in vivo would not be readily tunable. Alternatively, if a
synthetic polymer were used alone as a bulk gel, it is not clear that T cell migration would be
possible (unless the polymer had a collagen-like nanofibrous structure), and the diffusion and
nutrient access provided by the porous structure would be lost. These trade-offs between
complex composite versus simple gels can best be addressed by performing in vivo experiments
to observe cell attraction to and organization within scaffolds/gels in treated animals. At this
stage, the rate of material degradation will become important as well, as successful tissue
engineering often requires a degradable material. Photopolymerized PEG gels can be made
degradable by the inclusion of enzyme-sensitive cross-links (76), and preliminary studies in our
lab have confirmed that these remain active after acetic acid treatment.
In summary, our in vitro studies thus far have revealed roles for adhesion proteins, cell
composition, chemokines, and architecture in influencing T cell migration within 3D artificial
structures. Such basic studies could be continued further, in concert with improvements to the
scaffold as described above. The introduction of degradability, optimization of the chemokine
delivery system, and simplifying the fabrication process could result in a clinically useful device.
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Appendix A Abbreviations used
Ab = antibody
BSA = bovine serum albumin
cone. = concentration
ECM = extracellular matrix
M = million (cells) or molar (solutions)
O/N = overnight
resus. = resuspend
RT = room temperature
v = volume
wt = weight
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Appendix B Preparation of common buffers
Important note: Any buffer that is to be used with cells should be filtered (using a 0.2 ýIm filter)
in a sterile laminar flow hood.
B. 1 Buffers for cell culture and isolation
B.1.1 RPMI complete cell culture medium (RPMI-10):
1) Mix together:
a. RPMI 1640 (with 2 mM L-glut) powder at 10.4 g/L in water
b. 10 mM HEPES acid
2) Bring solution pH to ~ 7.1-7.2 if necessary. Usually with this amount of HEPES it is
already at the right pH prior to filtering.
3) In a sterile hood, add:
a. fetal calf serum (FCS) to 10% (v/v)
b. 100 U/mL penicillin/100 [tg/mL streptomycin
c. 50 tiM 2-mercaptoethanol
4) Sterile filter as usual with bottle top filter.
B.1.2 Serum-free RPMI (SF-RPMI):
Prepare as for complete medium, but do not add FCS.
B.1.3 2-Mercaptoethanol Stock Solution:
Neat 2-mercaptoethanol (2-ME) is at 14.3 M.
To prepare 50 mM stock: add 143 ýtL 2-ME to 40 mL water (re-make every ~ 4 months).
B.1.4 Red blood cell (RBC) lysis buffer:
175 mM ammonium chloride in water, sterile-filtered.
Collagenase solutions:
Collagenase D ordered from Roche is typically 0.15 Wunsch/mg, 250 Mandl/mg. It should be
reconstituted at 4000 Mandl/mL in HBSS and stored frozen. (Note: Current Protocols in
Immunology claims conversion of 750 Mandl/Wunsch unit.) Enzyme activity is dependent on
the presence of calcium.
Liberase comes in several speciality enzyme blends, which have high activity (~ 4 W/mg).
Recommended usage is at 1:50.
110
B.1.5 MACS Buffer:
PBS pH 7.4, containing:
0.5 % BSA
0.1% NaN3
2 mM EDTA (MW = 416.23 4 0.832 g/L)
B.1.6 Lipopolysacharride (LPS) stock:
Prepare stock solution at 1 mg/mL in sterile PBS. Vortex thoroughly and if necessary also
sonicate for 5-10 rmin.
B.2 Buffers for common assays
B.2.1 Hank's Balanced Salt Solution (HBSS):
Note: usually make calcium and magnesium free (HBSS-CMF) version.
5.4 mM KC1 (0.402 g)
0.3 mM Na2HPO4 (*7H 20) (0.09 g; 0.0426 g for anhydrous) ["dibasic"]
0.4 mM KH2PO 4 (0.054 g) ["monobasic"]
4.2 mM NaHCO 3 (0.353 g)
137 mM NaCl (8.0 g)
5.6 mM D-glucose (1.0 g)
0.2 g phenol red (optional)
1.3 mM CaC12 (0.14 g; optional)
0.5 mM MgCl2*6H20 (0.10 g; optional)
0.6 mM MgSO 4*7H,O (0.10 g; optional)
Add H20 to 1 liter and adjust pH to 7.4 with 1 M HC1 or 1 M NaOH.
Filter sterilize and store up to 1 month at 4 oC.
B.2.2 FACS staining buffer
Prepare HBSS-CMF, containing:
0.1% (w/v) sodium azide (NaN3)
1.0% (w/v) bovine serum albumin (BSA; fraction V)
Store at 40 C up to 1 year.
B.2.3 Propidium Iodide Stock Solution:
I mg/mL in PBS (store protected from light at 40 C). Final usage typically 1.25 [tg/mL.
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B.2.4 ELISA Buffers:
Reagent Diluent - 1% BSA in PBS, pH 7.4 (10 g BSA in 1 liter PBS)
Blocking Buffer - 1% BSA, 5% sucrose, 0.05% NaN, in PBS.
Wash Buffer - 0.05% Tween 20 in PBS, pH 7.4 - make from tablets (Calbiochem, Inc)
Stop Solution - 1 M H,SO 4 (- 53 mL per L H,O).
H2SO 4 MW = 98.1, density = 1.84 g/cm3
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Appendix C Cell Isolation and Treatments
C.1 General treatments
C.1.1 Cell centrifugation/washing procedures:
1) Cell suspensions are typically centrifuged for 5 min at 1300 rpm on a centrifuge with a
GH-38 rotor (~200-400 g) to form a cell pellet.
2) Liquid is aspirated from the cell pellet using a clean pipet hooked up to vacuum.
3) The cells are initially resuspended in a small volume of buffer or medium.
4) Only then should a large volume of solution for washing or culturing be added.
C.1.2 Pertussis toxin (PTX) treatment:
Materials:
PTX (Sigma): P7208 - 50 pg.
Reconstitute with 500 [tL water - results in PBS because lyophilized with salts.
Stable for 6 months.
PTX B oligomer (Sigma): P159 - 40 gg.
Reconsitute with water or buffer. This is used as a control.
Procedure:
Initial concentration is 100 [tg/mL; desire 2-100 ng/mL for final conc.
1) For 100ng/mL = 1:1000 overall, dilute 1:10 followed by 1:100.
2) Incubate cells (at 10M/mL) for 10 min with PTX
a. I usually did in full medium, though PBS was used in original report.
3) Wash 3 times.
4) Rest cells for 90-120 min at 37 TC before use.
C.2 Cell isolation
C.2.1 Splenocyte preparation:
Dissection:
1) Put mouse in euthanizing chamber.
2) Turn on CO2 at low pressure for ~ Imin.
3) Raise pressure to high and leave on for ~ 4 min.
4) Pull on mouse leg to test for limpness (absence of reflex) and therefore death.
5) Cut open the mouse torso, through the skin but not the thin membrane below initially.
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6) Wipe fur off of scissors, then cut through the membrane film, toward left side of mouse.
7) Remove spleen with tweezers, tearing away pancreatic filaments without bursting open
the spleen. Put in ice cold RPMI (e.g., in a conical tube).
8) Make a cut in the mouse lungs to doubly ensure death, put in plastic bag and dispose of in
carcass freezer.
Isolation:
1) Prepare a 50 mL Falcon conical tube and cell strainer (70 itm).
2) Burst and press spleen through pre-wet filter using a syringe plunger.
3) Wash with 10 mL RPMI (20 mL for 2 spleens) and continue pressing.
4) Centrifuge cells as usual, resuspend in 100 (or 200) jtL complete RPMI.
5) Add 5 mL RBC lysis buffer, invert tube once to mix, incubate 5 min at RT.
6) Add 7.5 mL complete RPMI, 7.5 mL SF-RPMI, invert once, then centrifuge.
7) Resuspend in 100 tiL RPMI, then add 10 mL RPMI and 10 mL SF-RPMI. Tap/flick tube
to promote dead cell clump formation and floating, then filter through new cell strainer
(40 [tm) into new 50 mL conical tube.
8) Take an aliquot for cell counting, then centrifuge as usual.
9) Resuspend in MACS buffer, appropriate labeling buffer, or culture medium.
Note: Resuspending a spleen in SF-RPMI alone seems to promote fat precipitation in a way that
can lose a lot of cells. However, prior to MACS separation it is desirable to get rid of as much
serum as possible. For this reason, I use a 50/50 mix in steps 6 and 7.
C.2.2 Lymphocyte isolation from splenocytes (or lymph nodes):
Materials:
Ab cocktail (all from BD Biosciences): CD8a, CD1 lb, B220, and NKl.1, each at 1 ltg/mL.
Anti-biotin microbeads are sold as a stand-alone item from Miltenyi Biotech (130-090-485).
Isolation:
1) Degas MACS buffer using vacuum line and prepare cells as usual (must lyse RBCs in
splenocytes, but not in lymph node cells because there are very few).
2) Suspend cells in MACS buffer at 100M cells/mL.
3) Add 8 [iL Ab-cocktail per mL cells and incubate 10 min.
4) Wash cells two times with 10-20x staining volume.
5) Resuspend in 40 jIL buffer + 10 jiL anti-biotin microbeads for 20M cells, or scale up
accordingly for more cells. (Has not been tested for < 20M cells.)
6) Incubate 15 min.
7) Wash once with 10-20x staining volume.
8) Perform MACS separation as usual.
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C.2.3 Lymphocyte non-specific priming:
Procedure:
1) Add 150-200 ýtL of antibody solution (10 plg/mL each CD3 and CD28) to 6-8 wells of a
24-well tissue culture plate, and incubate at 37 TC for at least 90 min.
2) Meanwhile, harvest CD4+ T cells from splenocytes and/or lymph node cells as usual.
3) Count T cells, and resuspend at 1.1-1.3 M cells/mL.
4) Rinse tissue culture plate with PBS 3X prior to use, then plate cells at 1 mL per well.
5) After ~ 48 h, prepare IL-2 in fresh culture medium, and plate 0.67 mL per well in a fresh
tissue culture plate. The final IL-2 concentration in step (6) should be 5 ng/mL.
6) Observe the 2-day-old T cells to ensure that they are blasting (enlarged). In a sterile hood,
pipet several times to mix, then add 0.33 mL of cells to each well in the fresh plate. Thus,
each well in the old plate will be split into three wells in the new plate.
C.2.4 BMDC (bone marrow dendritic cell) extraction and preparation:
Dissection:
1) Euthanize mouse with carbon dioxide gas in chamber.
2) Pin mouse legs down in a stretched out position.
3) Cut open the mouse, and cut down from thigh to as close as possible to the ankle.
4) Strip muscle away from tibia with forceps; cut through bone at ankle.
5) Move tibia around until it breaks at knee (shiny part), or cut at knee if needed.
6) Strip muscle away from femur, cutting as well if necessary.
7) Move femur around until can tell where hip socket is; cut femur as close to hip socket as
possible.
8) Repeat procedure for other leg if desired.
(Store bones in 10 mL cold RPMI 1640 as they are collected one by one.)
Isolation:
1) Put bones into a 10 cm culture dish, and add ~ 10 mL more media.
2) Prepare a 50 mL Falcon conical tube and cell strainer (70 pm).
3) Use 26G needle and 1 mL syringe to inject one bone at a time with medium, while
holding the bone over the prepared cell strainer. (Cut the ends of the bone off first if
necessary to open it up well enough.
4) Keep washing out the red bone marrow/blood until the bone appears white.
5) Lyse red blood cells as for spleen, count cells, and resuspend at IM cells per mL.
6) Add 5ng/mL of GM-CSF to cells.
a. 0.5-1 pL per mL depending on stock solution
b. Expect 15-25M cells per leg.
7) Plate 1 mL of cells/media/GM-CSF per well in 24-well plate.
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Culturing:
On days 2, 4, and 6:
1) Gently remove 0.7 mL medium from each well, minimally disturbing cells.
2) Replace with pre-warmed fresh medium + GM-CSF at 5 ng/mL.
C.2.5 Splenic DC Preparation:
Collagenase D solution: 2 mg/mL of >= 0.15 Wunsch U/mg enzyme should be used. This means
using Roche stock solution at ~1:8 by volume.
Procedure:
1) Isolate spleen and put in petri dish with collagenase D (5 mL/spleen).
2) Inject spleen with 0.5 mL solution (1 mL, ~26 G needle).
3) Incubate for 45-60 min.
4) Pass through 70 [tm cell strainer.
5) Collect, wash to final volume of 14 mL, count.
6) Resuspend in 100 [tL buffer + 25 ýtL CD Ic beads (this is 1/4 of is recommended by
Miltenyi; Rob says we can use even less) per 100M cells.
7) Incubate 15 min.
8) Wash with 10-20x buffer.
9) Separate on MACS column as usual.
10) Repeat on second column for better purity.
Notes:
* The Miltenyi protocol suggests using HEPES-buffered saline, but I have used Hank's
Balanced Salt Solution instead.
* I have used as little as 2 mL per spleen at 1 mg/mL enzyme.
* Expect about 1-3M cells per spleen.
* Total prep time: 2-2.5 hours.
C.2.6 MACS column separation:
MS (Mini) columns:
Resuspend cells in 0.5 mL buffer per 100 M cells.
Place column onto magnet, then wash with 0.5 mL MACS buffer.
Add cells to column and collect eluent (for negative selection).
Wash 3x with 0.5 mL each.
For positive selection, remove column from magnet, then place 1 mL onto column and use
plunger to quickly collect cells.
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Max cells: 200M
Max positive cells: 10M
LS (Midi) columns:
Resuspend cells in 0.5 mL buffer per 100 M cells.
Place column onto magnet, then wash with 3 mL MACS buffer.
Add cells to column and collect eluent (for negative selection).
Wash 4x with 3 mL each.
For positive selection, remove column from magnet, then place 5 mL onto column and use
plunger to quickly collect cells.
Max cells: 2000M
Max positive cells: 100M
C.3 Fluorescent Labeling of Cells
Unless noted otherwise below, most dye stocks are stored frozen at -20 'C, and can be thawed
and re-frozen multiple times over a period of 1-2 months at least. Dyes that have not yet been
reconstituted with DMSO are good for 1-2 years frozen.
RED DYES
C.3.1 CMTMR (Molecular Probes):
Background:
* Excitation/Emission Max = 541/565 nm.
* Inherited by daughter cells through at least four divisions.
* Bright for at least 72 hours.
* Does not require enzymatic cleavage to activate fluorescence
* Transformed into cell-impermeant reaction products once inside cell.
* MW = 554.04
Procedure:
1) Prepare stock on order of 10 mM in DMSO. [e.g., 1 mg/mL for 36 mM]
2) Prepare cell suspension at 100M/mL in serum free medium.
3) Prepare diluted CMTMR (see 4a) and immediately proceed to step 4.
4) Add lx volume cells to 9x volume of CMTMR solution and rapidly invert/mix.
a. final dilution of CMTMR should be 0.5-25 itM
b. final dilution of cells is 10M/mL
5) Incubate for 15-45 minutes at growth temperatures. [usually 20 min]
6) Wash with 10x volume pre-warmed medium.
7) Resuspend cells in lx volume pre-warmed medium and incubate for 30 min at 37 'C.
8) Wash cells twice with cold PBS.
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Comments:
* This dye seems to leak from cells despite extra incubation and washing.
* The dye is then taken up by PEG gels over time.
C.3.2 PKH26 Red (Sigma)
Background:
* Excitation/Emission Max = 551/567 nm.
* Incorporated into lipid regions of the cell membrane.
* Avoid volumes less than 100 [tL or greater than 1 mL.
Procedure:
All should be done at room temperature, under sterile conditions, in polypropylene tubes.
1) Wash cells with serum-free medium, centrifuge.
2) Add Diluent C (e.g., 1 mL for 10' cells): pipet but do not vortex.
3) Prepare 4e-6 M dye in Diluent C (e.g., 4 ELL in 1 mL).
4) Add cells to dye, mix by pipetting, and incubate for 2-5 min (inverting tube periodically).
5) Add equal volume (e.g., 2 mL) of serum or 1% BSA; incubate 1 min.
6) Add equal volume of complete medium (e.g., 4 mL), and centrifuge 10 min.
7) Transfer cell pellet to new tube for further washing with complete medium, 3x.
Comments:
Uniformity of cell staining may vary; some cells (e.g., fibroblasts) may be very spotty.
C.3.3 SNARF-1 (Molecular Probes):
Background:
* Excitation/Emission Max = 488-530/580&640.
* pH indicator if fluorescence emission monitored at two wavelengths.
* Succininudyl ester and thiol-reactive acetate are designed for long-term cellular retention.
* MW = 592.56 (carboxylic acid, acetate, succinimidyl ester) - S22801.
Procedure:
1) Stock is typically prepared at 1-10 mM in DMSO.
a. stored at -20 oC, in single-use aliquots ONLY!
b. 50 [tg means resuspend in 8.4-84.3 [L and then add 1 [tL of dye to 1 mL cells for
10-1 [tM final concentration, respectively
2) Literature reports 10-60 min incubation at 1-20 [tM in serum-free medium.
3) May use Pluronic F-127 to promote dispersion of SNARF (very nonpolar) in buffers.
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GREEN DYES
C.3.4 CMFDA (Molecular Probes):
Same as CMTMR except that it does require enzymatic cleavage to activate fluorescence.
Background:
Excitation/Emission Max = (?)
MW = 464.86
Procedure:
1) Prepare stock at 1-10 mM (1 mg/mL gives 2.15 mM).
2) Final usage is 1-20 RM.
a. for sensitive cells dilute 1:10, then use 2-4 jIL of this per mL (per 10M cells).
[-0.5-1 [tM final]
b. for bright staining use 2-4 RIL directly
Comments:
Photobleaching, of course, but quite reasonable if doing confocal (not epifluorescence) imaging.
C.3.5 CFSE (Molecular Probes):
Background:
CellTrace Proliferation Kit: C34554 ($98)
CFDA, SE (5,6) C 1157 ($164, 25 mg)
Excitation/Emission Max = 492/517 nm; MW = 557.
For long-term exps., 5-10 uM dye recommended.
Should be visible for 8 divisions on flow cytometer.
Remains associated with apoptotic cells for a few days.
Can't be measured directly after labeling because of the extremely high fluorescence, unless use
0.625-1.25 uM. (Most CFSE taken up at first is not stably incorporated.)
Protocol 1: Kit
Make 5 mM stock using one vial and 18 uL DMSO.
Suspend cells in warm PBS/0.1% BSA at 1M cells/mL.
Add 2 uL stock/mL cells for a 10 uM concentration (0.5-25 uM typical).
Incubate at 37 C for 10 min.
Quench staining with 5 volumes ice-cold culture medium: incubate 5 min on ice.
Pellet cells, resuspend in fresh medium; repeat 2x.
Protocol 2: Kit, Alternate Method (ensure complete probe modification)
Dilute 5 mM CFSE in warm PBS (or other) to working concentration (0.5-25 uM).
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Resuspend cells in PBS/CFSE directly; incubate 15 min at 37 C.
Pellet cells, resuspend in fresh warm medium: incubate 30 min.
Wash cells again.
Protocol 3: Current Protocols Method for High Cell Numbers (Unit 4.9)
Prepare 50 M cells/mL in HBSS.
Dilute a 5 mM CFSE stock 1:100 in PBS - 50 uM solution.
Add 110 uL CFSE/mL cells for 5 uM concentration. (Strategy for addition: put drop of CFSE on
non-wetted part of conical while holding horizontally; rapidly invert.)
Incubate 5 min at RT.
Add 10 volumes PBS/5% FCS and pellet cells (at RT!): wash 3x.
Harvesting: wash in 3 mL PBS, resuspend in 150 uL 0.5 mM EDTA/PBS, incubate 5 min at 37
C to dissociate aggregates; centrifuge, resuspend in PBS/5% FCS for FACS.
Protocol 4: Current Protocols Method for Low Cell Numbers (Unit 4.9)
Prepare 0.5-10 M cells/mL in PBS/5% FCS; otherwise same.
Comments:
Have gotten cell death (~ 50%) before with all protocols.
FAR RED DYES
C.3.6 DDAO (Molecular Probes):
Background:
* Ex/Em Max = ~ 600-650 (broad); ~ 665
Procedure: As for CFSE.
VARIOUS
C.3.7 fura-2 AM (Molecular Probes)
Background:
* Ex Max: 335 at high conc. Ca", 363 at low conc. Ca" (ratiometric dye).
* Em. Max: ~ 505-515
* MW = 1002
Procedure:
1) Stock typically prepared at 1 mg/mL = 1 mM in DMSO.
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2) Typical usage at 0.1-5 pLM. For example:
a. Add 0.1 mL cells to 2.5 [tL fura/0.9 mL serum-free medium.
b. After 25 min, wash 2-3x in complete medium.
C.3.8 DiDyes (Molecular Probes)
Background:
* Info here is for the readily cell-loadable ones. Also have DiI, DiD, DiO, DiA, DiR, Ph.
* Ex/Em Max = 497/513 SP-DiO; 556/573 SP-DiI; 555/570 DiI(3)-DS
* MW = 993.54 Di(3)-DS; 1145.73 SP-DiI; 1115.55 SP-DiO.
* Sulfonated derivates may be stored at RT for 6 months.
Procedure:
1) Stock is typically 1-2 mg/mL in DMF, DMSO, or ethanol. [DMF for SP-DiO.]
2) Dilute in HBSS or D-PBS at 1-2 yM for working concentration. (~-pL/mL.)
3) Incubate cells for <=5 min at 37C, then 15 min at 4C.
4) Wash with PBS, resuspend in fresh medium.
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Appendix D Peptide/Protein Modifications
D. 1 Acrylation of co-polymerization materials
D.1.1 Peptide acrylation:
Materials:
Reaction buffer: 0.1M NaHCO3 (MW 84.01), 0.5 M NaCl at pH 8.3
Acryloyl-PEG-N-hydroxysuccinimide ester (NHS-PEGA) at MW 3400. (Previously from Nektar
Therapeutics, now sold by Laysan Bio, Inc.)
Peptides used in the past:
adhesion - GWGRGDSP (MW 830.9)
enzyme-sensitive - GWGLGPAGK (MW 842.0)
Procedure:
1. Peptide is dissolved in reaction buffer in a small scintillation vial with stir bar.
a. The final concentration will be 5 mg/mL of peptide (taking into account that it is only
75% pure). Initially it is dissolved in a smaller volume, reserving 1-1.5 mL for
dissolution of the Acrl-PEG-NHS.
2. Acrl-PEG-NHS is prepared at 0-50% molar excess with respect to the peptide.
a. Stored frozen, the closed bottle should be moved to RT a few minutes prior to use to
equilibrate and thus minimize water contamination
b. The powder should be dissolved at the last minute in - 1 mL of buffer, by vortexing
in an eppendorf tube.
3. The Acrl-PEG-NHS solution is added dropwise to the stirring peptide solution.
4. Stir for 2-3 hours.
5. Dialyze mixture in a 3500MW cassette from Pierce, while changing the deionized water two
times, including one overnight soak.
Sample Calculation: 40 mg protein (775 MW) in 5 mL; add 0.1976 g PEG-NHS in 1 mL. Note:
If both sides of the peptide will undergo reaction (as with the lysine-APGL construct), the
amount of NHS-PEGA must be doubled.
Assay to confirm reaction:
The peptide-PEG conjugate may be tested on the UV-vis spectrophotometer: the final ratio of
absorbance at 280:260 nm should be - 0.60-65 (not so high as 0.8) for a single PEG tether on the
peptide. For PEG-peptide-PEG materials, the absorbance ratio may remain higher.
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D.1.2 Biocytin acrylation:
Materials:
EZ-link biocytin from Pierce (MW 372.5)
Procedure:
Basically the same as peptide acrylation. Briefly:
1. Biocytin is reacted with NHS-PEGA.
a. Use 1-1.33 moles NHS-PEG-A: 1 mole biocytin.
2. React 2-3 h at room temperature, with stirring.
3. Dialyze 1 h
a. in 3500 MW cutoff cassette (Pierce) if used excess NHS-PEGA.
b. in 500 MW cutoff tube (Spectrum Laboratories) if used even ratio.
4. Filter and freeze solution, lyophylize overnight.
5. Resuspend in buffer at, e.g., 40 mg/mL - freeze aliquots at -20 OC.
Note: Aliquots are good for at least a month when thawed and left at 4 OC.
D.2 Protein tagging
D.2.1 Background on proteins
* Fibronectin (FN)
- from bovine plasma
- MW 450 KDa
- Sigma product #F 4759
- reconstitution in water results in Tris buffer.
* Laminin (LMN)
- from Engelbreth-Holm-Swarm murine sarcoma
- MW 810 KDa
- Sigma product #L 2020
- supplied in Tris pH 7.5 buffer with 150 mM NaCl
* ICAM-1
- recombinant protein
- MW 77 KDa (120 under reducing conditions)
- lyophilized with 50 mM Tris-citrate, 2 mM CaCl2, pH 6.2.
D.2.2 Fluorescent labeling
Use Fluorescein (or FITC, Rhodamine) labeling kit from Pierce Biotechnology. The kit is worth
the money because it includes 1 mg pre-weighed vials of the label.
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1. For ideal labeling, dialyze protein into BupH Borate buffer (pH 8.5), with 0.05-1 mL
protein at 1-10 mg/mL.
a. e.g., use Pierce dialysis cups (3500 MW cutoff)
b. dialyze I h at RT in 500 mL buffer
2. 24-fold molar excess of dye is ideal (MW NHS-fluorescein = 473.4); they suggest
dissolving NHS-fluorescein as I mg in 100 [tL DMF: react for I h at RT.
3. For < 100 [L, use slide-a-lyzer with > 100 mL PBS: I h at RT.
4. For large volumes, using desalting column is recommended.
a. wash column with 25 mL PBS; use no > 1 mL sample per one column.
b. add 0.5 mL sample, PBS aliquots until no protein runs through.
D.2.3 Biotinylation of mg level of protein
Kit does not come with pre-weighed vials - not worth it - order reagent directly.
Mutiple options available - I usually used the longest linker (LC-LC):
MW Sulfo-NHS-LC-biotin = 557
MW Sulfo-NHS-LC-LC-biotin = 669.75
1. Recommended buffer is BupH PBS, with 2-10 mg/mL protein.
2. 12-fold (10 mg/mL) or 20-fold (2 mg/mL) excess of sulfo-NHS-biotin is recommended
for incorporating 3-5 biotin per protein molecule; they suggest dissolving 2 mg biotin in
100 ILL ultrapure water, but 1 mL usually works better for my protein etc amounts.
3. React for 2 h on ice or 30 min at RT.
4. Desalting is recommended purification method:
a. equilibrate 10 mL column with 30 mL PBS.
b. apply sample in 0.5-1 mL aliquots: collect.
c. pool protein-containing fractions from testing 280 nm absorbance.
Note: Despite desalting being recommended, dialysis seems to work fine. The advantage of
dialysis is that there is no need to re-concentrate the protein afterward.
D.2.4 Simultaneous labeling with biotin and fluorophore
Adding NHS-fluorescein and sulfo-NHS-biotin at the same time is probably best. However,
adding a fluorophore will inevitably change the degree of biotin labeling. We have found it
difficult to make double-labeled proteins that work well thus far.
D.2.5 Biotinylation of small quantities (< 100 Rg) of protein
Materials:
Biotin-XX Microscale Protein Labeling Kit (B30010, Molecular Probes).
(Sold together with biotin assay as B30756.)
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Procedure:
Preparation, first time only:
* Prepare 1 M NaHCO 3: 1 mL deionized water + vial
- store the rest in fridge for two weeks, or freeze for long-term use.
Biotinylation, each time:
1. Prepare protein at 1 mg/mL in PBS.
a. e.g., 50 RLg of ICAM-1 = 50 [L resuspension in water
b. ICAM-1 lyophilized in Tris, so must be dialyzed into PBS
2. Optional desalting using ElutaTube microdialysis vials
a. Fill wth 200 [tL deionized water, hydrate > 5 min at RT
b. Dialyze in 500 mL for 0.5 h at RT, then 1.5 h at 4 oC.
c. Repeat 3 times (at 4 oC whole time).
3. Transfer protein to reaction tube (e.g., 50 [tL), add 1/10 volume of NaHCO 3 (e.g., 5 [tL).
4. Add 10 [tL DI water to vial of reactive biotin and add immediately to rxn. tube.
a. amount for ICAM-1 labeling: 0.65 [tL
5. Incubate 15 min at RT.
Purification, each time:
1. Gently rock gel resin (Component E) to resuspend.
2. Fill spin filter to lip with gel resin (c. 800 [tL).
3. Centrifuge at 16000 g for 15 sec (including run-up time).
4. See figures for appropriate resin amount; correct as necessary.
a. rinse collection tube with buffer if resin has gotten in there.
b. to exchange buffer, centrifuge through bed at low speed a few times.
5. Place up to 50 ptL rxn. onto center of resin bed.
6. Centrifuge for total of 1 min at 16000 g (high side of resin on outside).
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Appendix E Scaffold preparation and analysis
E. 1 Scaffold fabrication
E.1.1 Protocol for making templates
Materials:
* Low polydispersity poly(methyl methacrylate) (PMMA) particles from Fluka (via Sigma-
Aldrich).
Size ([tm) 20 40 60 80
Catalogue # 90549 84657 77006 90544
* Kit for preparing poly(dimethyl siloxane) - e.g., Sylgard 184 silicone elastomer kit.
* Annular cutting tool (4.5 mm diameter, -4 mm height) from MIT Machine Shop.
* Shaker with 3/8 inch orbit from IKA or Labline.
Procedure:
1. Mix ~15:1 (base:curing agent) of the two-part PDMS kit and pour into petri dish. Per 10
cm Petri dish, use about -~12 mL of solution (makes c. 20 cut-outs).
2. Let bubbles settle at ambient conditions 1-2 h (or rid in vacuum oven for 20-30 min),
then leave on top of glassware oven O/N. (Allow to cool briefly on next day.)
3. Use annular cutting tool to make hole and razor blade to cut out surrounding square area
to make walls for a well; stick wells onto coverslips.
4. Arrange and tape down coverslips on the shaker when ready to make templates.
5. Sphere preparation: centrifuge 10 wt% solids solutions for 2 min/2000 rpm, resuspend in
70% ethanol at 55-65 wt %.
6. Add 15-30 ptL of resuspended PMMA microspheres per well. Cover with a taped down
Petri dish to slow the rate of evaporation. Turn shaker on 350-450 rpm.
7. Once the spheres are partly but not completely dry (- 10-15 min), turn off shaker and add
another 15-30 [tL of PMMA solution. Turn shaker back on.
8. Repeat step 5 again if desired. In total, wells should receive - 50 p.L each.
9. This time, let scaffolds shaker until completely dry (2-4 h).
10. Check under microscope for how well they have ordered.
11. For scaffolds that are not well ordered enough, resuspend microspheres with 70% ethanol
directly in the well (- 30 [tL), and shake again (2-4 h).
12. Most scaffolds should now be well ordered (except for slight disorder in the very center,
often) but can be resuspended again if not.
Note: Larger sphere sizes (40-80 pm) only need lower level shaking (350-450), while smaller
sphere sizes (20-30 pLm) need higher level shaking (450-500). Further, smaller spheres typically
need to be more concentrated to order well.
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E.1.2 Protocol for making polymer scaffolds
Prepolymer solution stocks and other materials required:
* Fluor 570 = methacryloxethyl thiocarbonyl rhodamine
- Polysciences, Inc # 23591
* HBS = HEPES-buffered saline (see Appendix A)
* HPK = 1-hydroxy-cyclohexylphenylketone
* PEGDMA = poly(ethylene glycol)-dimethacrylate, 1000 Da
* TEOA = triethanolamine
Buffer stock: 20tl, (0.0224g) TEOA per mL HBS.
Initiator stock: 0.2g HPK per mL 70% ethanol (make fresh!)
Optional:
Fluor 570 stock: 0.1% w/v aqueous.
Biotin-PEGA
Peptide-PEGA
Alternative initiator:
DMPA = 2,2-dimethyl-2-phenyl-acetophenone
Procedure:
1. Weigh semi-solid PEG, add to the HBS/TEOA, and vortex to dissolve.
2. Add ethanol, any optional components, and finally the initiator.
3. Filter the solution through a 0.2 [rm filter (e.g., Acrodisc from Pall corporation).
4. Add 8-12 jtL prepolymer solution to an edge of the template.
5. Centrifuge 3 min. at 1500 rpm. It should look slightly wet but not overly so. If it looks
dry, add 1-2 [LL more of pre-polymer solution and wait 10-20 sec.
6. Expose to UV light for 90 seconds, immediately transfer construct to acetic acid.
7. Exchange process: change acetic acid after 2-4 hours (Ix), next day (3x), third day (lx),
then to PBS (3-4x over 24 h), sterile PBS (lx), dip into 70% ethanol, sterile PBS (2-3x
over 24h and long-term storage). All at - 8 mL/scaffold.
Note: on first acetic acid exchange, remove scaffolds from the PDMS well/coverslip. Removing
them at this time reduces tearing because they are swollen rather than slightly dry.
Recipes:
Base recipe: 0.2 g PEGDMA per 1 mL of 3:1 buffer stock:ethanol, 40 utL initiator stock.
Fluorescent recipe: add 30 [tL Fluor 570 stock per 1 mL base recipe (0.003 wt % final).
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Peptide recipe: 160:1 PEGDMA:RGD-PEGA molar ratio is typical (e.g., 240 uL per 1 mL
prepolymer solution buffer when using 0.03 g/mL stock peptide solution.)
Biotin-containing recipe: 1:500 by moles means ~0.0018 g bio-PEGA per 0.2 g PEGDMA, or ~
40 [xL stock solution per mL prepolymer.
COOH-containing recipe: add up to 2 uL MAA to base recipe - post-processing differs.
E.1.3 Protocol for protein conjugation to scaffolds
Procedure for biotinylated scaffolds:
All steps should be done 4 oC, while shaking gently (100-200 rpm).
1. Per scaffold, add 1 mL of 1 [pg/mL of SAv (with or without a conjugated fluorophore
such as Alexa-647) in PBS. Incubate 12-24 h.
2. Wash with 1.5 mL PBS (3+ exchanges over 12-24 h).
3. Add 5-20 1pg/mL protein in PBS. Incubate 12-24 h.
4. Wash with 1.5 mL PBS (3+ exchanges) for 4-6 h.
This procedure was used for most experiments described in the main document.
Procedure for MAA-containing scaffolds - aqueous:
Activation buffer: 0.1 M MES, 0.5 M NaC1, pH 6.0
Alternative: pH 5 MES for step 1; pH 7-8.5 phosphate or carbonate buffer for step 2.
MW NHS = 115.09; MW EDC = 191.7 g/mol.
1. Equilibrate EDC and NHS to RT before opening.
2. React scaffold with 2 mM EDC and 5 mM NHS for 30-45 min. (per mL: 0.4 mg EDC,
0.6 mg NHS, 1.1 mg sulfo-NHS - prep 10 mL or more.)
3. Add 20 mM 2-mercaptoethanol (1.4 [tL per mL); wait 5 min.
4. Add protein (conc.?) and react for 2-3 h at RT.
5. (May quench by adding hydroxylamine to 10 mM.)
This procedure was tested as an alternative for making protein-coated scaffolds. It appeared to
result in weak protein attachment; however, studies were not exhaustive.
Procedure for MAA-containing scaffolds - organic:
MW NHS = 115.09; MW DCC = 206.33 g/mol.
1. Equilibrate scaffolds in DCM.
2. Replace DCM with rxn mixture: 27.4 mM each of NHS, DCC in DCM.. (Per 10 mL:
0.0315 g NHS, 0.0565 g DCC; this is 3x of Darrell's old recipe.)
3. React for 8 h - overnight at RT.
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4. Rinse with DCM several times.
5. Briefly equilibrate with DMSO, (75/25 DMSO/PBS), 50/50 DMSO PBS.
6. Add about 1 mL of 10 [g/mL protein to each scaffold: react 2-3 h at RT.
This procedure was tested as yet another alternative. Protein attachment seemed to work quite
well; however, removal of all organic solvent and chemical precipitates was difficult.
E.1.4 Protocol for making attached scaffolds surrounded with bulk gel
Glass Preparation:
1. Dip round (imaging) coverslips in trichlorovinylsilane (4 wt. % in methanol).
2. Incubate 20 min.
3. Rinse slides thoroughly with methanol (and optionally, water).
4. Put slides in vacuum oven, turn off the vacuum once pressure gauge hits 30, then leave
slides in that atmosphere for 30-60 min.
5. Note: flush silane with nitrogen before putting it back into chemical fridge.
Scaffold Preparation/Treatment:
I. Prepare a square-shaped PDMS well that is large enough to surround the (round)
template with a bit of room to spare all around.
2. Add pre-polymer to a template prepared on a normal coverslip and photopolymerize for
30 seconds.
3. Meanwhile, spincoat a thin layer of pre-polymer onto a silanized coverslip at low speed.
4. Slice off template-polymer composite using a razor, remove its surrounding (round)
PDMS well, and place it onto the silanized coverslip. Polymerize for 30 seconds more.
5. Set the square PDMS well down around the template, add 70-100 [LL of pre-polymer
solution (gently, so as not to disturb/lift off the template), and polymerize for a final 30
seconds.
6. Wash with acetic acid as usual, then transfer to DCM and continue with protein
attachment protocol as for MAA scaffolds in organic solution. This method results in the
most stable removal of PMMA and attachment of protein.
7. Cells can be injected into attached scaffolds, which results in excellent packing.
However, trace DCM can result in cell death. Further, about half of the scaffolds may
detach from the silanized coverslip after undergoing all of the washing steps. This
method is thus ultimately inefficient and undesirable.
E.2 Supplementary assays for proteins attached to scaffolds
E.2.1 Scaffold immunostaining:
Procedure:
All steps should be done at 4 oC for 12-24 h, while shaking gently (100-200 rpm).
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1. Incubate scaffold with 0.5 mL antibody diluted to 1-10 [tg/mL (in FACS buffer).
2. Rinse 3x in quick succession, then soak in FACS buffer.
3. Rinse 3x in quick succession prior to imaging or addition of next reagent.
4. Repeat for secondary step(s) as necessary.
Specific antibodies:
Anti-fibronectin (250 [tg/mL) L.
Secondary antibodies (2 mg/mL) at 1:500
FITC ICAM-1 Ig (500 [pg/mL) diluted 1:50.
E.2.2 Determining protein concentration with microBCA assay:
Objective: Calculate protein concentration of modified (biotinylated) proteins after
processing/dialysis in order to get accurate value of biotin groups per protein.
Materials:
* MicroBCA kit (Pierce 23235)
* PBS or other appropriate diluent
* Protein to be tested
* (Protein standard)
Procedure (test tube - UV-vis spectrophotometer):
1) Pre-heat water bath in large crystallizing dish to 60 TC.
a. use combination heater/stirplate, on low stir speed (100-200 rpm)
2) Prepare protein samples and standards at 2x final concentration 0.8-1 mL each).
a. include a blank (no protein) sample
b. they recommend using BSA as a standard (final conc. 0.5-200 gg/mL)
3) Prepare Pierce working reagent (WR) at 25:24:1 ratio of kit components MA:MB:MC.
a. prepare enough to mix 1:1 with each protein sample or standard
b. final volume should be 1.6-2 mL, to adequately fill disposable UV cuvettes
4) Mix each protein sample/standard with an equal volume of WR, mix well.
5) Incubate tubes in water bath for I h.
6) Cool tubes to RT (e.g., immerse in RT/cool water repeatedly).
7) Tare spectrophotometer on cuvette filled with water, at 562 nm.
8) Measure absorbance of each sample at 562 nm, ideally within 10 minutes.
Analysis:
* Subract the blank (no protein) reading from all samples/standards.
* Prepare a standard curve from the protein standard values.
* Use the curve-fit (linear) to determine the protein sample concentrations.
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Notes:
* This procedure may also be done on a microplate reader (see Pierce documentation if
interested); however, the detection limit is less sensitive.
* BSA concentration does not necessarily correlate well with the concentration of another
protein. For example, ICAM-1 has a higher absorbance, and can be used at even lower
concentrations as a standard (e.g., 0.25, 0.5, 1, 2 [Lg/mL)
* The cuvettes do sometimes vary by a few thousandths absorbance units in their baseline
readings.
- For rapid but accurate testing, I usually do the following:
* Fill first cuvette with water, measure absorbance.
* Transfer water to next cuvette in the box.
* Fill first cuvette with sample, measure, and set aside (in case of error).
* Measure baseline of second cuvette.
* Repeat for all samples...
- Perform all solution transfers with disposable glass pipets, keeping a box nearby.
- Keep extra water nearby, as the level will eventually lower after many transfers.
E.2.3 HABA protocol for biotin content
Objective: Measure biotin groups on protein when don't need a supersensitive assay (e.g., used
this for measuring biotin groups on fibronectin).
Method: Biotin displaces HABA from avidin, decreasing absorption at 500 nm.
Materials:
Buffer: PBS (or TBS if desired)
Avidin (Pierce): usually we keep stock at 2 mg/mL.
HABA (Pierce): available in kit or sold separately as a powder.
Prep HABA/Avidin solution: 1 mg Avidin + 60 [xL HABA + 1.94 mL PBS is basis.
e.g., 500 RL Avidin, 60 [tL HABA, 1.44 mL PBS if use normal Avidin stock.
Stable for 2 weeks in fridge - may filter if precipitate forms.
Procedure:
1. Test H/A solution: should have As0 = 0.9-1.3 = reading 1 = RI.
2. Add biotinylated protein to the same cuvette: mix and get A500 = R2.
a. wait for value to be constant >15 sec
b. if sample is absorbance is <0.3, dilute and repeat the assay
3. Junsang recommends always making a standard curve with free biotin!!!
a. 1 mM stock = 0.244 mg/mL stock (JSD has in PBS pH 6.0)
b. use b/w c. 0.2 and 5 [tg/mL curve = 50x dilution on down
4. If using cuvettes, dry thoroughly in between samples.
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Calculation:
Abs = e 1 C (1 = 1 cm for most cuvettes)
E = 34000 mL/(M-'cm -') for H/A
1. Calculate mmoles protein/mL = conc (mg/mL) / MW
e.g., 3 mg/mL 450 KDa FN - 6.666 e-6 mmole/mL
e.g., I mg/mL 890 KDa LMN - 1.235 e-6 mmole/mL
2. Calculate change in absorbance, accounting for dilution
* e.g., 10x diluted protein means delta A = 0.9 R1 - R2
- because CHABA- 2 is 0.9 of CHABA-1
* I usually use 488 buffer + 12.5 pL protein solution
- equation is thus 0.975 R1 - R2
3. Calculate biotin concentration (mmole/mL)
C = AA/34000
4. Calculate mmoles biotin/mmoles protein
* e.g., for 10x diluted protein: C3/C1 * 10
* For my typical case, multiply by 40 (dilution factor) instead.
E.2.4 Determining biotin content on small amounts of protein
Objective: measure biotin on small amounts of expensive protein (e.g., ICAM-1).
FluoReporter biotin quantitation kit (F30751, Molecular Probes).
Ex/Em = 495/519.
Requires estimate of protein concentration:
1. Simplest determination = mg protein x % yield / volume (mL) recovered
a. assume 79-95% recovery for protein with ICAM-1 MW
2. Better alternative: A280 of conjugate soln. vs. 1 mg/mL soln. of protein alone.
3. Best alternative: Protein assay kit (Q33210) - requires 5 [tL.
Procedure:
96-well microplate format.
Requires 600 ng of singly biotinylated IgG; lower MW or >1 biotin requires less protein.
Detects 4-80 pmol biotin (50-fold higher sensitivity cf. HABA assay).
1. Allow components to come to RT before opening.
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2. Add 1 mL of provided 10X PBS to 9 mL DI water (per two assays).
3. Add 1.75 mL PBS to Biotective Green (Comp. A).
a. may be refrigerated for up to 5 days.
4. If needed, reconstitute protease (Comp. C) in 50 [tL PBS.
a. may be aliquotted and frozen.
5. Optional protease digestion.
a. dilute bio-protein in PBS to 50 iL.
b. add 1 CIL protease stock soln.
c. digest IgG as a positive control: 3 tiL + 154 [tL PBS + 3 [L protease.
d. incubate O/N at 37 TC.
6. Biocytin standard: 843 itL PBS + 6.8 [tL biocytin (Comp. B).
a. serial dilution in triplicate (+ PBS alone as neg. control), 50 RL each.
7. Dilute bio-protein in PBS - e.g., assume 1-20 degree of labeling.
8. Add 50 [tL of bio-protein samples, pos. controls to appropriate wells.
9. Add 50 [tL Biotective Green reagen to each well; incubate 5 min at RT.
10. Measure on fluorescence reader (c. 485/530) within 15 min.
Analysis:
Plot fluorescence (x) vs. amount of biocytin (y).
Use quadratic fit, or straight line fit through two bracketing values.
DOL of positive control(s) varies from lot to lot; should get within 0.5 of value.
Note: biocytin is a good control for proteolytically cleaved biotin; goat IgG also provided.
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Appendix F Experiments in 2D (no scaffolds)
F.1.1 Protocols for protein surface preparation
Objective: Prepare surfaces to test cell spreading and/or sticking to various ECM components.
Also used to prepare surfaces for testing cell migration in the presence of chemokine.
Materials:
* 1% BSA in PBS, or blocking buffer
- used as negative control, and post-treatment block.
* Adhesion protein of interest
Procedures for protein preparation:
Initial prep for various ECM proteins.
- Fibronectin (Sigma F4759): 1 mg/mL in water, dissolve 30' min at 37 °C, store
aliquots in freezer.
- Laminin (mouse, Sigma L2020): slowly thaw in fridge (from freezer).
- ICAM-1, VCAM-1 (recombinant, R&D systems)
- Laminin (human,):
- CN I, III from calf skin: 1 mg/mL dissolution in pH 3 aq. AA (0.25%).
- CN IV (Sigma C0543): 1 mg/mL dissolution in pH 3 aq. AA.
- CN IV - gel: 1.5-3 mg/mL dissolution in pH 3 water/AA;.
- Vitrogen CN I - gel: std. 9:1 procedure; 60 min gel, best w/out CO2.
- Vitrogen CN I: film same as gel, but dry it out, rehydrate with sterile H20.
Procedure for protein coating:
* Dilute protein in SF-RPMI or HBSS
- Laminin (mouse): incubate at 2 tg/cm2 .
- Fibronectin (Sigma F4759): 5 [tg/cm 2, air dry 45 min at RT, rinse if desired.
- ICAM-1, VCAM-1: dilute to 10 [tg/mL in PBS, incubate at 4 TC O/N.
- CN I, III from calf skin: incubate at 10 ptg/cm2.
- CN IV (Sigma C0543): incubate at 10 [tg/cm 2 for a few hrs at RT or 37 'C; dry
O/N.
- CN IV - gel: std. 9:1 CN: 10x medium/NaHCO 3 procedure, with CN pH to 7.4,
then gel 20-40 min.
* For testing cell specific adhesion on ECM-treated plates, must use serum-free medium.
* After incubation time (1-3 h), can rinse cells with warm serum-free medium, and gently
turn over/blot plate to test strength of cell adhesion.
* Cells may be observed by optical microscopy, and/or fluorescence if labeled.
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Notes:
For sample calculations, see for example notebook page 111.133.
BD Biosciences CN I: perfect results with 800 uL CN + 40 uL 0.1M NaOH + 110 uL (slightly
basic) 10x medium. Sigma CN IV: perfect results with 8:1:1 mix.
24-well plate has ~ 1.54 cm 2 per well surface area.
8-well Lab-Tek has --0.7-0.8 cm 2 per well surface area.
F.1.2 2D Chemokinesis Experiments:
Chamber Preparation:
Coat Lab-Tek chambers with fibronectin (may be done same day), or ICAM-1 or VCAM-1
(overnight procedure). See Appendix F. 1.1.
Cell Preparation:
1) Prepare cell suspension from spleen and/or lymph nodes of young mouse.
a. (If using splenocytes, first lyse red blood cells.)
2) Perform MACS according to manufacturer's protocol.
3) Label ~ 40% of cells with fura-2 AM or CMFDA (see Appendix C.3).
4) Add chemokine to final cell resuspension (e.g., 1-5 ptg/mL), allow to equilibrate 5-20 min
on the microscope, and begin imaging.
Imaging:
Typically do hour-long runs at 30-second intervals in four quadrants.
Positive chemokine concentrations are ~ 1*-5 [Lg/mL.
* Previous CK reconstitution was calculated incorrectly: really was using 2.5 [tg/mL.
Note: Be sure to note age (and sex) of mouse!!!
F.1.3 Protocol for chemokine stability testing
Overview:
To assess chemokine (CK) stability, diluted CK solutions are prepared at staggered intervals, and
interrogated by ELISA on the same day.
Sample dilutions:
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1. For CCL21 at 2000 and 200 ng/mL: 1.5 [tL of 100 pg/mL CCL21 in 75 pL, and 1.5 /L
of 1:10 CCL21 dilution.
2. Test (for example) CCL21 in RPMI-10 and 1% BSA at 37 TC with shaking.
3. Final dilutions for ELISA should be about 1:4000 and 1:400, respectively. (12.5 [tL of
1:100 or 1:10 in 0.5 mL of Reagent Diluent).
4. Previous testing was done for 2h, 1 d, 2d, and 5 d before the ELISA was performed.
F.1.4 Chemotaxis filterplate assay method
Adapted from Dr. Richard Colvin
Preparation:
* Cell number: ~ 25000 cells on top often good; aim for 500-600 coming through.
* Volumes: bottom = 31, top = 25-50 uL.
* Perform chemotaxis assay at 37 C for c. 2 hours (primary cells).
Assay:
1) hold plate at angle and rinse off top with distilled water, to wash away cells.
2) spin for 5 min/1500 rpm.
3) remove top (break seal at two points w/spatula, open like a hinge).
4) aspirate supernatant, quickly moving from center-bottom of each well to next well; leave
behind 5-10 uL.
5) leave at -80 C O/N (or less long; O/N usually most convenient)
6) use cyquant (C7026) - A(1:400) + B(1:30); may want to double B or add other
detergents, depending on signal. use ~ 2 mL/plate (20 uL.well); incubate 2-5 h.
7) read on fluorescence plate reader (485/520).
Controls:
* cyquant alone for background
* cell calibration curve: - 100K, doubling dilutions downward (10 uL).
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Appendix G Scaffold-cell integration
G. 1 Cell loading
G.1.1 Cell loading, general (medium):
1. Put scaffold in 96-well round-bottom plate, with scaffold flatter side up.
2. Add 10 ItL cells on top, incubate 3 min at 37 oC.
3. Spin for 1 min at 800 rpm.
4. Repeat steps 2-3 one or more times as needed.
5. Dip scaffold in 200 [tL fresh warm medium to remove surface cells.
6. Place gently in Lab-Tek filled with 100-150 glL medium.
a. alternatively, place in POC chamber (Zeiss), surround with 100-150 [tL medium,
and close chamber by adding second coverslip and metal cover.
7. Image scaffold/cells; remove some medium if scaffold floats.
8. Add more medium (100+ RiL) for long term culture.
G.1.2 Cell loading, general (collagen):
1) Put scaffold in 96-well round-bottom plate, with scaffold flatter side up.
2) Add 10 ptL cells on top, incubate 3 min at 4 oC.
3) Spin for 1 min at 800 rpm.
4) Repeat steps 2-3 one or more times as needed.
5) Place scaffold gently in Lab-Tek chamber.
6) Surround with 60-100 tL collagen.
7) Add more medium (100+ tiL) for long term culture.
G.1.3 Fibroblast (e.g., BLS4) cell loading:
Note: to get good loading of BLS4 in scaffolds without clumping, it is important to do extended
EDTA treatment prior to trypsinization.
1. Warm all components to 37 TC prior to use.
2. Aspirate cell medium and rinse cells briefly with warm PBS.
3. Aspirate PBS, add 3 parts EDTA (0.02 % solution).
4. Incubate 10 min.
5. Leave EDTA there, and add 1 part trypsin/EDTA (0.25% / 2.21 mM).
6. Incubate 2-5 min, then ads 10 mL complete medium.
7. Wash, count, and resuspend cells.
8. Add 500K or fewer cells per scaffold, added in ~ 20 [tL as usual.
G.2 Cell migration experiments
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G.2.1 T cell migration in protein-coated scaffolds
1) Protein-coated scaffolds should be prepared ahead of time according to Appendix E.1.3,
and washed several times in PBS the morning of the experiment.
2) Meanwhile, naive T cells should be prepared according to Appendix C.2.2, or activated T
cells should be removed from culture well plates by pipetting and counted.
3) The selected T cells should be labeled with CMFDA (see Appendix C.3.4) or other
appropriate fluorescent dye.
4) Finally, the cells should be loaded into the scaffold as described in Appendix G. 1
(-500M cells/mL).
a. For experiments where soluble CCL21 is added, the final concentration must be
taken into account. For example, CCL21 must be added to a 10 [tL cell
suspension at 20 [tg/mL for a final concentration of 2 [tg/mL in 100 [tL.
5) Cells may be imaged immediately or after a delay following incubation. Typically,
intervals of 30 sec and total imaging times of 0.5-3 h were used.
G.2.2 T cell migration in composite scaffolds
As described in Appendix above, but with the following modifications:
1) Composite scaffolds may not necessarily contain any coating proteins.
2) Cells should be loaded at 4 oC.
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Appendix H GENERAL SUPPORT ASSAYS
H.1 Flow Cytometry
H.1.1 Flow cytometry general protocol:
Note: this method is designed for the simplest calculations and quickest procedure possible,
without compromising results. Once the method is familiar, it should only take ~ 45-50 minutes
per staining step, plus initial time to retrieve and count cells.
Reagents:
* All antibody(Ab)/reagent dilutions may be performed in eppendorf tubes.
* All centrifuging may be done at the standard 5 min/1200 rpm.
* For multi-colour samples, need to prepare: sample (all Abs at once), single color controls
(one antibody at a time), and an isotype control (all ITC Abs at once).
* FACS buffer: 1% BSA, 0.1% NaN3 in HBSS (or PBS is okay) pH 7.4.
* PI stock solution: 1 mg/mL
* final PI concentration: 1.25 Cpg/mL. To achieve this, add 5 CtL of a 1:10 dilution of the PI
stock solution per 400 [tL of cells/FACS buffer.
* Final cell suspension: minimum 0.4 mL (100,000/mL); ideally ~ 500,000+/mL.
* CD16/32 solution: prepare at 10 ptg/mL (1:50) in FACS buffer just prior to use (i.e.,
while spinning down cells): prepare enough for 1 extra sample.
* FITC, biotin antibodies: typically are used at 10 pxg/mL (1:25 for 2x stock).
* PE antibodies: typically are used at 2 [Lg/mL (1:50 for 2x stock).
* For antibodies, prepare 60 tL per cell sample (but add 50 pL), due to losses.
* For SAv conjugates, prepare enough for one extra sample.
* SAv-APC: typically used at 1:100; SAv-PE: typically used at 1:1000.
* Cychrome Abs, SAv-Cychrome similar to PE, but somewhat less bright.
* Spin Abs before using (0.5 min, 1000's of rpm, especially PE).
Preparation:
1. Count cells: you will typically use 105-106 cells per sample (e.g., 400,000).
2. Resuspend cells in FACS buffer, or in CD 16/32 (diluted in FACS buffer): 50 uL per
sample. Cells should be resuspended in ~ 10% excess volume due to losses.
3. Plate 50 ptL of cells per sample well in a 96 v-bottom plate. Wait 10 min if doing Fc
blocking (CD 16/32) step. Otherwise proceed to step 4 immediately. Note: While
waiting for Fc block (or spinning down cells), prepare antibody dilutions.
4. Add 50 jtL of appropriately diluted antibodies (i.e., 2x the final desired dilution) to the
cell samples. Note: CD16/32 does not need to be washed out first.
5. Incubate 20 min. over ice. Add 100 [pL FACS buffer to each sample, and centrifuge.
Check for cell pellets; flick buffer out by shaking plate over bio-trash.
6. Resuspend each sample in 200 tL; centrifuge, flick buffer out. Repeat.
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7. If using secondary antibodies, resuspend cells directly in 100 ýtL of diluted secondary (or
resuspend in 50 [tL buffer, then add 50 [tL secondary if desired). Repeat steps 5 and 6; or
if only primary antibodies are used, proceed to step 8.
8. After the final (third) wash, resuspend the cells in 200 [tL FACS buffer, and add them to
individual FACS tubes containing 200-800 [tL of FACS buffer or PI-containing FACS
buffer (not if you are using Cychrome!), if desired.
H.1.2 Flow cytometry: specific antibodies and resulting data
FACS for Naive T cell Determination
Background:
CD62L is highly expressed on naYve cells, and low on effectors (but high on memory).
CD44 is upregulated on memory cells compared to naYve cells.
Notes/Calculations:
Ab isotype amount 2x stock
TCR-FITC Ar Ham IgG2, L1 10 [pg/mL 1:25
CD62L-PE rat IgG2a,K 2 [tg/mL 1:50
CD44-CyC rat IgG2b,K
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Figure A 1 Phenotype of CD4÷ T cells obtained by magnetic sorting. Cells were tested after
magnetic sorting of splenocytes for CD4+cells by negative selection. (A) Live cells were gated
using PI staining. The resulting cells were primary CD4+. (B) The CD4÷ cells were examined for
expression of markers distinguishing naive and memory T cells. A majority were naYve.
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Figure A 2 T cell receptor (TCR) expression on different mouse strains. CD4 + cells were
sorted using negative magnetic selection as previously described. Expression of the Vc2 and
Vf35 TCR chains was then examined on C57BL/6 (A) and OTII (B) mice. Due to the significant
expression of Vca2 on C57BL/6 cells, it is best to gate on both TCR when analyzing co-cultures
that contain both cells (if one wants to examine only cells that can respond to OVA peptide).
FACS for T Activation Determination:
Background:
CD69 and CD25 (IL2-c chain) are upregulated upon stimulation of T cells.
Notes/Calculations:
Antibodies
Ab isotype amount 2x stock
CD4-biotin rat IgG2b, K 10 [tg/mL 1:25
CD25-PE rat IgG2b, K 2 [tg/mL 1:50
CD69-FITC hamster IgG 1, L3 10 itg/mL 1:25
(CD4-CyC rat IgG2a, K 2 [tg/mL 1:50
CD69-FITC hamster IgG 1, L3 10 tg/mL 1:50
Prep Abs. at 2x concentration, then mix with cells 1:1 (50 ýtL each).
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FACS for T blast phenotype:
Background:
CD8 T cells proliferate more quickly than CD4 and may take over blast cultures even if initially
present at low frequencies, so we tested phenotype of our proliferating blasts. We also looked at
viability over time, to determine the best time to use the cells in experiments.
Notes/Calculations:
Antibodies
Ab isotype amount 2x stock
TCR-FITC Ar Ham IgG2, L1 5 tg/mL 1:50
CD4-PE Rat IgG2B, K 1 g/mL 1:100
CD8-APC Rat IgG2A, K 1 p~g/mL 1:100
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Figure A 3 T cell blast phenotype. (A-D) Day 4 T blasts were assessed by flow cytometry. (A
and C) T cells were tested with antibodies to T cell receptor (TCR), and CD4 or CD 8 markers.
(B) T cells were tested with relevant isoptype control antibodies matched to CD4 and TCR. (D-
E) Day 4 (D) and day 7 (E) T cell blast viability was assessed by PI staining.
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H.2 Enzyme-linke immunosorbent assay (ELISA)
H.2.1 ELISA protocol
Materials:
Reagent Diluent, Blocking Buffer, Wash Buffer, Stop Solution - see Appendix B.2.4.
Substrate Solution: 1:1 mixture of A and B from R&D (H20 2 and tetramethylbenzidine)
Notes:
Be sure to test the OD of a sample-free but treated control: expected value = 0.03-0.06.
Procedure:
I. Use 100 [tL per well of capture Ab in PBS: incubate sealed plate O/N at RT.
2. Aspirate and wash wells 3x with wash buffer; blot against paper towel.
3. Block plates (200-300 [tL blocking buffer) for at least 1 hour at RT.
4. Repeat 3x wash step.
5. Add samples: typical maximum = 4 ng/mL (e.g., 1 [tL in 10 mL): perform doubling
dilutions in eppendorfs using 1 mL for max. concentration, then transferring 0.5 mL to
0.5 mL reagent diluent: add 100 [tL per well.
6. Tap gently to mix, seal plate then incubate samples 2 h at RT.
7. Repeat 3x wash step.
8. Add 100 [tL per well of detection Ab (in RD): (1-)2h at RT.
9. Repeat 3x wash step.
10. Add 100 ltL SAv-HRP per well (usually 1:200 dilution): 20 min at RT.
11. Repeat 3x wash step.
12. Add 100 [pL substrate soln. per well: incubate 20-30 min. at RT, out of light.
13. Add 50 pL. stop solution per well: gently tap to mix, observer w/in 30 min.
14. Perform readings at 450 nm and 540 or 570 nm for wavelength correction.
15. (Analysis:: subtract value at 540 from value at 450 and use standard curve.)
Alternate Protocols:
BD
Ia. Capture Ab at 1-4 [tg/mL in binding solution (pH6 or 9 phosphates) O/N at 4 OC.
2a. Blocking buffer has 1% BSA (in PBS) only.
3a. Samples incubated for 2-4 h at RT or O/N at 4 TC.
4a. Detection Ab at 0.5-2 [tg/mL: I h at RT.
5a. SAv-HRP diluted in blocking buffer/tween.
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Miller Lab
la. Capture Ab O/N at 4 TC in PBS.
2a. Blocking step may be done O/N at 4 oC.
3a. Standards from 20 ng/mL down.
4a. Samples may be incubated O/N at 4 OC with shaking.
H.2.2 Specific Chemokine Information
From R&D: reconstitute capture with sterile PBS (e.g., 0.5 mg/mL); reconstitute detection with
20 mM Trizma base, 150 mM NaCI, 0.1% BSA, pH 7.3.
SLC:
* capture at 2 ug/mL, and detection at 50 ng/mL
* suggested two-fold dilution series beginning at 2 ng/mL
* usually 2 ng/mL in non-linear regime, cut this data point during analysis.
ELC: like SLC, except use detection at 100 ng/mL.
From BD: comes as a liquid: both capture and detect at 0.5 mg/mL.
IL-2: 500 - 4 pg/mL dilution series (despite usual BD is 2000 - 15).
Detection Ab diluted from 500 - 1 [tg/mL: 20 [pL per 10 mL.
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Figure A 4 Typical calibration curve for CCL21 ELISA data. Highest (2000 pg/mL) and
lowest (15.625 pg/mL) data points were removed due to being outside the linear region, and
outside the detection limit, respectively.
s
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H.3 High-pressure liquid chromatography (HPLC)
H.3.1 HPLC protocol
Sample Prep
* Previously used 10 mg sample in 0.5 mL for peptide
* S-75 column instructions say:
- protein <= 10 mg
- filter sample or centrifuge at 10,000 g for 10 min
- 0.5-0.75 mL/min good starting point.
- 25 iiL sample volume good starting point.
Superdex-75 Column Info
* Maximum back-pressure is 1.8 MPa.
* Approx. 24 mL bed volume.
* Optimum separation range 3 K-70 K for globular proteins.
* Equilibration after long-term storage
- 50 mL water at 0.5 mL/min
- 50 mL eluant at 0.5 mL/min
* Equilibration for storage
- 50 mL water
- 50 mL 20% ethanol
Procedure
5. Turn on computer, all components (4 power switches).
6. Load D7000-HSM program.
7. For system status hit i button and hit initialize to ready system.
8. Open a sample table, then data acquisition to get immediate read.
9. Must start manually: hit pump on to start, slowly work up flowrate.
10. See sheet for troubleshooting rise in backpressure if necessary.
11. Hit autozero to re-zero absorbance (top box) when necessary - get steady.
12. Before using autosampler, hit "WASH" key to clean flow path.
13. Run samples.
To flush
1. Turn pump off.
2. Open rightmost valve.
3. Turn pump on, hit purge.
4. Hit purge again to stop.
For flush, just goes source -> pump -> out. (Normally source -> pump -> mixer -> autosampler -
> quad filter -> column -> detector -> waste.)
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Writing a method
Note: Beware of pitfalls/redundancies where you need to set a parameter twice or it won't work
correctly. Below I will describe the buttons going left-to-right (upper row first).
* Configuration
- make sure correct components are selected
- to recognize multiple solvents, switch to gradient mode "low"
* Information
- fill out solvent info, method description, etc
* Pump
- set pressure limit!
- set flowrate, solvents desired, etc
* Autosampler
- defaults should mostly be fine
- may experiment with cut or loop and injection volume
* Detector
- defaults should mostly be fine
- set the correct end time here
* Various reports stuff
- defaults should mostly be fine
- set intensity range and time axes
Writing a sample table
* Needs to refer to the same method on both tabs (upper left to toggle between tabs)
* Injection volume needs to agree with method on both pages
* Rest is straightforward (mostly use defaults)
H.3.2 HPLC calibration data
Ran standard kit from Bio-Rad at 0.2 mL/min on an S75 column in pure PBS.
MW (g/mol) Time (min)
158000 46.2
44000 55.4
17000 67.6
1350 96.6
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S-75 calibration 0.2 mL/min
y = -0.0397x + 6.942
RZ = 0.9916
20 40 60
Time (min)
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5
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0
Figure A 5 Sample calibration for HPLC.
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